Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Alfirevic Z, Mujezinovic F, Sundberg K



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2009, Issue 1

http://www.thecochranelibrary.com



TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
BACKGROUND	3
OBJECTIVES	3
МЕТНОДЯ	3
RESULTS	5
DISCUSSION	10
AUTHORS' CONCLUSIONS	13
ACKNOWLEDGEMENTS	13
REFERENCES	14
CHARACTERISTICS OF STUDIES	17
DATA AND ANALYSES	29
Analysis 1.1. Comparison 1 Second trimester amniocentesis versus control, Outcome 1 Not complied with allocated procedure.	36
Analysis 1.3. Comparison 1 Second trimester amniocentesis versus control, Outcome 3 Multiple insertions.	
	36
Analysis 1.4. Comparison 1 Second trimester amniocentesis versus control, Outcome 4 Second test performed.	37
Analysis 1.5. Comparison 1 Second trimester amniocentesis versus control, Outcome 5 Laboratory failure.	37
Analysis 1.6. Comparison 1 Second trimester amniocentesis versus control, Outcome 6 All non-mosaic abnormalities.	38
Analysis 1.13. Comparison 1 Second trimester amniocentesis versus control, Outcome 13 Vaginal bleeding after test.	38
Analysis 1.14. Comparison 1 Second trimester amniocentesis versus control, Outcome 14 Amniotic leakage after test.	39
Analysis 1.20. Comparison 1 Second trimester amniocentesis versus control, Outcome 20 All known pregnancy loss	20
(including termination of pregnancy).	39
Analysis 1.21. Comparison 1 Second trimester amniocentesis versus control, Outcome 21 Termination of pregnancy (all).	40
Analysis 1.24. Comparison 1 Second trimester amniocentesis versus control, Outcome 24 Spontaneous miscarriage.	40
Analysis 1.26. Comparison 1 Second trimester amniocentesis versus control, Outcome 26 Perinatal deaths	41
Analysis 1.27. Comparison 1 Second trimester amniocentesis versus control, Outcome 27 Stillbirths	41
Analysis 1.28. Comparison 1 Second trimester amniocentesis versus control, Outcome 28 Neonatal deaths.	42
Analysis 1.29. Comparison 1 Second trimester amniocentesis versus control, Outcome 29 All recorded deaths after	()
	42
Analysis 1.30. Comparison 1 Second trimester amniocentesis versus control, Outcome 30 Anomalies (all recorded).	43
Analysis 1.31. Comparison 1 Second trimester amniocentesis versus control, Outcome 31 Talipes.	43
Analysis 1.35. Comparison 1 Second trimester amniocentesis versus control, Outcome 35 Neonatal respiratory distress	
7	44
Analysis 2.1. Comparison 2 Early versus second trimester amniocentesis, Outcome 1 Not complied with allocated	
I manual sector se	44
	45
Analysis 2.3. Comparison 2 Early versus second trimester amniocentesis, Outcome 3 Multiple insertions.	45
Analysis 2.4. Comparison 2 Early versus second trimester amniocentesis, Outcome 4 Second test performed.	46
Analysis 2.5. Comparison 2 Early versus second trimester amniocentesis, Outcome 5 Laboratory failure.	46
Analysis 2.6. Comparison 2 Early versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities.	47
Analysis 2.7. Comparison 2 Early versus second trimester amniocentesis, Outcome 7 True mosaics.	47
Analysis 2.9. Comparison 2 Early versus second trimester amniocentesis, Outcome 9 Maternal contamination.	48
Analysis 2.11. Comparison 2 Early versus second trimester amniocentesis, Outcome 11 False negative chromosomal diagnosis.	48
Analysis 2.12. Comparison 2 Early versus second trimester amniocentesis, Outcome 12 Reporting time	50
Analysis 2.14. Comparison 2 Early versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.	50
Analysis 2.20. Comparison 2 Early versus second trimester amniocentesis, Outcome 20 All known pregnancy loss (including termination of pregnancy).	51
Analysis 2.21. Comparison 2 Early versus second trimester amniocentesis, Outcome 21 Termination of pregnancy (all).	51
Analysis 2.24. Comparison 2 Early versus second trimester anniocentesis, Outcome 24 Spontaneous miscarriage.	52

i

test. 52 Analysis 2.27. Comparison 2 Early versus second trimester anniocentesis, Outcome 28 Neonatal deaths. 53 Analysis 2.28. Comparison 2 Early versus second trimester anniocentesis, Outcome 28 Neonatal deaths. 53 Analysis 2.29. Comparison 2 Early versus second trimester anniocentesis, Outcome 29 All recorded deaths after viability. 54 Analysis 2.30. Comparison 2 Early versus second trimester anniocentesis, Outcome 31 Talipes. 55 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 1 Not complied with allocated procedure. 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 2 Sampling failure. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 4 Sampling transitions. 59 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 4 Sampling transitions. 61 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 6 Laboratory failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 7 True mosaice abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 7 True mosaice abnormalities. 65 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester a
Analysis 2.28. Comparison 2 Early versus second trimester amniocentesis, Outcome 29 All recorded deaths after viability. 53 Analysis 2.29. Comparison 2 Early versus second trimester amniocentesis, Outcome 30 Anomalies (all recorded). 54 Analysis 3.31. Comparison 2 Early versus second trimester amniocentesis, Outcome 31 Talipes. 55 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Not complied with allocated procedure. 56 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling failure. 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple insertions. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 Lucome 5 Laboratory failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaice abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaice. 64 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaice. 64 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaice.<
Analysis 2.29. Comparison 2 Early versus second trimester anniocentesis, Outcome 29 All recorded deaths after viability. 54 Analysis 2.30. Comparison 2 Early versus second trimester anniocentesis, Outcome 30 Anonalies (all recorded). 54 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 1 Not complied with allocated procedure. 56 Analysis 3.2. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 2 Sampling failure. 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 3 Multiple insertions. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 4 Second test performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 5 Laboratory failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 6 All non-mosaic abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 7 True mosaics. 65 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 9 Maternal contamination. 64 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester anniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester anni
Analysis 2.30. Comparison 2 Early versus second trimester amniocentesis, Outcome 30 Anomalies (all recorded). 54 Analysis 2.31. Comparison 2 Early versus second trimester amniocentesis, Outcome 31 Talipes. 55 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 1 Not complied with allocated procedure. 56 Analysis 3.2. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling failure. 58 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 61 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 Confined mosaics. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 Ture mosaic. 64 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcom
Analysis 2.31. Comparison 2 Early versus second trimester amniocentesis, Outcome 31 Talipes. 55 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 1 Not complied with allocated procedure. 56 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling failure. 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple insertions. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory failure. 61 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 71 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis,
Analysis 2.31. Comparison 2 Early versus second trimester amniocentesis, Outcome 31 Talipes. 55 Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 1 Not complied with allocated procedure. 56 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling failure. 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple insertions. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory failure. 61 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 71 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis,
Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 1 Not complied % Analysis 3.2. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling % failure. % Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple % insertions. % Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test % performed. % % Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory % failure. % % Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic % abnormalities. % % Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. % Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined % mosaics. % % Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false % positive after birth. % % Ana
with allocated procedure.56Analysis 3.2. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling failure.58Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple insertions.59Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed.59Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed.61Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities.63Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities.64Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics.66Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 Maternal contamination.67Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth.69Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.72Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.73Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after test.72Analysis 3.16. Comparison 3 Chorionic villus sampling versus
Analysis 3.2. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test 61 Performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory 63 failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 contamination. 67 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 positive after birth. 69 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 69 bleeding after test. 72 72<
failure. 58 Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple insertions. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth. 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test. 73 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after test. 73
Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic 64 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 69 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test. 71 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Va
insertions. 59 Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Maternal contamination. 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth. 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test. 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.
Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic 64 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined 66 Malysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 Nalysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 61 Nalysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 61 bleeding after test. 72 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 73 bleeding after test. 73 73 Analysis 3
performed. 61 Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic 64 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined 66 mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 contamination. 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 positive after birth. 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 72 Leakage after test. 72 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 73 bleeding after test.<
Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined 66 Malysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 positive after birth. 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 nalysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 bleeding after test. 72 73 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 leakage after test. 73 73 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 74 bleeding after test. 73 73 Analysis 3.15.
failure. 63 Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities. 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined mosaics. 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination. 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth. 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth. 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test. 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after 20 weeks. 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks. 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic 64 Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics. 65 Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 Positive after birth. 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 72 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 71 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 74 bleeding after test. 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 75 Analysis 3.16. Comparison 3 Chorionic vi
abnormalities.64Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics.65Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined mosaics.66Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination.67Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth.69Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.71Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.72Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.73Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after 20 weeks.75Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks.76Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal76
Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics.65Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined mosaics.66Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination.67Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth.69Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.71Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.72Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after 20 weeks.73Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks.76Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks.76
Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined 66 Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 Positive after birth. 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Ieakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
mosaics.66Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination.67Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth.69Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.69Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.71Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.72Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.73Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal
Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal 67 Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 71 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 72 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
contamination.67Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth.69Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.71Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.72Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.73Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after 20 weeks.75Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks.76Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal76
Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false 69 Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Ieakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
positive after birth.69Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.71Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.72Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.73Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after 20 weeks.73Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks.75Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal76
Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Ieakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 74 bleeding after 20 weeks. 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
negative after birth. 71 Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 72 Ieakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 73 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Ieakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 73 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
bleeding after test. 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 73 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
bleeding after test. 72 Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 73 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
leakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
leakage after test. 73 Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 28 weeks. 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal
bleeding after 20 weeks. 75 Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks. 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 76 Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal 76
28 weeks
Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal
Analysis 3.18. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 18 Delivery
Analysis 3.19. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 19 Delivery
before 33 weeks. 81
Analysis 3.20. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 20 All known
pregnancy loss (including termination of pregnancy).
Analysis 3.21. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 21 Termination
of pregnancy (all)
Analysis 3.24. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 24 Spontaneous
miscarriage
Analysis 3.25. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 25 Spontaneous
miscarriage after test
Analysis 3.26. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 26 Perinatal
deaths
Analysis 3.27. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 27 Stillbirths. 92
iocentesis and chorionic villus sampling for prenatal diagnosis (Review) ii

Analysis 3.28. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 28 Neonatal deaths.	94
Analysis 3.29. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 29 All recorded deaths after viability.	96
Analysis 3.30. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 30 Congenital	70
	0.0
anomalies (all recorded).	98
Analysis 3.31. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 31 Talipes.	100
Analysis 3.32. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 32 Hemangiomas	
(localised vascular lesions of the skin and subcutaneous tissue).	101
Analysis 3.33. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 33 Limb reduction defects.	101
Analysis 3.38. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 38 Result given in	L
less than 7 days (not prespecified)	102
Analysis 3.39. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 39 Result given in	L
less than 14 days (not prespecified)	103
Analysis 3.40. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 40 Result given in	1
less than 21 days (not prespecified)	104
Analysis 3.41. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 41 Result given in	1
more than 21 days (not prespecified).	105
Analysis 3.42. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 42 Not wanting	
another baby at 22 weeks' gestation (not prespecified).	106
Analysis 4.1. Comparison 4 Transcervical versus transabdominal CVS, Outcome 1 Not complied with allocated	
procedure	107
Analysis 4.2. Comparison 4 Transcervical versus transabdominal CVS, Outcome 2 Sampling failure.	108
Analysis 4.3. Comparison 4 Transcervical versus transabdominal CVS, Outcome 3 Multiple insertions.	108
Analysis 4.4. Comparison 4 Transcervical versus transabdominal CVS, Outcome 4 Second test performed.	109
Analysis 4.5. Comparison 4 Transcervical versus transabdominal CVS, Outcome 5 Laboratory failure.	109
Analysis 4.6. Comparison 4 Transcervical versus transabdominal CVS, Outcome 6 All non-mosaic abnormalities.	110
Analysis 4.7. Comparison 4 Transcervical versus transabdominal CVS, Outcome 7 True mosaics	110
Analysis 4.8. Comparison 4 Transcervical versus transabdominal CVS, Outcome 8 Confined mosaics.	111
Analysis 4.13. Comparison 4 Transcervical versus transabdominal CVS, Outcome 13 Vaginal bleeding after test.	111
Analysis 4.14. Comparison 4 Transcervical versus transabdominal CVS, Outcome 14 Amniotic leakage after test.	112
Analysis 4.20. Comparison 4 Transcervical versus transabdominal CVS, Outcome 20 All known pregnancy loss (including termination of pregnancy).	
Analysis 4.21. Comparison 4 Transcervical versus transabdominal CVS, Outcome 21 Termination of pregnancy (all).	112
Analysis 4.24. Comparison 4 Transcervical versus transabdominal CVS, Outcome 24 Spontaneous miscarriage.	113
Analysis 4.24. Comparison 4 Transcervical versus transabdominal CVS, Outcome 24 Spontaneous miscarriage after test.	115
Analysis 4.25. Comparison 4 Transcervical versus transabdominal CVS, Outcome 26 Perinatal deaths.	114
Analysis 4.26. Comparison 4 Transcervical versus transadominal CVS, Outcome 26 Perinatal deaths.	114
	-
Analysis 4.28. Comparison 4 Transcervical versus transabdominal CVS, Outcome 28 Neonatal deaths.	115
Analysis 4.30. Comparison 4 Transcervical versus transabdominal CVS, Outcome 30 Anomalies (all recorded).	116
Analysis 4.31. Comparison 4 Transcervical versus transabdominal CVS, Outcome 31 Talipes.	116
Analysis 5.1. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 1 Not complied with allocated	117
	117
Analysis 5.2. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 2 Sampling failure.	117
Analysis 5.3. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 3 Multiple insertions.	118
Analysis 5.4. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 4 Second test performed.	118
Analysis 5.5. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 5 Laboratory failure.	119
Analysis 5.6. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 6 All non-mosaic abnormalities.	119
Analysis 5.7. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 7 True mosaics.	120
Analysis 5.8. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 8 Abnormalities confined to non-	
fetal tissues.	120
Analysis 5.9. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 9 Maternal contamination.	121

Analysis 5.10. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 10 Known false positive after	
birth	121
Analysis 5.11. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 11 Known false negative after	
birth	122
Analysis 5.12. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 12 Reporting time.	122
Analysis 5.13. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 13 Vaginal bleeding after test.	123
Analysis 5.14. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 14 Amniotic leakage after test.	123
Analysis 5.15. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 15 Vaginal bleeding after 20 weeks.	124
Analysis 5.16. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 16 Prelabour ruptured membranes	
less than 28 weeks.	124
Analysis 5.18. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 18 Delivery before 37 weeks.	125
Analysis 5.19. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 19 Delivery before 33 weeks.	125
Analysis 5.20. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 20 All known pregnancy loss	
(including termination of pregnancy).	126
Analysis 5.21. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 21 Termination of pregnancy	
(all)	126
Analysis 5.24. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 24 Spontaneous miscarriage.	127
Analysis 5.25. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 25 Spontaneous miscarriage after	
test.	128
Analysis 5.26. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 26 Perinatal deaths.	120
Analysis 5.27. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 27 Stillbirths.	120
Analysis 5.28. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 28 Neonatal deaths.	125
Analysis 5.29. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 29 All recorded deaths after	150
viability.	120
,	130
Analysis 5.30. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 30 Anomalies (all recorded).	131
Analysis 5.32. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 32 Talipes equinovarus.	132
Analysis 5.33. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 33 Haemangioma.	132
Analysis 5.35. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 35 Neonatal respiratory distress	
syndrome.	133
Analysis 5.36. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 36 Birthweight below 10th	
	133
Analysis 5.37. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 37 Birthweight below 5th	
centile	134
Analysis 6.2. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 2 Sampling	
failure	134
Analysis 6.3. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 3 Multiple	
insertions	135
Analysis 6.20. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 20 All	
known pregnancy loss (including termination of pregnancy).	135
Analysis 6.24. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 24	
Spontaneous miscarriage	130
Analysis 6.25. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 25	
Spontaneous miscarriage after test	130
Analysis 6.38. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 38 Bloody	
tap (not prespecified)	137
HAT'S NEW	137
STORY	137
ONTRIBUTIONS OF AUTHORS	137
ECLARATIONS OF INTEREST	137
DURCES OF SUPPORT	138
IDEX TERMS	138

[Intervention Review]

Amniocentesis and chorionic villus sampling for prenatal diagnosis

Zarko Alfirevic¹, Faris Mujezinovic², Karin Sundberg³

¹School of Reproductive and Developmental Medicine, Division of Perinatal and Reproductive Medicine, The University of Liverpool, Liverpool, UK. ²Department of Gynecology and Obstetrics, University Clinical Center Maribor, Maribor, Slovenia. ³Clinic for Fetal Medicine and Ultrasound 4002, Copenhagen University Hospital, Copenhagen, Denmark

Contact address: Zarko Alfirevic, School of Reproductive and Developmental Medicine, Division of Perinatal and Reproductive Medicine, The University of Liverpool, First Floor, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK. zarko@liverpool.ac.uk. (Editorial group: Cochrane Pregnancy and Childbirth Group.)

Cochrane Database of Systematic Reviews, Issue 1, 2009 (Status in this issue: Unchanged) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. DOI: 10.1002/14651858.CD003252 This version first published online: 21 July 2003 in Issue 3, 2003.

Last assessed as up-to-date: 28 June 2008. (Help document - Dates and Statuses explained)

This record should be cited as: Alfirevic Z, Mujezinovic F, Sundberg K. Amniocentesis and chorionic villus sampling for prenatal diagnosis. *Cochrane Database of Systematic Reviews* 2003, Issue 3. Art. No.: CD003252. DOI: 10.1002/14651858.CD003252.

ABSTRACT

Background

A major disadvantage of second trimester amniocentesis is that the results are available relatively late in pregnancy (after 16 weeks' gestation). Chorionic villus sampling (CVS) and early amniocentesis can be done in the first trimester of pregnancy and offer an earlier alternative.

Objectives

To assess comparative safety and accuracy of second trimester amniocentesis, early amniocentesis, transcervical and transabdominal CVS.

Search strategy

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (January 2008).

Selection criteria

All randomised trials comparing amniocentesis and CVS by either transabdominal or transcervical route.

Data collection and analysis

Two review authors independently assessed eligibility and trial quality and performed data extraction.

Main results

We included a total of 16 randomised studies.

One study in a low-risk population (N = 4606) with a background pregnancy loss of around 2% found that a second trimester amniocentesis will increase total pregnancy loss by another 1%. This difference did not reach statistical significance and the confidence intervals (CI) around this excess risk were relatively large (risk ratio (RR) 1.41; 95% CI 0.99 to 2.00). In the same study, compared with no intervention, the increase in spontaneous miscarriages following second trimester amniocentesis was statistically significant (2.1% versus 1.3%; RR 1.60; 95% CI 1.02 to 2.52).

Early amniocentesis is not a safe early alternative to second trimester amniocentesis because of increased pregnancy loss (7.6% versus 5.9%; RR 1.29; 95% CI 1.03 to 1.61) and higher incidence of talipes compared to CVS (RR 4.61; 95% CI 1.82 to 11.66).

Compared with a second trimester amniocentesis, transcervical CVS carries a significantly higher risk of total pregnancy loss (RR 1.40; 95% CI 1.09 to 1.81) and spontaneous miscarriage (9.4%; RR 1.50; 95% CI 1.07 to 2.11). One study compared transabdominal CVS with second trimester amniocentesis and found no significant difference in the total pregnancy loss between the two procedures.

Transcervical CVS is more technically demanding than transabdominal CVS, with more failures to obtain sample and more multiple insertions. However, the results related to comparative pregnancy loss between transabdominal and transcervical CVS are inconclusive, with significant heterogeneity between studies.

Authors' conclusions

Second trimester amniocentesis is safer than early amniocentesis or transcervical CVS, and is the procedure of choice for second trimester testing. Transabdominal CVS should be regarded as the procedure of first choice when testing is done before 15 weeks' gestation. Diagnostic accuracy of different methods could not be assessed adequately because of incomplete karyotype data in most studies.

PLAIN LANGUAGE SUMMARY

Amniocentesis and placental sampling for pre-birth diagnosis

Many women want to be reassured that their unborn baby is healthy. It is important that screening and diagnostic tests used are accurate and safe and can be done early enough in pregnancy to allow them the choice of terminating the pregnancy. Second trimester amniocentesis is most often used, at around 16 weeks' gestation. A needle is inserted through the abdominal wall into the uterus to remove amniotic fluid. Early amniocentesis or chorionic villus sampling (CVS) to withdraw placental tissue can be done before 15 weeks. Either a transabdominal or vaginal (transcervical) approach is used for CVS.

We identified a total of 16 randomised controlled trials for the review. One study of 4606 women in a low-risk population found that a second trimester amniocentesis increased spontaneous miscarriages, 2.1% versus 1.3% with no intervention.

Early amniocentesis was not a safe early alternative to second trimester amniocentesis because of increased pregnancy loss and a higher incidence of deformed or club foot (talipes). It is also technically more demanding and involves a greater number of needle insertions, laboratory failures and false negative results.

Transcervical CVS also increased the risk of total pregnancy compared with a second trimester amniocentesis, mostly because of spontaneous miscarriages. Transabdominal CVS may be safer than the transcervical route, but the data are limited. Transcervical CVS is also more technically demanding than transabdominal CVS, with more failures to obtain sample and more multiple needle insertions required. It is more likely to cause vaginal bleeding immediately after the procedure, in approximately 10% of women.

BACKGROUND

Most women wish to be reassured that their unborn baby is healthy. Inevitably, any screening programme that aims to provide such reassurance will cause anxiety while waiting for the test results. The additional problems are 'false positive' screening tests (maternal serum screening and ultrasound) and lack of therapeutic options for chromosomal abnormalities. The aim is, therefore, to select screening and diagnostic tests that are both accurate and safe and can be done early in pregnancy to allow the choice of termination of pregnancy.

Ultrasound is the method of choice for detection of anatomical problems (e.g. absent kidneys, spina bifida), but provides no information on the genetic constitution of a fetus. Maternal serum screening, alone or in combination with ultrasound, is often used to identify fetuses at risk of Down's syndrome, but the definitive chromosomal diagnosis can only be made from fetal cells.

Fetal cells suitable for genetic testing could be obtained from maternal blood or preimplantation embryos. However, the former test is still being developed, while the latter requires in vitro fertilisation, which is often not feasible. At present, only analysing fetal cells from amniotic fluid, placenta (chorionic villus tissue) or fetal blood can make an accurate prenatal diagnosis .

Second trimester amniocentesis, a needle puncture through the overlying skin into the uterus and amniotic cavity followed by aspiration of amniotic fluid, is traditionally performed around 16 weeks' gestation. Observational data from the 1970s suggested that, at this gestation, relatively large amounts of amniotic fluid (up to 20 ml) could be aspirated without significant technical difficulties. This amount of amniotic fluid was needed to yield a sufficient number of viable fetal cells to minimise the risk of laboratory failure. In 1977, the MRC Canadian Study reported a rate of successful culture of only 82% below 15 weeks, compared to 94% at 16 weeks or above. Another disincentive to perform earlier sampling was a belief that aspiration of large amounts of amniotic fluid earlier in gestation would be more likely to cause neonatal orthopaedic (talipes) and respiratory complications (respiratory distress syndrome).

A major disadvantage of second trimester amniocentesis is that a final result is usually available only after 17 weeks' gestation. Such a long waiting period for a diagnosis can be very distressing for couples, particularly when most obstetricians are reluctant to offer a surgical termination late in pregnancy. Earlier options include chorionic villus sampling (CVS) and early amniocentesis.

CVS was first described in China in the mid-1970s (China 1975) and developed further in the Western world during the 1980s. The procedure involves aspiration of placental tissue rather than amniotic fluid. Ultrasound guided aspiration can be performed using either percutaneous transabdominal or the transvaginal/transcervical approach. Currently, the choice of the approach and the choice of instruments tend to be based upon the operator's personal preference (Alfirevic 2002).

There is an understandable desire to perform CVS as early as possible. Technically, this can be done successfully as early as six weeks' gestation. However, a few clusters of limb reduction defects have been reported following CVS, with a trend toward an increased incidence of these defects when CVS was done before nine weeks' gestation (for review of the evidence *see*: Jackson 1993). Subsequent, large epidemiological follow-up studies failed to confirm this association (Froster 1996), but most clinicians delay this procedure until after 10 weeks' gestation.

Early amniocentesis (9 to 14 weeks' gestation) was introduced in the late 1980s. It is technically the same as a 'late' procedure, except that less amniotic fluid is removed. Ultrasound needle guidance is considered to be an essential part of the procedure because of the relatively small target area. The presence of two separate membranes (amnion and chorion) until 15 weeks' gestation creates an additional technical difficulty. Only the amniotic (inner) sac should be aspirated, because the outer sac does not contain sufficient numbers of living fetal cells. Sundberg 1995 reviewed observational studies of early amniocentesis and found 12 published series with more than 100 pregnancies per study (5242 pregnancies in total). Unintended pregnancy loss varied between 1.9% and 4.7%, and laboratory failure varied between 0% and 20%. The karyotyping success rate may be increased by using filter techniques in which amniotic cells are retained on a filter after aspiration while the rest of the amniotic fluid (cell free) is re-injected into the amniotic cavity (Sundberg 1991).

OBJECTIVES

The objective of this review is to compare the safety and accuracy of all types of amniocentesis (i.e. early and late) and chorionic villus sampling (e.g. transabdominal, transcervical) for prenatal diagnosis.

METHODS

Criteria for considering studies for this review

Types of studies

We have included all randomised comparisons of late amniocentesis (after 15 weeks' gestation), early amniocentesis (before 15 weeks' gestation) and chorionic villus sampling (either transabdominally or transvaginally) with each other or with no testing. We have excluded quasi-randomised studies (e.g. alternate allocation).

Types of participants

Pregnant women requesting invasive prenatal diagnostic testing for fetal chromosomal or genetic disorders.

Types of interventions

Second trimester amniocentesis (after 15 completed weeks of gestation).

Early amniocentesis (before 15 completed weeks of gestation (i.e. 14 weeks and 6 days or less)).

Transabdominal, transcervical or transvaginal chorionic villus sampling.

Types of outcome measures

All the sought outcomes can be divided into the following groups.

(i) Outcomes related to technical difficulties in sampling

- Non-compliance with allocated procedure
- Sampling failure
- Multiple insertions
- Second test performed

(ii) Outcomes related to cytogenetic analysis

- Laboratory failure
- All non-mosaic abnormalities
- All mosaics (karyotypes with two or more cell lines)
- True mosaics
- Confined mosaics (two or more cell lines present in the placenta but not in the fetus)
- Maternal contamination
- Known false positive after birth
- Known false negative after birth
- Reporting time (interval between sampling and result)

(iii) Pregnancy complications

- Vaginal bleeding after test
- Amniotic leakage after test
- Vaginal bleeding after 20 weeks
- Prelabour ruptured membranes less than 28 weeks
- Antenatal hospital admission
- Delivery less than 37 weeks
- Delivery less than 33 weeks

(iv) Pregnancy outcome

- All known pregnancy losses (including terminations of pregnancy)
- Termination of pregnancy (all)
- Spontaneous miscarriage (pregnancy loss before viability - usually 24 weeks of pregnancy)
- Spontaneous miscarriage after test (pregnancy loss in women who had the test actually performed)
- Perinatal mortality (stillbirths and neonatal deaths in the first week of life)
- Stillbirths
- Neonatal death (death in the first week of life)

• All recorded deaths after viability

(v) Neonatal complications

- Anomalies (all recorded)
- Talipas (clubfoot)
- Talipes equinovarus (the foot is plantar flexed, inverted and markedly adducted)
- Hemangiomas (localised vascular lesions of the skin and subcutaneous tissue)
- Limb reduction defects
- Admission to special care baby unit
- Neonatal respiratory distress symptom (defined by authors)
- Birthweight less than the 10th centile
- Birthweight less than the 5th centile

While we have sought all the above outcomes, only those with data appear in the analysis table. The data that were not prespecified by the review authors, but reported by the authors, have been clearly labelled as such ('not prespecified').

Search methods for identification of studies

Electronic searches

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (January 2008).

The Cochrane Pregnancy and Childbirth Group's Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:

- quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);
- 2. weekly searches of MEDLINE;
- 3. handsearches of 30 journals and the proceedings of major conferences;
- 4. weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.

Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Specialized Register' section within the editorial information about the CochranePregnancyandChildbirthGroup. Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.

We did not apply any language restrictions.

Data collection and analysis

We have assessed all trials for methodological quality using the criteria in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008), with a grade allocated to each trial

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

on the basis of allocation concealment. We have scored allocation concealment as A (adequate) for telephone randomisation and the use of sealed envelopes; B (unclear) for trials where randomisation is not clearly described or prone to bias (e.g. open cards, toss of a coin). We have excluded inadequate designs (C), such as alternate allocation and the use of record numbers. We have planned no other formal or informal qualitative analysis, as there were no planned exclusions based on quality.

We extracted the data onto hard-copy' data sheets, entered onto the Review Manager computer software (RevMan 2008), checked for accuracy by another co-author, and analysed using the Review Manager software. We extracted the data by allocated intervention, irrespective of compliance with the allocated intervention, in order to allow an intention-to-treat analysis. We have not included women who were randomised and subsequently either excluded or lost to follow up in the denominator data.

We calculated a weighted estimate of risk ratio for each outcome. Most of the outcomes were uncommon, therefore, odds ratios were similar to risk ratio for most analyses. We tested for heterogeneity between the trials using a I^2 test. In the absence of heterogeneity, we pooled the results using a fixed-effect model. When we found significant ($I^2 > 50\%$) and unexplained heterogeneity, we used more conservative random-effects model.

The data that were not prespecified were collected, reported and clearly labelled as such ('not prespecified'). The possibility that these outcomes are often reported only if they reach statistical significance after a 'post-hoc' data dredging had to be borne in mind. In order to minimise the risk of biased reporting of 'soft outcomes', particularly when clinicians are not blinded to the allocation as is the case in evaluation of invasive procedures, we based our conclusions on the prespecified outcomes.

RESULTS

Description of studies

See: Characteristics of included studies; Characteristics of excluded studies.

(1) Second trimester amniocentesis versus control (no testing)

Tabor 1986 was a multicentre study that included low-risk Danish women aged 25 to 34 years between 1980 and 1984. Seventy-three per cent (4606/6305) of all eligible women took part. Five doctors performed all procedures; the most experienced operator performed 54%. Amniocentesis was performed with a full bladder using a linear 3.5 MHz transducer with a channel guide for the needle in the middle of the probe. A 20-gauge needle (0.9 mm outer diameter) was passed through the channel, creating an angle of 90° between the needle and the linear probe.

(2) Early versus second trimester amniocentesis

CEMAT 1998 was a multicentre trial carried out under the auspices of the Medical Research Council of Canada. Both early and mid-trimester amniocentesis were done with a freehand technique, using a 22-gauge needle under continuous ultrasound guidance. Each operator had done at least 30 early amniocenteses before participating. Eleven millilitres of amniotic fluid were aspirated during early amniocentesis and 20 ml during second trimester amniocentesis. No more than two attempts were carried out on the same day.

(3) Chorionic villus sampling (CVS) versus amniocentesis

In the Canada 1992 trial, women allocated to have CVS had the transcervical procedure, while in the MRC 1991 trial CVS was carried out in whatever procedure was deemed suitable by the obstetrician (72% by the transcervical and 28% by the transabdominal approach). In the MRC 1991 trial of the 1592 women randomised to amniocentesis with follow-up data, 1417 (89%) are known to have had an amniocentesis. In the Finnish arm of the MRC trial, all CVS procedures were carried out by transcervical approach. In the Canada 1992 trial, a pre-entry ultrasound could not be performed in all centres. As a consequence, 14.2% of women with non-viable, multiple or advanced pregnancies were subsequently excluded, after randomisation, from some analyses. The Denmark 1992 trial was designed as a three-way randomisation of women classified as low genetic risk (transabdominal CVS versus transcervical CVS versus amniocentesis). Borrell 1999 randomised women to transcervical CVS (9 to 13 weeks) or amniocentesis (15 to 18 weeks). This trial was stopped prematurely when second trimester biochemistry screening was introduced.

(4) CVS trials

USNICHD 1992 was a large multicentre collaborative study under the auspices of the US National Institute of Child Health comparing transabdominal and transcervical CVS. In total 3999 women were randomised. Transcervical CVS was performed with a 1.5 mm plastic catheter and abdominal procedure with a spinal needle (18- to 22-gauge). Brambati 1991 randomised 78.6% of eligible women referred for genetic counselling at six to eight weeks' gestation. A single operator performed all procedures (both transabdominal and transcervical). Transcervical CVS was performed using a cannula with an outer diameter of 1.45 mm and the transabdominal procedure was done with a spinal needle (1.1 mm outer diameter). A maximum of two passes was allowed in one sampling session. Bovicelli 1986 reported the results of his study in a letter to The Lancet. Transcervical CVS was performed using a flexible 16gauge silver cannula. The transabdominal procedure was carried out with a double-needle system with an 18-gauge guide needle and an aspiration needle of gauge 21. Tomassini 1988 was a single centre trial from Varese (Italy) where 44 women were assigned to transcervical or transabdominal procedure by "random selection". Denmark 1992 randomised women at high genetic risk to either transabdominal or transcervical CVS.

(5) Early amniocentesis versus transabdominal CVS

Five completed randomised controlled trials have been identified so far.

The trial from Uppsala, Sweden by Cederholm and Axelsson (Uppsala 1997) randomised 86 women to early amniocentesis or CVS. The data for 86 randomised women are 'lumped together' with the data for 235 women who selected the procedure 'by choice'. We are therefore, at present, unable to include the randomised data set in the intention-to-treat analysis.

NICHD EATA Group Trial (NICHD EATA 2004) was a large multicentre collaborative study carried out between 1997 and 2001 under the auspices of the US National Institute of Child Health and Human Development and Centre for Evaluation and Health Technology Assessment of the Danish National Board of Health. The trial randomised 3775 women from 3803 eligible women who consented to participation in a total group of 6370 women who were screened for eligibility. Eighty-seven per cent of the women were randomised at Rigshospitalet, Denmark, 7% at 11 U.S. centres, and 6% at two Canadian centres. In the early amniocentesis group, a 22-gauge spinal needle was used and 1 ml of amniotic fluid aspirated for each week of a pregnancy. In the CVS group, a single- (19- to 20-gauge) or double-needle technique (18to 20-gauge) was used with the larger 'guide' needle introduced to the margin of the chorion, followed by the sample needle passing through the guide needle into the villi. To participate in the trial, operators were required to have completed at least 25 amniocenteses and 25 transabdominal CVS between 77 and 104 days of gestation. Thirty-two operators were certified to perform procedures at the 14 clinical centres. Two sampling passes were allowed. A second procedure, if required, could only be performed seven days after the first attempt.

In the King's 1996 and the Leiden 1998 trials, recruited women were given the choice between early amniocentesis, transabdominal CVS or randomisation. In the King's 1996 trial, 37% opted for randomisation (555/1492), 38% for early amniocentesis (562/1492), and 25% for CVS (375/1492). In the Leiden 1998 trial, 55% of women were randomised (115/210), 33% chose early amniocentesis and 12% chose CVS.

The procedure for transabdominal CVS was similar in three included trials. King's 1996 and Leiden 1998 used a 20-gauge needle. The tip of the needle was moved 5 to 10 times while applying negative pressure by manual aspiration through a 20-ml syringe. In the Copenhagen 1997 trial, a double-needle technique was used with a guide needle of 1.2 mm (18-gauge) and an aspiration needle of 0.8 mm (21-gauge).

There were important differences in the early amniocentesis technique used in Copenhagen 1997 compared to King's 1996 and Leiden 1998. In Copenhagen 1997, the filter system was used which allowed re-injection of the majority of the entire aspirated volume back into the amniotic cavity. Early amniocentesis in the King's 1996 and the Leiden 1998 trials was done by straightforward aspiration of 11 ml of amniotic fluid, of which the first 1 ml was discarded. King's 1996 and Leiden 1998 used a 20-gauge and a 22-gauge needle, respectively.

(6) Use of ultrasound

Nolan 1981 compared ultrasound directed taps with taps without benefit of ultrasound scans. Amniocenteses in the 'experimental' group were not 'ultrasound-guided' in the true meaning of this term. Today, the term 'ultrasound guided procedure' is used to describe needle insertion under simultaneous ultrasound guidance using either 'freehand' technique or a needle guide mounted on the ultrasound probe. In the study by Nolan 1981, scans were performed before the procedure with the main aim to inform the operator on the placental position. The physician who had benefit of the ultrasound report made attempts to avoid the placenta. In the control group, the physician selected "what was considered the best site for introduction of the needle".

Risk of bias in included studies

(I) Second trimester amniocentesis versus control

The trial by Tabor 1986 is of high quality and remains a gold standard in the field of fetal medicine. For the majority of women, a secretary using a table of random numbers did randomisation. Some women were randomised using sequentially numbered sealed envelopes. The compliance with allocated procedure was 98.3% in the study group. Only 22 women in the control group had an amniocentesis (1%). Most procedures were performed at or beyond 16 weeks' gestation; 17% of amniocenteses were performed at 15 weeks' gestation and 3.6% at earlier gestations.

(2) Early versus second trimester amniocentesis

Given the size of the study (N = 4374), CEMAT 1998 had a very high follow-up rate (99.2%). In the early amniocentesis group, 87.8% of the procedures were performed before 13+0 weeks of gestation. Only 3.5% of women had 'early amniocentesis' after 14+0 weeks. Most mid-trimester amniocenteses were performed between 15+0 and 15+6 weeks (68.8%) with 10.3% before 15 weeks and 0.8% before 14 weeks.

(3) CVS versus second trimester amniocentesis

Randomisation was organised by telephone in all four trials (Borrell 1999; Canada 1992; Denmark 1992; MRC 1991), apart from the Finnish arm of the MRC trial (MRC (Finland) 1993), where sequentially numbered sealed envelopes were used. The outcome of pregnancy is reported for all women in the Canada 1992 trial, 99% of women in the MRC 1991 trial, and 93% in the Denmark 1992 trial.

Denmark 1992 had quite a complex three-arm design with the amniocentesis arm performed only in 'low-risk' women. Among women designated as low risk, 3302 women took part in the direct comparison between transabdominal CVS (N = 1076), transcervical CVS (N = 1068) and amniocentesis (N = 1158) and a

further 897 in the comparison between two CVS techniques (493 high-risk and 404 low-risk women). Two reports from this trial were published after the randomisation was stopped in November 1990, with a marked difference in the total number of randomised women (3407 in the report published in *Ultrasound in Obstetrics and Gynaecology* and 4199 women in *The Lancet*). For the comparison between CVS and amniocentesis only, the data on total pregnancy loss have been reported according to 'intention to treat'. The type of pregnancy loss has been reported only for subgroups of women who completed the study (93.2%).

There was a significant dropout rate in Borrell 1999 (33.5%) due to pre-procedure miscarriages and failure to attend allocated procedure. Also, 43 women in the CVS group and seven women in the amniocentesis groups changed the allocated procedure and were excluded from the final analysis. This resulted in an uneven number of women for whom the outcome of pregnancy was reported (314 with CVS and 358 with amniocentesis). A large and uneven dropout rate may be a source of significant bias and data from this trial have to be interpreted with caution.

None of the trials was designed to assess the diagnostic accuracy of prenatal testing adequately. A complete follow up of all randomised pregnancies with cytogenetic confirmation would be necessary to determine the accurate number of false positive and false negative results.

Due to the different timing of the tested procedures, adequate blinding of women, investigators and outcome assessors was virtually impossible. However, the type of main outcome measures makes significant bias unlikely.

(4) CVS trials

USNICHD 1992 included only women in whom placental position allowed both transabdominal and transcervical approach. Around 70% of potentially eligible women were excluded because of placental position, thus reducing external validity (generalisability) of this study. The description of the randomisation procedure has not been included in the trial reports of USNICHD 1992. The outcome data were not presented for women in whom sampling was not attempted (3.2%). For the majority of important clinical outcomes including type of pregnancy loss, intention-totreat analysis is not possible because the data were presented only for women with genetically normal pregnancies (91.5%).

Brambati 1991 used telephone randomisation and excluded 38 women after randomisation (3.2%) because of non-viable pregnancies at the time of sampling.

A full assessment of the trial by Bovicelli 1986 is limited, because the study is reported only as a brief letter to *The Lancet*. Women were "randomly assigned" to transcervical or transvaginal CVS.

(5) Early amniocentesis versus CVS

NICHD EATA 2004 aimed to recruit 6200 cytologically normal pregnancies in order to detect possible 50% increase in pregnancy loss following early amniocentesis. The study failed to reach prespecified sample size within the funding period, in part because of a change in the eligibility criteria. Initially the procedures were to be performed between 11 and 14 weeks (77 to 104 days). However, protocol revisions first eliminated week 11 (before recruitment began), and subsequently week 12 after reports indicated an increased risk of talipes equinovarus after early amniocentesis in those weeks. Thus, more than 90% of the procedures were performed at 13 to 14 weeks (91 to 104 days).

Three other included studies (Copenhagen 1997; King's 1996; Leiden 1998) were also stopped before the intended sample size was reached. King's 1996 aimed to recruit 4400 women. However, by March 1993 recruitment was collapsing because of "...widespread publicity that CVS

can cause fetal limb abnormalities and is associated with a high risk of spontaneous abortion, and that non-invasive screening by ultrasonography and maternal serum biochemistry can provide sufficient reassurance to avoid invasive testing". The final report of the trial published in 'Fetal Diagnosis and Therapy' in 1996 stated that 840 women had early amniocentesis (278 after randomisation) and 652 women had CVS (277 after randomisation). Leiden 1998 was stopped after the interim data analysis that was prompted by the first report of the King's 1996 trial in *The Lancet* in 1994. Copenhagen 1997 aimed to recruit more than 3000 women in each group. The combination of slow recruitment and observed clustering of talipes equinovarus cases in the early amniocentesis group prompted the trialists to stop the trial early.

NICHD EATA 2004 used adequate concealment of allocation - telephone randomisation interactive voice response computerbased system. According to our prespecified criteria, Copenhagen 1997 and Leiden 1998 also used adequate concealment of allocation, i.e. central telephone randomisation and consecutively-numbered sealed envelopes, respectively. The randomisation method used in King's 1996 (sealed envelopes that are not numbered sequentially) is known to be a potential source of biased allocation. Sequential numbering aims to prevent manipulation of the schedule of random assignment by those recruiting participants to the trial. In the King's 1996 trial, potentially eligible women were excluded because of increased fetal nuchal translucency thickness (an anatomical marker of chromosomal abnormality).

Again, as in the above comparisons adequate blinding of women, investigators and outcome assessors was not possible. Analysis on all randomised women (intention-to-treat) was available for all principal measures of outcome. The percentage of women who received the allocated intervention varied significantly ranging from 100% in the King's 1996 trial and 95% (1103/1160) in the Copenhagen 1997 trial to 90% (104/115) in the Leiden 1998 trial. Unfortunately, in the Leiden 1998 trial the number of women who did not receive the intervention according to allocation was not evenly distributed between the groups. In the early amniocen-

tesis group, all 55 women had amniocentesis (one was done in the mid-trimester). In the other group seven women randomised to transabdominal CVS received early amniocentesis and three transcervical CVS. Two women randomised to CVS, who in fact had early amniocentesis, suffered early pregnancy loss.

(6) Ultrasound assisted amniocentesis

It was not possible to ascertain the method of randomisation in the study by Nolan 1981. Judging from the number of randomised women (112 versus 111) and the placental position, the groups appear to be well balanced. Ultrasound was performed in both groups, but revealed only in the experimental group. A scan report was, however, revealed in 14 cases in the control group (12.6%). The type of ultrasound-assisted amniocentesis used in this trial is nowadays considered obsolete.

One of the common criticisms of Cochrane reviews with included trials that span over several decades is the lack of relevance of earlier studies on the current clinical practice. One of our peer reviewers commented that earlier studies like MRC 1991 were undertaken when CVS was being developed as a technique, i.e. practitioners were on their learning curve. This is certainly one of the possible sources of heterogeneity. However, in everyday practice women will always be exposed to operators with varying degrees of skills and experience and data from very skilled and experienced operators have also limited external validity (generalisibility).

Effects of interventions

(I) Second trimester amniocentesis versus control

The study by Tabor 1986 provides the best estimate of an excess pregnancy loss in low-risk women caused by amniocentesis. An increase of 1% in total pregnancy loss (3.2% versus 2.2%) does not reach statistical significance, but an increase in spontaneous miscarriages of 0.8% (2.1% versus 1.3%) is statistically significant (RR 1.60; 95% CI 1.02 to 2.52). However, it is important to note that 95% CI for absolute risk difference ranges from 0% to 2% for both outcomes. There was no difference in vaginal bleeding between the two groups, but amniotic fluid leakage was more common after amniocentesis (1.7% versus 0.4%; RR 3.90; 95% CI 1.95 to 7.80).

(2) Early versus second trimester amniocentesis

Compared to an early amniocentesis, mid-trimester procedure is safer and technically less demanding. Total pregnancy loss after early amniocentesis was significantly higher (RR 1.29; 95% CI 1.03 to 1.61) and the number of congenital anomalies was also significantly increased in the early amniocentesis group. In particular the number of babies with talipes equinovarus was higher in the CEMAT 1998 trial (1.3% versus 0.09%). If one restricts the analysis to women who actually had early amniocentesis ('on treatment' analysis) the risk of talipes is even higher.

Early amniocentesis required more multiple needle insertions compared with mid-trimester amniocentesis. Early amniocente-

sis was also more demanding for cytogeneticists with 1.8% laboratory failures after early procedure and only 0.2% after midtrimester amniocentesis. There were three known false negative cytogenetic results in the early amniocentesis group and none after mid-trimester amniocentesis. Two reports resulted in the incorrect information with regard to the sex chromosomes, and in one case a very subtle chromosome abnormality at the terminal end of chromosome one was missed and detected postnatally. Interestingly, a false positive rate was reported to be 3.6% for early amniocentesis and 8% for mid-trimester amniocentesis. The actual numbers could not be extracted from the trial reports, so this outcome is not shown in the outcome table. It appears that most of these false positive results were so called 'pseudomosaics' not reported to the physicians.

(3) Transabdominal or transcervical CVS versus second trimester amniocentesis

3.1. Transcervical CVS versus second trimester amniocentesis

Four trials compared transcervical CVS with second trimester amniocentesis (Borrell 1999; Canada 1992; Denmark 1992; MRC (Finland) 1993). Total pregnancy loss was consistently higher after transcervical CVS (RR 1.40; 95% CI 1.09 to 1.81). In the transcervical CVS group the total pregnancy loss varied from 7.3% in the MRC (Finland) 1993 trial to 19.5% in the Borrell 1999 trial. Interestingly, the statistical test for heterogeneity was significant despite the fact that the results look quite similar in terms of the size and direction of the observed differences in total pregnancy loss. However, overall difference is statistically significant even when more conservative random-effects model is used for analysis. The sensitivity analysis suggests that the heterogeneity is caused by the differences between the two largest trials (Canada 1992; Denmark 1992). The increase in pregnancy loss after transcervical CVS in the Denmark 1992 trial was statistically significant (95% CI 1.30 to 2.22), but not in the Canada 1992 trial (95% CI 0.92 to 1.30). Unsurprisingly, spontaneous miscarriages were the main contributor to the pregnancy loss in all four trials.

3.2. Transabdominal CVS versus second trimester amniocentesis

A subgroup of Denmark 1992 compared transabdominal CVS with second trimester amniocentesis and found no significant difference in the total pregnancy loss between the two procedures (6.3% versus 7%; RR 0.90; 95% CI 0.66 to 1.23).

3.3. CVS by any route versus second trimester amniocentesis

Two trials presented data that allowed the comparison between CVS performed by any route and mid-trimester amniocentesis (Denmark 1992; MRC 1991). Overall loss was higher after CVS and this difference was statistically significant (RR 1.43; 95% CI 1.22 to 1.67). Again, an increase in spontaneous miscarriages after CVS was the main contributing factor (RR 1.51; 95% CI 1.23 to 1.85).

Overall, the test had to be repeated more commonly after transcervical CVS compared with second trimester amniocentesis. Also, there were more problems in analysing placental tissue obtained from CVS compared with amniotic fluid analysis. In the transcervical CVS group, laboratory failure occurred in 1.7% cases compared with only 0.07% after amniocentesis; there were also more cytogenetic abnormalities confined only to placenta and more false positive and false negative results. However, cytogenetic results presented here should be interpreted with caution. They probably underestimate the true incidence of inaccurate results in both the CVS and amniocentesis groups because the majority of fetal losses were not karyotyped post-mortem, either because of technical difficulties or concerns about medico-legal implications. The lack of complete cytogenetic follow up in all trials makes unbiased analysis on all randomised women impossible.

Complications were uncommon after both procedures and there were no reports that these were ever life-threatening. Vaginal bleeding following the procedure was much more common after transcervical CVS, although there was no difference in the incidence of vaginal bleeding later in pregnancy. There was no significant difference in the amniotic fluid leakage following the procedure and prelabour spontaneous rupture of membranes before 28 weeks in MRC 1991, but this observation should be interpreted cautiously because data on ruptured membranes are missing for large numbers of women. Interestingly, one participating centre (MRC (Finland) 1993) reported significant increase in ruptured membranes after transcervical CVS. No differential effect was detected on antenatal admission to hospital.

In the sub-project of the Canada 1992 trial, Spencer and Cox (Spencer 1987; Spencer 1988) and Robinson (Robinson 1988) compared the psychological effects of transcervical CVS and amniocentesis. In mid-pregnancy, women allocated to amniocentesis were more anxious, and felt less attachment to their babies, although by 22 weeks these differences seemed to have disappeared. (Data are not available in a form suitable for inclusion in a metaanalysis.) Nevertheless, at 22 weeks there was a suggestion of a persistent differential effect manifested in a decreased desire for another child associated with amniocentesis (7/26 in the CVS group compared with 13/25 after amniocentesis).

Possible links between CVS, amniocentesis and congenital anomalies could not be explored fully because of incomplete reporting and relatively small number of participants. There have been several reports in the past suggesting the presence of congenital anomalies (limb deformities in particular) in infants exposed to CVS in the first trimester. The available data from included randomised trials do not support this observation. However, it must be remembered that the relationship may be gestation-dependent. The majority of procedures were carried out after nine weeks' gestation and therefore do not address the possibility that CVS carried out very early in pregnancy may increase the risk of congenital abnormalities.

(4) Transbdominal versus transcervical CVS

Compared with transabdominal CVS, total pregnancy loss and spontaneous miscarriages were higher after transcervical CVS, but this was due to the excess loss in the transcervical arm of the Denmark 1992 trial. This trial (Denmark 1992) reported total pregnancy loss after transcervical CVS of 12.4% compared with 7.4% after transabdominal CVS. Corresponding figures for spontaneous pregnancy loss were 8.2% and 3%. However, total pregnancy loss and miscarriage rate in four other trials (Bovicelli 1986; Brambati 1991; Tomassini 1988; USNICHD 1992) were almost identical in both groups. Because of these differences, the tests for heterogeneity for these two outcomes were statistically significant (I² = 72.3%). When the fixed-effect model is used to summarise the results for these two outcomes, transabdominal CVS is associated with a significant reduction in total pregnancy loss (RR 1.23; 95% CI 1.06 to 1.42) and spontaneous miscarriage (RR 1.75; 95% CI 1.33 to 2.29). However, in the presence of heterogeneity it is prudent to apply a more conservative random-effects model. When we applied this statistical model, the differences in pregnancy loss and miscarriage between transabdominal and transcervical CVS were not statistically significant any more.

Congenital anomalies were reported only in two studies (Brambati 1991; Denmark 1992;) but the numbers are too small for meaningful comparisons.

Transcervical CVS was more likely to fail, although there was a disproportionate contribution of the data from USNICHD 1992 (weight 91%). Transcervical CVS appears to be more technically demanding, requiring more multiple insertions and causing more vaginal bleeding. As far as cytogenetic analysis is concerned, both procedures are comparable.

(5) Early amniocentesis (EA) versus transabdominal CVS

Although the difference in combined total pregnancy did not reach statistical significance (RR 1.15; 95% CI 0.86 to 1.54), there were more spontaneous miscarriages after early amniocentesis (RR 1.76; 95% CI 1.17 to 2.64).

There was no difference in the overall incidence of anomalies in the newborn infants (RR 1.14; 95% CI 0.57 to 2.30). However, interstudy heterogeneity was significant for this outcome, with no obvious explanation for the observed differences between Copenhagen 1997 and Leiden 1998. Both groups have specifically highlighted two types of anomalies: talipes equinovarus and haemangiomas. The incidence of talipes in the EA group was 0.9% compared with 0.1% in the CVS group (RR 4.61; 95% CI 1.82 to 11.66).

An increased number of haemangiomas after CVS seen in Leiden 1998 has not been seen in the other two studies (RR 0.87; 95% CI 0.69 to 1.10). Only the Leiden Trial reported long-term follow up of randomised infants, and none of them had abnormal results on the Dutch version of the Denver Developmental Screening Test when visited at home between six and nine months of age. Transabdominal CVS appears to be more technically demanding, with more technical difficulties during the procedure, i.e. sampling failure, multiple insertions and need for second test. However, the overall incidence of these complications was low. There were no statistically significant differences in the rate of laboratory failures or number of women with various chromosomal abnormalities. However, the numbers are too small for any meaningful comparison between two methods.

In Copenhagen 1997, the EA samples required a mean of 9.5 days (range 5 to 19) for culturing compared to 6.1 days (range 4 to 14) for the CVS samples. In the Leiden 1998 trial, the mean culture time in the EA group was 13.8 days for the Amniomax culture and 15.6 for the Chang culture compared to eight days in the CVS group. In the NICHD EATA 2004 EA, 10.3 days were needed to obtain the result (standard deviation (SD) 2.5), compared with 6.3 days (SD 3). These results were not pooled because they were not normally distributed.

(6) Ultrasound guided amniocentesis

The trial by Nolan 1981 evaluated the type of ultrasound assisted procedure that is nowadays considered obsolete (i.e. this was not an ultrasound-guided procedure in the true meaning of this term). There were no differences in the reported outcomes, but the study

Type of fetal loss	Combined Total	Combined %	95% CI
Less than 20 weeks of preg- nancy	22/2133	1.1	0.7-1.5
More than 20 weeks of preg- nancy	17/1775	0.9	0.5-1.4
Less than 24 weeks of preg- nancy	122/14057	0.9	0.6-1.3
More than 24 weeks of preg- nancy	57/4195	1.0	0.5-1.8
Less than 28 weeks of preg- nancy	283/14915	1.7	1.3-2.2
More than 28 weeks of preg- nancy	134/14596	0.9	0.7-1.2

Table 1. Complications after amniocentesis

was too small to assess the true impact of the placental localisation by ultrasound before the needle insertion.

DISCUSSION

The best estimate of an 'excess' risk after second trimester amniocentesis comes from Tabor 1986. In a low-risk population with a background pregnancy loss of around 2%, a mid-trimester amniocentesis will increase this risk by another 1%. Despite relatively large numbers of randomised women (4606) in Tabor 1986, such an increase in total pregnancy loss did not reach statistical difference, with confidence intervals for an excess pregnancy loss ranging from almost 0 to 2%. How robust are these figures and should they be used for routine counselling? It is unlikely that a trial of similar size and quality will ever be repeated. In the absence of other randomised data, therefore, any written or oral information for women considering second trimester amniocentesis should include the data from Tabor 1986. A systematic review of studies published after 1995 revealed lower absolute risks of pregnancy loss (Table 1) (Mujezinovic 2007). It is impossible to say if observed differences are random variations, or true improvement in the safety of the procedure in the last decade.

Less than 14 days after AC	102/17047	0.6	0.5-0.7
Less than 30 days after AC	85/10727	0.8	0.4-1.2
Less than 60 days after AC	66/9406	0.7	0.5-0.9
Total pregnancy loss	627/49413	1.9	1.4-2.5
Multiple insertions	226/12142	2.0	0.9-3.6

 Table 1. Complications after amniocentesis
 (Continued)

The benefits of earlier diagnosis of fetal genetic abnormalities by chorionic villus sampling (CVS) must be set against possible higher risks of pregnancy loss and diagnostic inaccuracies when compared with second trimester amniocentesis. Unfortunately, the data related to the risk of pregnancy loss following CVS and amniocentesis are inconsistent. Second trimester amniocentesis was consistently safer than transcervical CVS, whilst Denmark 1992 showed no clinically significant difference in the pregnancy loss between transabdominal CVS and second trimester amniocentesis. One would therefore expect a clear benefit of transabdominal CVS in the 'head to head' comparisons with transcervical CVS. Unfortunately, the data are quite heterogeneous; for example, Denmark 1992 showed expected benefits of transabdominal CVS, but other trials did not. It is likely that operator skill and preferences played an important role in these studies. It is unrealistic to expect that any given operator will be equally skilled and experienced in all three methods. The question whether any added risks of early procedures, transcervical CVS in particular, disappear in the hands of skilled operators remains one of the main controversies of fetal medicine. In most included trials, the operators were required to perform at least 20 successful early procedures in order to participate. Some performed thousands successfully and therefore, undoubtedly, the experience between operators varied. Interestingly, in the MRC 1991 trial, there was no clear evidence that individual operators' performance improved with more experience over the course of the study.

Women who request early diagnostic procedures (e.g. because of religious or personal prohibitions on later pregnancy termination, or because of a very high risk of fetal abnormalities) should be counselled about the relative risks of the various options. Concern about the safety and diagnostic accuracy of the first trimester CVS has led some clinicians to advocate early amniocentesis. Somewhat unexpectedly, the preliminary data from the King's 1996 and Leiden 1998 trials suggested an important increase in pregnancy loss following early amniocentesis, both before and after fetal viability. However, pooled data from the final reports of these two trials and Copenhagen 1997 are not so conclusive. Although the increase in spontaneous miscarriages after early amniocentesis remains statistically significant, the difference in total pregnancy loss is not (3.5% versus 3.0%, RR 1.15; 95% CI 0.86 to 1.54). In order to test the hypothesis that the total pregnancy loss after early amniocentesis is, indeed, 0.5% higher compared with CVS, around 40,000 women would need to be recruited (power 80%, confidence level 95%). Such a trial is likely to be considered unethical given the causal relationship between early amniocentesis and talipes (*see* below).

As far as CVS is concerned, transabdominal CVS appears to be safer than the transcervical route. However, this observation is heavily influenced by the data from Denmark 1992. Increase in pregnancy loss following transcervical procedure has not been replicated in four other direct comparisons between transcervical and transabdominal procedures (Bovicelli 1986; Brambati 1991; Tomassini 1988; USNICHD 1992). Transcervical approach does require multiple insertions more often and causes vaginal bleeding in approximately 10% of cases. The subgroup analysis from Denmark 1992 showed no differential effect on the pregnancy loss between transabdominal CVS and mid-trimester amniocentesis. It would be reassuring if the results achieved by Smidt-Jensen and colleagues could be replicated by other centres (71% of all procedures in the Denmark 1992 trial were performed by Smidt-Jensen himself). The results of the systematic review of observational studies (Mujezinovic 2007) are broadly consistent with the randomised data (Table 2).

Table 2.	Complications	after	chorionic	villus	sampling
----------	---------------	-------	-----------	--------	----------

Type of fetal loss	Combined total	Combined proportions	95% CI
Less than 20 weeks of preg- nancy	8/555	1.5	0.7-2.7
More than 20 weeks of preg- nancy	4/555	0.8	0.2-1.7
Less than 22 weeks of preg- nancy	11/665	1.7	0.9-2.9
More than 22 weeks of preg- nancy	3/665	0.5	0.1-1.2
Less than 24 weeks of preg- nancy	44/3402	1.3	1.0-1.7
More than 24 weeks of preg- nancy	3/1775	0.2	0.03-0.5
Less than 28 weeks of preg- nancy	229/12462	2.0	1.0-3.0
More than 28 weeks of preg- nancy	17/10144	0.2	0.1-0.3
Less than 14 days after CVS	5/852	0.7	0.3-1.4
Less than 30 days after CVS	7/607	1.3	0.5-2.3
Less than 60 days after CVS	4/169	2.6	0.8-5.6
Less than 6 weeks after CVS	4/169	2.6	0.8-5.6
Total pregnancy loss	566/24457	2.0	1.4-2.6
Multiple insertions	1324/15693	7.8	3.1-14.2

The question about diagnostic accuracy of prenatal testing remains unanswered, and our hypothesis that both CVS and amniocentesis are equally accurate remains untested because of incomplete follow up. Having said that, we do acknowledge the ethical and potential medico-legal problems in trying to obtain adequate cytogenetic follow up on all randomised women. A higher incidence of abnormal karyotypes is to be expected in the CVS group because of possible spontaneous loss of pregnancies with abnormal karyotype that occur between randomisation and a mid-trimester amniocentesis group. With this proviso, the available data suggest that accurate diagnosis is more likely following second trimester amniocentesis. Abnormalities confined to placenta (placental mosaics) pose a particular problem for women who opt for CVS. Although the absolute numbers are small, both false positive and false negative results have such a devastating effect that observed differences should not be ignored.

Another area of concern is the possibility of a causal relationship

between some fetal abnormalities and invasive procedures in early pregnancy. The difference in the incidence of congenital anomalies observed after early amniocentesis and CVS was not statistically significant (4.4% versus 3.8%). However, an increased incidence of talipes equinovarus after early amniocentesis has been specifically highlighted, with 24/2612 cases in the early amniocentesis group compared to only 5/2693 cases in the CVS group (RR 4.61; 95% CI 1.82 to 11.66). Early amniocentesis enthusiasts may argue that the possibility of ascertainment bias needs to be borne in mind when the data from unblinded trials are interpreted. However, it would be virtually impossible to blind women and clinicians to the type of invasive prenatal test actually carried out because the type and handling of the obtained tissue (amniotic fluid or chorionic villi) are distinctly different. Under those circumstances, one may look harder for certain type of anomalies, i.e. talipes, in babies known to have early amniocentesis, and not record them when causation is unlikely (after CVS). In our view the above data are compelling and every effort should be made that amniocentesis is not performed before 15 weeks' gestation.

Observational data have suggested an increased incidence of haemangiomas in infants born following chorionic villus sampling (Burton 1995). Like a risk of oromandibular/limb hypogenesis and isolated limb disruption defects (NICHHD 1993), the association with CVS remains controversial. Plausible mechanisms include transient fetal hypoperfusion secondary to bleeding into the sampling site and/or the release of vasoactive substances from the placenta causing vasoconstriction or haemorrhage in the fetus. It is reassuring that there were no reported oromandibular limb hypoplasias in the three trials, which may reflect the fact that all procedures were done after nine weeks' gestation. Also, a small increase in the haemangiomas after CVS was not statistically significant.

AUTHORS' CONCLUSIONS

Implications for practice

Parents considering prenatal diagnosis must be fully informed about the risks and benefits of the alternative procedures before they make a choice. Second trimester amniocentesis is safer than early amniocentesis or transcervical chorion villus sampling (CVS). If earlier diagnosis is required, transabdominal CVS is preferable to early amniocentesis or transcervical CVS.

Although CVS technique is more likely to result in an ambiguous result, the diagnostic accuracy of different methods could not be assessed adequately because of incomplete karyotype data in most studies.

Implications for research

New methods of prenatal diagnosis should be rigorously evaluated before deciding whether they should be introduced into clinical practice. Measures of outcome must include total pregnancy loss (antenatal and neonatal), detailed description of anomalies, diagnostic accuracy, and women's views of the alternative procedures. Ascertainment bias should be reduced as much as possible, i.e. neonatal assessors should be blinded to the allocated procedure.

ACKNOWLEDGEMENTS

We are grateful to Sarah Ayers from the National Perinatal Epidemiology Unit in Oxford for providing unpublished data from the MRC 1991 and MRC (Finland) 1993 trials and to Frank Vandenbussche and Helen Nagel for useful additional information and unpublished data from Leiden 1998. Earlier drafts of this review were improved following useful comments by Amy Durban (USA) and Gill Gyte (UK) who were our consumer referees; Professor Martin Whittle who was one of the peer reviewers; and Simon Gates, statistical adviser to the Cochrane Pregnancy and Childbirth Group.

Sara Brigham who extracted data and co-wrote the first version of this review.

As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team) and the Group's Statistical Adviser.

References to studies included in this review

Borrell 1999 {published data only}

Borrell A, Fortuny A, Lazaro A, Costa D, Seres A, Pappa S, et al. Firsttrimester transcervical chorionic villus sampling by biopsy forceps versus mid-trimester amniocentesis: a randomized controlled trial project. *Prenatal Diagnosis* 1999;**19**:1138–42.

Bovicelli 1986 {published data only}

Bovicelli L, Rizzo N, Montacuti V, Morandi R. Transabdominal vs transcervical routes for chorionic villus sampling. *Lancet* 1986;**2**: 290.

Brambati 1991 {published data only}

Brambati B. Advantages and risks of transcervical and transabdominal CVS methods [abstract]. Proceedings of 11th European Congress of Perinatal Medicine; 1988 April 10-13; Rome, Italy. 1988:141. Brambati B, Oldrini A, Lanzani A, Terzian E, Tognoni G. Transabdominal vs transcervical chorionic villus sampling: a randomized trial [abstract]. *Human Reproduction* 1988;**3**:811–3.

* Brambati B, Terzian E, Tognoni G. Randomized clinical trial of transabdominal vs transcervical chorionic villus sampling methods. *Prenatal Diagnosis* 1991;**11**:285–93.

Canada 1992 {published data only}

* Collaborative. Canadian multi-centre randomized clinical trial of chorion villus sampling and amniocentesis: first report. *Lancet* 1989; **1**:1–6.

Feeny D, Townsend M, Furlong W, Tomkins DJ, Robinson GE, Torrance GW, et al.Health-related quality-of-life assessment of prenatal diagnosis: chorionic villi sampling and amniocentesis. *Genetic Testing* 2002;**6**:39–46.

Hamerton JL. Chorionic villus sampling vs amniocentesis. *Lancet* 1989;**1**:678.

Kaplan P, Normandin JJ, Wilson GN, Plauchu H, Lippman A, Vekemans M. Malformations and minor anomalies in children whose mothers had prenatal diagnosis: comparison between CVS and amniocentesis. *American Journal of Medical Genetics* 1990;**37**(3):366– 70. [MEDLINE: 2260567]

Lippman A, Tomkins DJ, Shima J, Hamerton JL. Canadian multicentre randomized clinical trial of chorion villus sampling and amniocentesis. *Prenatal Diagnosis* 1992;**12**:385–408.

Muggah H, Hunter AGW, Ivey B, Cox DM. Difficulties encountered in a randomization trial of CVS vs amniocentesis for prenatal diagnosis. *Clinical Genetics* 1987;**32**:235–9.

Robinson GE, Carr ML, Olmsted MP, Wright C. Psychological reactions to pregnancy loss after prenatal diagnostic testing: preliminary results. *Journal of Psychosomatic Obstetrics and Gynaecology* 1991;**12**: 181–92.

Robinson GE, Garner DM, Olmsted MP, Shime J, Hutton EM, Crawford BM. Anxiety reduction after chorionic villus sampling and genetic amniocentesis. *American Journal of Obstetrics and Gynecology* 1988;**159**:953–6.

Spencer JW, Cox DN. A comparison of chorionic villi sampling and amniocentesis: acceptability of procedure and maternal attachment to pregnancy. *Obstetrics & Gynecology* 1988;**72**:714–8.

Spencer JW, Cox DN. Emotional responses of pregnant women to chorionic villi sampling or amniocentesis. *American Journal of Ob-* stetrics and Gynecology 1987;157:1155-60.

CEMAT 1998 {published data only}

* Collaborative. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. The Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group. *Lancet* 1998; **351**(9098):242–7.

Farrell SA, Summers AM, Dallaire L, Singer J, Johnson JA, Wilson RD. Club foot, an adverse outcome of early amniocentesis: disruption or deformation? CEMAT. Canadian Early and Mid-Trimester Amniocentesis Trial. *Journal of Medical Genetics* 1999;**36**:843–6.

Johnson J, Wilson R. CEMAT (Canadian early (EA) vs. midtrimester (MA) amniocentesis trial) prospective randomized evaluation: amniocentesis procedure details [abstract]. *American Journal of Obstetrics and Gynecology* 1998;**178**(1):22.

Johnson JM, Wilson RD, Singer J, Winsor E, Harman C, Armson BA, et al. Technical factors in early amniocentesis predict adverse outcome. Results of the Canadian early (ea) versus mid-trimester (ma) amniocentesis trial. *Prenatal Diagnosis* 1999;**19**:732–8.

Johnson JM, Wilson RD, Winsor E, Kalousek D, Soanes S, Sorensen S, et al. The early amniocentesis study: a randomized clinical trial of early amniocentesis vs mid-trimester amniocentesis [abstract]. *International Journal of Gynecology & Obstetrics* 1994;**46**:41.

Johnson JM, Wilson RD, Winsor EJ, Singer J, Dansereau J, Kalousek DK. The early amniocentesis study: a randomized clinical trial of early amniocentesis versus midtrimester amniocentesis. *Fetal Diagnosis and Therapy* 1996;**11**(2):85–93.

Robinson GE, Johnson JAM, Wilson RD, Gajjar M. Anxiety reduction after early and mid-trimester prenatal diagnostic testing. *Archives* of Women's Mental Health 1998;1:39–44.

Wilson R. CEMAT (Canadian early (EA) vs. midtrimester (MA) amniocentesis trial) prospective randomized evaluation: final primary results [abstract]. *American Journal of Obstetrics and Gynecology* 1998;**178**(1 Pt 2):2.

Wilson RD, Johnson J, Windrim R, Dansereau J, Singer J, Winsor EJ, et al. The early amniocentesis study: a randomized clinical trial of early amniocentesis and midtrimester amniocentesis. II. Evaluation of procedure details and neonatal congenital anomalies. *Fetal Diagnosis and Therapy* 1997;**12**(2):97–101.

Winsor E, Tomkins D, Lalousek D, Farrell S, Wyatt P, Fan YS. Cytogenetic aspects of the Canadian early and mid-trimester amniotic fluid trial (CEMAT). *Prenatal Diagnosis* 1999;**19**:620–7.

Winsor E, Wilson R. CEMAT (Canadian early (EA) vs. midtrimester (MA) amniocentesis trial) prospective randomized evaluation: Comparison of amniotic fluid culture characteristics between EA and MA [abstract]. *American Journal of Obstetrics and Gynecology* 1998;**178** (1 Pt 2):26.

Copenhagen 1997 {published data only}

Sundberg K. Potential and problems with ultrasound in fetal diagnosis at 10-11 weeks and amniocentesis at 12 weeks. *Acta Obstetricia et Gynecologica Scandinavica Supplement* 1994;**73**(161):SP31.

* Sundberg K, Bang J, Smidt Jensen S, Brocks V, Lundsteen C, Parner J, et al.Randomised study of risk of fetal loss related to early amniocentesis versus chorionic villus sampling. *Lancet* 1997;**350**(9079): 697–703.

Sundberg K, Lundsteen C, Philip J. Comparison of cell cultures,

chromosome quality and karyotype obtained after CVS and early amniocentesis with filter technique. *Prenatal Diagnosis* 1999;**19**:12–6.

Denmark 1992 {published data only}

Smidt-Jensen S. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. *Geburtshilfe und Frauenheilkunde* 1993;**53**:822.

Smidt-Jensen S, Permin M, Philip J. Sampling success and risk by transabdominal chorionic villus sampling, transcervical chorionic villus sampling and amniocentesis: a randomized study. *Ultrasound in Obstetrics & Gynecology* 1991;**1**:86–90.

Smidt-Jensen S, Permin M, Philip J, Lundsteen C, Zachary J, Fowler S, et al.Randomized comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. *Lancet* 1992;**340**: 1237–44.

Smidt-Jensen S, Philip J. Comparison of transabdominal and transcervical CVS and amniocentesis: sampling success and risk. *Prenatal Diagnosis* 1991;**11**:529–37.

* Smidt-Jensen SL, Permin M, Philip J, Lundsteen C, Gruning K, Zachary J, et al.Amniocentesis, transabdominal and transcervical chorionic villus sampling compared in a randomised trial. *Ugeskrift for Laeger* 1993;**155**:1446–56.

King's 1996 {published data only}

Byrne D, Marks K, Azar G, Nicolaides K. Randomized study of early amniocentesis vs chorionic villus sampling: a technical and cytogenetic comparison of 650 patients. *Ultrasound in Obstetrics & Gynecology* 1991;**1**:235–40.

Greenough A, Yuksel B, Naik S, Cheeseman P, Nicolaides KH. Invasive antenatal procedures and requirement for neonatal intensive care unit admission. *European Journal of Pediatrics* 1997;**156**(7):550–2.

* Nicolaides K, de Lourdes Brizot M, Patel F, Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation. *Lancet* 1994;**344**:435–9.

Nicolaides KH, Brizot ML, Patel F, Snijders R. Comparison of chorion villus sampling and early amniocentesis for karyotyping in 1,492 singleton pregnancies. *Fetal Diagnosis and Therapy* 1996;**11** (1):9–15.

Thilaganathan B, Snijders R, Nicolaides K. Randomised study of chorionic villus sampling vs amniocentesis at 10-13 weeks gestation. *International Journal of Gynecology & Obstetrics* 1994;**46**:75.

Thompson PJ, Greenough A, Nicolaides KH. Lung function following first-trimester amniocentesis or chorion villus sampling. *Fetal Diagnosis and Therapy* 1991;**6**:148–52.

Thompson PJ, Greenough A, Nicolaides KH. Lung volume measured by functional residual capacity in infants following first trimester amniocentesis or chorion villus sampling. *British Journal of Obstetrics and Gynaecology* 1992;**99**:479–82.

Leiden 1998 {published data only}

Nagel HTC, Vandenbussche FPHA, Keirse MJNC, Oepkes D, Oosterwijk JC, Beverstock G, et al.Amniocentesis before 14 completed weeks as an alternative to transabdominal chorionic villus sampling: a controlled trial with infant follow-up. *Prenatal Diagnosis* 1998;**18** (5):465–75.

* Vandenbussche F, Kanhai H, Keirse M. Safety of early amniocentesis. *Lancet* 1994;**344**(8):1032.

MRC (Finland) 1993 {unpublished data only}

Ammala P, Hiilesmaa V, Teramo K, Koskul HV. Randomised trial comparing first trimester transcervical chorion villus sampling and second trimester amniocentesis. Proceedings of 13th World Congress of Gynaecology and Obstetrics (FIGO); 1991 Sept 15-20; Singapore. 1991:22.

* Ammala P, Hiilesmaa VK, Liukkonen S, Saisto T, Teramo K, von Koskull H. Randomized trial comparing first-trimester transcervical chorionic villus sampling and second-trimester amniocentesis. *Prenatal Diagnosis* 1993;**13**:919–27.

MRC 1991 {published data only}

Collaborative. Medical Research Council European trial of chorion villus sampling. *Lancet* 1991;**337**:1491–9.

NICHD EATA 2004 {published data only}

Philip J, NICHD EATA Study Group. Greater risk associated with early amniocentesis compared to chorionic villus sampling: an international randomized trial [abstract]. *American Journal of Obstetrics* and Gynecology 2002;**187**(6 Pt 2):S69.

* Philip J, Silver RK, Wilson RD, Thom EA, Zachary JM, Mohide P, et al.Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. *Obstetrics & Gynecology* 2004;**103** (6):1164–73. [MEDLINE: 15172848]

Philip J, Silver RK, Wilson RD, Thom EA, Zachary JM, Mohide P, et al.Late first-trimester invasive prenatal diagnosis--secondary publication. An international randomized trial [Invasiv prøvetagning ved prænatal diagnostik sent i første trimester – sekundærpublikation]. Ugeskrift for Laeger 2005;**167**(11):1293–6. [MEDLINE: 15830503]

Nolan 1981 {published data only}

Nolan GH, Schmickel RD, Chantaratherakitti P, Knickerbocker C, Hamman J, Louwsma G. The effect of ultrasonography on midtrimester genetic amniocentesis complications. *American Journal of Obstetrics and Gynecology* 1981;**140**:531–4.

Tabor 1986 {published data only}

Tabor A, Bang J, Norgaard-Pedersen B. Feto-maternal haemorrhage associated with genetic amniocentesis: results of a randomized trial. *British Journal of Obstetrics and Gynaecology* 1987;**94**:528–34.

* Tabor A, Madsen M, Obel EB, Philip J, Bang J, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 lowrisk women. *Lancet* 1986;1:1287–93.

Tabor A, Philip J. Incidence of fetal chromosome abnormalities in 2264 low-risk women. *Prenatal Diagnosis* 1987;7(5):355–62. [MEDLINE: 3303006]

Tomassini 1988 {published data only}

Tomassini A, Campagna G, Paolucci M, Ferrario D, Zarini E, Tibiletti MG, et al.Transvaginal CVS vs transabdominal CVS (our randomised cases). XI European Congress of Perinatal Medicine; 1988 April 10-13; Rome, Italy. 1988:1101–4.

USNICHD 1992 {published data only}

* Collaborative. Transcervical and transabdominal chorionic villus sampling are comparably safe procedures for first trimester prenatal diagnosis: preliminary analysis. *American Journal of Human Genetics* 1990;**47**:A278.

Jackson L, Zachary J, Fowler S, Desnick R, Golbus M, Ledbetter D, et al.A randomized comparison of transcervical and transabdominal chorionic-villus sampling. *New England Journal of Medicine* 1992; **327**:594–8.

References to studies excluded from this review

ARIA Trial 2006 {published data only}

* Hewison J, Nixon J, Fountain J, Cocks K, Jones C, Mason G, et al.Amniocentesis results: investigation of anxiety. The ARIA trial. *Health Technology Assessment* 2006;**10**(50):1–78. [MEDLINE: 17134598]

Hewison J, Nixon J, Fountain J, Hawkins K, Jones CR, Mason G, et al.A randomised trial of two methods of issuing prenatal test results: the ARIA (amniocentesis results: investigation of anxiety) trial. *BJOG: an international journal of obstetrics and gynaecology* 2007;**114** (4):462–8. [MEDLINE: 17378819]

Chang 1994 {published data only}

Chang JC. Simultaneous mid-trimester AC & placental biopsy - Experience of 92 cases. *International Journal of Gynecology & Obstetrics* 1994;**46**:41.

Corrado 2002 {published data only}

Corrado F, Dugo C, Cannata ML, Di Bartolo M, Scilipoti A, Stella NC. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 2002;**100**(2):196–8. [MEDLINE: 11750964]

Fischer 2000a {published data only}

Fisher RL, Bianculli KW, Sehdev H, Hediger ML. Does light pressure effleurage reduce pain and anxiety associated with genetic amniocentesis? A randomized clinical trial. *Journal of Maternal Fetal Medicine* 2000;**9**:294–7.

Fischer 2000b {published data only}

Fischer R, Bianculli K, Sehdev H, Hediger M. Does light pressure effleurage reduce pain and anxiety associated with genetic amniocentesis: a randomized clinical trial. *American Journal of Obstetrics and Gynecology* 2000;**182**(1):S186.

Gordon 2007 {published data only}

Gordon MC, Ventura-Braswell A, Higby K, Ward JA. Does local anesthesia decrease pain perception in women undergoing amniocentesis?. *American Journal of Obstetrics and Gynecology* 2007;**196** (1):55.e1–4. [MEDLINE: 17240233]

Horovitz 1994 {published data only}

Horovitz J, Verdier G, Roux D, Hocke C, Taine L, Maugey B, et al. Prenatal diagnosis in multiple pregnancies: transabdominal CVS (59 cases) vs amniocentesis (56 cases). *International Journal of Gynecology & Obstetrics* 1994;**46**:41.

Ketupanya 1997 {published data only}

Ketupanya A, Mutamara S, Vuthivong J, Kungvanpong D, Samativatr S. Amnifiltration in early amniocentesis for cytogenetic evaluation: randomized clinical trial. *Acta Obstetricia et Gynecologica Scandinavica* 1997;**76**(167):40.

Leach 1978 {published data only}

Leach G, Chang A, Morrison J. A controlled trial of puncture sites for amniocentesis. *British Journal of Obstetrics and Gynaecology* 1978; **85**:328–31.

Leung 2002 {published data only}

Leung WC, Lam YH, Wong Y, Lau ET, Tang MH. The effect of fast reporting by amnio-PCR on anxiety levels in women with positive biochemical screening for Down syndrome--a randomized controlled trial. *Prenatal Diagnosis* 2002;**22**(3):256–9. [MEDLINE: 11920905]

Levine 1977 {published data only}

Levine SC, Filly RA, Golbus MS. Ultrasonography for guidance of amniocentesis in genetic counselling. *Clinical Genetics* 1978;14: 133–8.

Pistorius 1998 {published data only}

Pistorius L, Howarth G, Freislich L, Pattison R, Mantel G, Honey E, et al.Amniocentesis and the taptest in proteinuric hypertension in pregnancy "tappet"; a randomised controlled trial. Proceedings of the 17th Conference on Priorities in Perinatal Care; 1998; South Africa. 1998:96.

Shalev 1994 {published data only}

Shalev E, Weiner E, Yanai N, Shneur Y, Cohen H. Comparison of first-trimester transvaginal amniocentesis with chorionic villus sampling and mid-trimester amniocentesis. *Prenatal Diagnosis* 1994;**14** (4):279–83. [MEDLINE: 8066037]

Shulman 1990 {published data only}

Shulman LP, Meyers CM, Simpson JL, Andersen RN, Tolley EA, Elias S. Fetomaternal transfusion depends on amount of chorionic villi aspirated but not on method of chorionic villus sampling. *American Journal of Obstetrics and Gynecology* 1990;**162**:1185–8.

SIlver 2003 {published data only}

Silver RK, Wilson RD, Philip J. Transplacental prenatal diagnosis at 13-14 weeks may increase the risk of gestational hypertension/preeclampsia. *American Journal of Obstetrics and Gynecology* 2003;**189**(6):S87.

Silver RK, Wilson RD, Philip J, Thom EA, Zachary JM, Mohide P. Late first-trimester placental disruption and subsequent gestational hypertension/preeclampsia. *Obstetrics & Gynecology* 2005;**105**(3): 587–92. [MEDLINE: 15738029]

Uppsala 1997 {published data only}

Cederholm M, Axelsson O. A prospective comparative study on transabdominal chorionic villus sampling and amniocentesis performed at 10-13 weeks' gestation. *Prenatal Diagnosis* 1997;**17**(4): 311–7.

Van Schoubroeck 2000 {published data only}

Van Schoubroeck D, Verhaeghe J. Does local anaesthesia at midtrimester amniocentesis decrease pain experience? A randomised trial in 220 patients. *Ultrasound in Obstetrics & Gynecology* 2000;**16**:536– 8.

Wax 2005 {published data only}

Wax JR, Pinette MG, Carpenter M, Chard R, Blackstone J, Cartin A. A randomized single blinded trial of subfreezing versus room temperature needles to reduce pain with amniocentesis. *Ultrasound in Obstetrics and Gynecology* 2005;**26**:430.

Wax JR, Pinette MG, Carpenter M, Chard R, Blackstone J, Cartin A. Reducing pain with genetic amniocentesis - a randomized trial of subfreezing versus room temperature needles. *Journal of Maternal-Fetal* & Neonatal Medicine 2005;**18**(4):221–4. [MEDLINE: 16318970]

Zwinger 1994 {published data only}

Zwinger A, Benešova O, Šmeral P, Mrazek M. The effectiveness of invasive procedures in prenatal diagnosis of genetic disorders. *International Journal of Gynecology & Obstetrics* 1994;**46**:41.

Additional references

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Alfirevic 2002

Alfirevic Z, von Dadelszen P. Instruments for chorionic villus sampling for prenatal diagnosis. *Cochrane Database of Systematic Reviews* 2003, Issue 1. [DOI: 10.1002/14651858.CD000114]

Burton 1995

Burton BK, Schultz CJ, Angle B, Burd LI. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). *Prenatal Diagnosis* 1995;**15**:209–14.

China 1975

Department of Obstetrics and Gynecology, Tietung Hospital, Anshan, China. Fetal sex prediction by sex chromatin of chorionic cells during early pregnancy. *Chinese Medical Journal* 1975;**1**:117–26.

Froster 1996

Froster UG, Jackson L. Limb defects and chorionic villus sampling: results from an international registry, 1992-94. *Lancet* 1996;**347**: 489–94.

Higgins 2008

Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org.

Jackson 1993

Jackson L, Wapner RJ. Chorionic villus sampling. In: Simpson JL, Elias S editor(s). *Essentials of prenatal diagnosis*. New York: Churchill Livingstone, 1993:45–62.

MRC Canadian Study

Medical Research Council. *Diagnosis of genetic disease by amniocentesis during the second trimester of pregnancy: report number 5.* Ottawa: MRC Canada, 1977.

Mujezinovic 2007

Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. *Obstetrics and Gynecology* 2007;**110**(3):687–94. [MEDLINE: 17766619]

NICHHD 1993

NICHHD. Report of the NICHHD workshop on chorionic villus sampling and limb and other defects. *American Journal of Obstetrics* and Gynecology 1993;**169**(1):1–6.

RevMan 2008

The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2008.

Robinson 1988

Robinson GE, Garner DM, Olmsted MP, Shime J, Hutton EM, Crawford BM. Anxiety reduction after chorionic villus sampling and genetic amniocentesis. *American Journal of Obstetrics and Gynecology* 1988;**159**:953–6.

Spencer 1987

Spencer JW, Cox DN. Emotional responses of pregnant women to chorionic villi sampling or amniocentesis. *American Journal of Obstetrics and Gynecology* 1987;**157**:1155–60.

Spencer 1988

Spencer JW, Cox DN. A comparison of chorionic villi sampling and amniocentesis: acceptability of procedure and maternal attachment to pregnancy. *Obstetrics & Gynecology* 1988;**72**:714–8.

Sundberg 1991

Sundberg K, Smidt-Jensen S, Philip J. Amniocentesis with increased yield, obtained by filtration and reinjection of the amniotic fluid. *Ultrasound in Obstetrics and Gynecology* 1991;**1**:1.

Sundberg 1995

Sundberg K, Jorgensen FS, Tabor A, Bang J. Experience with early amniocentesis. *Journal of Perinatal Medicine* 1995;**23**:149–58.

References to other published versions of this review

Alfirevic 2001a

Alfirevic Z, Gosden CM, Neilson JP. Chorion villus sampling versus amniocentesis for prenatal diagnosis (Cochrane Review). *The Cochrane Library* 2003, Issue 2.[Art. No.: CD000055. DOI: 10.1002/14651858.CD000055]

Alfirevic 2001b

Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. *Cochrane Database of Systematic Reviews* 2003, Issue 3. [DOI: 10.1002/14651858.CD003252]
 * Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Borrell 1999

Methods

Random telephone allocation using a table of random numbers.

Borrell 1999 (Continued)

Participants	Women requesting fetal karyotyping on the basis of advanced maternal age prior to 12th completed week. Exclusions included: multiple pregnancies, menstrual gestational age greater than 11 plus 6 weeks, or an indication for cytogenetic analysis other than advanced maternal age. 503 randomised to CVS group and 508 to the amniocentesis group.				
Interventions	Transcervical CVS performed from 9th to 13th week of pregnancy using round tipped curved steel forceps after initial ultrasound scan. Procedure performed under direct ultrasound guidance. Amniocentesis was performed from the 15th to 18th week of pregnancy using 22 G needle under direct ultrasound guidance.				
Outcomes	Diagnostic success and	l fetal loss rate.			
Notes		Trial prematurely discontinued when second trimester serum biochemistry screening was introduced. Lost to follow up was 33.5% (339/1011).			
Risk of bias					
Item	Authors' judgement	Description			
Allocation concealment?	Yes A - Adequate				
Bovicelli 1986					
Methods	Randomly assigned - method not described.				
Participants	Inclusion criteria: gestational age 9 to 13 weeks, viable embryo with an intact sac.				
Interventions	Transcervical performed under direct ultrasound guidance. 16 G cannula passed via the cervix to chorion frondosum and villi aspirated with suction. Transabdominal CVS was performed using continuous ultrasound guidance and an 18 G needle passed to reach the border of the chorion frondosum. A 20 G needle was then passed through this first needle and villi aspirated.				
Outcomes	Technical difficulty, fetal loss rate and speed of procedure.				
Notes					
Risk of bias					
Item	Authors' judgement	Description			
Allocation concealment?	Unclear B - Unclear				

Methods	Randomisation by telephone.			
Participants	Women aged between 19 and 48 years attending for first trimester fetal diagnosis of genetic diseases. Indications for fetal diagnosis included chromosomal aberration, sex determination for X linked diseases, metabolic diseases, DNA analysis for haemoglobinopathies and haemophilias. Gestational age between 8 and 12 weeks. Exclusion criteria: multiple pregnancy, vaginal infection, pending cerclage, vaginal bleeding and placenta inaccessible either via cervical canal or via abdominal wall.			
Interventions	TC and TA CVS were used in 1 session.	performed using a 20 G needle and no more than 2 cannula or needle insertion		
Outcomes	Technical difficulty and	d quantity of tissue obtained along with pregnancy outcome.		
Notes				
Risk of bias				
Item	Authors' judgement	Description		
Allocation concealment?	Yes	A - Adequate		
	Central randomisation	(unknown) and stratified according to age 35-38, >= 39 and centre.		
Methods	Participants from 12 c those referred for fetal pregnancy confirmed b Rh isoimmunisation, u 2787 women randomi 396 ineligible followin 1391 randomised to C	entres in Canada. Eligible women - aged 35 years or older at time of delivery or chromosome analysis. Less than 12 weeks' gestation. Viable singleton intrautering y ultrasound. Women excluded if dead or disorganized embryo, multiple pregnancy intreated cervical infection or gestation greater than 12 weeks. sed. g randomisation.		
Methods Participants	Participants from 12 c those referred for fetal pregnancy confirmed b Rh isoimmunisation, u 2787 women randomi 396 ineligible followin 1391 randomised to C	entres in Canada. Eligible women - aged 35 years or older at time of delivery o chromosome analysis. Less than 12 weeks' gestation. Viable singleton intrautering y ultrasound. Women excluded if dead or disorganized embryo, multiple pregnancy intreated cervical infection or gestation greater than 12 weeks. sed. g randomisation. WS (200 ineligible). mniocentesis (196 ineligible).		
Canada 1992 Methods Participants Interventions Outcomes	Participants from 12 c those referred for fetal pregnancy confirmed b Rh isoimmunisation, c 2787 women randomi 396 ineligible followin 1391 randomised to C 1396 randomised to ar TC versus second trim	entres in Canada. Eligible women - aged 35 years or older at time of delivery o chromosome analysis. Less than 12 weeks' gestation. Viable singleton intrauterin y ultrasound. Women excluded if dead or disorganized embryo, multiple pregnancy intreated cervical infection or gestation greater than 12 weeks. sed. g randomisation. VVS (200 ineligible). mniocentesis (196 ineligible). ester AC. abnormal karyotype, pregnancy complications, perinatal loss, neonatal complica		
Methods Participants Interventions	Participants from 12 c those referred for fetal pregnancy confirmed b Rh isoimmunisation, u 2787 women randomi 396 ineligible followin 1391 randomised to C 1396 randomised to ar TC versus second trim Technical difficulties, a	entres in Canada. Eligible women - aged 35 years or older at time of delivery o chromosome analysis. Less than 12 weeks' gestation. Viable singleton intrauterin y ultrasound. Women excluded if dead or disorganized embryo, multiple pregnancy intreated cervical infection or gestation greater than 12 weeks. sed. g randomisation. VVS (200 ineligible). mniocentesis (196 ineligible). ester AC. abnormal karyotype, pregnancy complications, perinatal loss, neonatal complica		
Methods Participants Interventions Outcomes	Participants from 12 c those referred for fetal pregnancy confirmed b Rh isoimmunisation, u 2787 women randomi 396 ineligible followin 1391 randomised to C 1396 randomised to ar TC versus second trim Technical difficulties, a	entres in Canada. Eligible women - aged 35 years or older at time of delivery o chromosome analysis. Less than 12 weeks' gestation. Viable singleton intrautering y ultrasound. Women excluded if dead or disorganized embryo, multiple pregnancy intreated cervical infection or gestation greater than 12 weeks. sed. g randomisation. VVS (200 ineligible). mniocentesis (196 ineligible). ester AC. abnormal karyotype, pregnancy complications, perinatal loss, neonatal complica		

Canada 1992 (Continued)

Allocation concealment?	Yes	A - Adequate		
CEMAT 1998				
Methods	Telephone randomisati	ion. Random allocation list computer generated.		
Participants	4368 participants in 12 centres. Inclusion criteria: prenatal diagnosis due to maternal age, newborn baby with a chromosomal abnormality, viable fetus with a crown rump length of 20-50 mm on ultrasound and consent to enter the trial. Exclusion criteria were: previous open neural tube defect detected by prenatal diagnosis, molecular or biochemical disorders found on prenatal tests, non viable fetus, multiple pregnancy, failed CVS, fetal anomaly or oligohydramnios, active vaginal bleeding, alloimmunised patient, recurrent unexplained miscarriages, intrauterine contraceptive device in utero, previous CEMAT trial randomisation.			
Interventions	Both groups underwent detailed fetal anomaly ultrasound examination at 15 and 20 weeks. Early amniocentesis group had amnio performed between 11 and 12 gestational weeks and second trimester between 15 and 16 weeks. All amniocentesis were performed under direct ultrasound guidance using 22 G, 9 cm or 14 cm needles.			
Outcomes	Pregnancy outcome, congenital anomalies, abnormal karyotype and technical difficulty.			
Notes				
Risk of bias				
Item	Authors' judgement	Description		
Allocation concealment?	Yes	A - Adequate		

Copenhagen 1997

Methods	Central telephone randomisation.
Participants	Women aged 35 years or over with risk factors including Down's syndrome in the family, a previous child with chromosomal abnormality, a parent who is a carrier of chromosomal abnormalities, history of a diseased or dead offspring, recurrent miscarriage, environmental exposure during pregnancy or anxiety. All women had a singleton pregnancy and gestational age confirmed by ultrasound. Exclusion criteria: high risk of genetic disease (25% or more), malformation suspected on ultrasound, intrauterine device, uterine haematomas and malformations. 579 women were assigned to CVS, 581 women to EA and 114/1274 (9%) were excluded.
Interventions	Transabdominal CVS was performed between 10 and 12 weeks with ultrasound guidance and a needle guide. The double needle technique was used (guide needle of 1.2 mm (18 G) and aspiration needle of 0.8 mm (21 G).

Copenhagen 1997 (Cor	ntinued)				
	Amniocentesis was done between 11 and 13 weeks with a needle guide and a 0.9 mm (20 G) standard AC needle. The filter system was used which allowed circulation of amniotic fluid (25 ml) back to the sac during sampling.				
Outcomes	Technical difficulties, a tions.	Technical difficulties, abnormal karyotype, pregnancy complications, perinatal loss, neonatal complica- tions.			
Notes	Trial was stopped early group.	y due to slow recruitment and due to clustering of talipes equinovarus in the EA			
Risk of bias					
Item	Authors' judgement	Description			
Allocation concealment?	Yes	A - Adequate			
Denmark 1992					
Methods	3-way randomisation of low-risk women (TA vs TC vs AC). A 2-way randomisation of high-risk women (TA vs TC). Central randomisation (unknown) with stratification for genetic risk.				
Participants	2 centres in Denmark from 1985-1990. Eligible low-risk women: age > 34 or father > 49, history of or anxiety about chromosomal abnormality, > 3 spontaneous miscarriages with viable fetus at 9-11 weeks. Eligible high-risk women: history of translocation, late termination or fetus at risk of metabolic disorder with a viable fetus at 9-11 weeks. Exclusions: active bleeding, intrauterine device, genital infection, severe mental illness, use of teratogenic drugs, history of neural tube defects and discrepant dating.				
Interventions	CVS vs second trimester AC. TA CVS vs second trimester AC. TC CVS vs second trimester AC. TC CVS vs TA CVS.				
Outcomes	Pregnancy outcome, antenatal complications and diagnostic accuracy.				
Notes					
Risk of bias					
Item	Authors' judgement	Description			
Allocation concealment?	Yes A - Adequate				

King's 1996

-				
Methods	Sealed opaque envelope containing a card for one of the procedures. Not sequentially numbered envelopes.			
Participants	Median age 38 years range (22-46). Inclusion criteria: ultrasonographic evidence of a viable fetus at 10-13 weeks 6 days' gestation (minimum CRL = 38 mm) and maternal request for karyotyping due to advanced maternal age, anxiety or family history of chromosomal abnormality. Exclusions: increased nuchal translucency, missed abortion, multiple pregnancy, major fetal abnormality, intrauterine device, multiple fibroids or large placental haemorrhage. EA was performed in 840 women (278 after randomisation) and CVS in 652 women (277 after randomisation).			
Interventions	EA versus CVS. Both procedures being carried out by Professor Nicolaides or under his direct supervision. A freehand technique and a 20 G needle was used for both EA and CVS. No local anaesthesia, prophylactic antibiotics or bed rest. EA: 11 ml of fluid aspirated, first 1 ml discarded. CVS: 6-10 ml of tissue aspirated manually through a 20 ml syringe.			
Outcomes	Technical difficulties, abnormal karyotype, pregnancy complications, perinatal loss and maternal compli- cations.			
Notes	Aimed to recruit 4400 women. However, by March 1993 recruitment collapsed because of widespread publicity that CVS can cause fetal limb abnormalities and is associated with a high risk of spontaneous abortion and that non invasive screening by ultrasonography and maternal serum biochemistry can provide sufficient reassurance to avoid invasive testing.			
Risk of bias				
Item	Authors' judgement	Description		
Allocation concealment?	Yes	A - Adequate		
Leiden 1998				
Methods	EA versus TA CVS. Women eligible were given the choice as to randomisation or to decide the method of prenatal diagnosis themselves. Randomisation was performed using sequentially numbered envelopes.			
Participants	Women requesting prenatal diagnosis due to age related risk. 212 women were recruited, 115 agreed to be randomised; 70 chose EA and 25 CVS. 2 women did not participate because fetal death was diagnosed before any intervention.			
Interventions	TA CVS was performed using a 20 G needle. AC was performed using a 22 G needle: 11 ml of amniotic fluid was aspirated, the first ml being discarded.			
Outcomes	Technical difficulties, abnormal karyotype, pregnancy complications, perinatal loss, neonatal complica- tions, Dutch version of Denver Developmental Screening Test at 6-9 months.			

Leiden 1998 (Continued)

Notes	Study stopped after 18 months following advice of the institutional ethical committee due to a higher incidence of fetal loss in the EA group.			
Risk of bias				
Item	Authors' judgement Description			
Allocation concealment?	Yes	A - Adequate		

MRC (Finland) 1993

Methods	Consecutively-numbered sealed envelopes.				
Participants	800 women in early pr	regnancy requesting prenatal diagnosis.			
Interventions	4 operators performed guidance.	all procedures - TC CVS with Portex cannula or AC at 16 weeks under ultrasound			
Outcomes	Pregnancy outcome, at	onormal karyotype, antenatal complications and diagnostic accuracy.			
Notes	This study was part of	This study was part of the international MRC trial.			
Risk of bias					
Item	Authors' judgement Description				
Allocation concealment?	Yes A - Adequate				
MRC 1991					
Methods	Central telephone randomisation. Random allocation in balanced blocks and stratified by centre. Finland - consecutively numbered, sealed, opaque envelopes.				
Participants	3248 recruited from 31 centres in Europe (21 in the UK, 4 in Italy, 2 in the Netherlands and 1 in Finland, Denmark, Switzerland and Germany). Prenatal diagnosis due to maternal age. Other indications were anxiety and previously affected child with chromosome anomaly. Centres eligible if each participating obstetrician had performed at least 30 procedures with > 10 mg of tissue in 23 out of 25 most recent cases. 1609 randomised to CVS and 1592 to AC.				
Interventions	First trimester CVS TC or TA approach versus second trimester AC.				
Outcomes	Pregnancy outcome, abnormal karyotype, antenatal complications and diagnostic accuracy.				

MRC 1991 (Continued)

Notes			
Risk of bias			
Item	Authors' judgement	Description	
Allocation concealment?	Yes	A - Adequate	
NICHD EATA 2004 Methods	Telephone randomisation interactive voice response computer-based system.		
Participants	14 clinical centres. Inclusion criteria: age of mother more than 34 years, previous affected child, positive screening test. Exclusion criteria: multiple pregnancy, familiar chromosome rearrangements, inherited enzyme disorders, serious maternal illnesses (insulin-dependent diabetes, severe hypertension, HIV), bleeding equal men- struation, IUD in situ, oligohidramnios, recognised fetal abnormalities. Total number of patients = 3775 (CVS group = 1914 and EAC group = 1861).		
Interventions	EAC group: 22 G spinal needle, 1 ml for each week CVS - single (19 to 20 G) and double needle technique (18 to 20 G). Larger guide needle to the margin of the chorion.		
Outcomes	oligohydramnios, gesta	al loss less than 28 weeks. Secondary outcome: all fetal loss, all neonatal death, ational age at the delivery, IUGR, respiratory distress syndrome, limb reduction	

 defects, talipes equinovarus, other congenital anomalies.

 Notes

 Risk of bias

 Item
 Authors' judgement

Description

Item	Muthors Judgement	Description
Allocation concealment	Yes	A - Adequate

Nolan 1981

Methods	Random allocation (method unknown).
Participants	223 women randomised.
Interventions	Mid-trimester amniocentesis with or without "the obstetrician having the benefit of ultrasound results". It appears that ultrasound was used to locate the placenta, i.e. the procedure was not performed under direct ultrasound guidance.

Nolan 1981 (Continued)

Outcomes	Number of taps, bloody taps.					
Notes						
Risk of bias						
Item	Authors' judgement Description					
Allocation concealment?	Unclear B - Unclear					
Tabor 1986						
Methods		cording to a table of random numbers. Randomisation code given out by a med- ospitalet, Copenhagen (majority). Some women were randomised by envelopes				
Participants	4606 women randomised between ages of 25 and 34. Exclusion criteria: women believed to be at risk of a child with a chromosomal abnormality, neural tube defect or increased risk of spontaneous abortion. Also women with known uterine abnormalities or intrauterine contraceptive devices were excluded along with multiple gestations.					
Interventions	Women in the study group were allocated to AC, all of which were carried out at the centre for prenatal diagnosis. The mean gestational age for AC was 16.4 +/-1.1 weeks. AC was carried out with a 20 G needle under direct ultrasound guidance. Women in the control group were allocated to the routine antenatal programme.					
Outcomes	Pregnancy outcome, abnormal karyotype and neonatal complications and congenital abnormalities.					
Notes						
Risk of bias						
Item	Authors' judgement	Description				
Allocation concealment?	Yes A - Adequate					
Tomassini 1988						
Methods	Random selection (method unknown).					
Participants	44 women between 9 and 12 weeks of gestation.					
Interventions	Transcervical CVS with ago-cannula or transabdominal procedure with a spinal needle (gauge size un- known) and a suction pistol.					

Tomassini 1988 (Continued)

Outcomes	Sampling failure, vaginal spotting and amniotic fluid leak, pregnancy loss.			
Notes				
Risk of bias				
Item	Authors' judgement	Description		
Allocation concealment?	Unclear	B - Unclear		
USNICHD 1992				
Methods	Random assignment.			
Participants	3998 patients recruited in 8 US collaborating centres. Inclusion criteria: favourable placental position allowing both procedures to be performed, gestational age between 49 and 90 days. Exclusion criteria: active genital herpes, active vaginal bleeding or cervical polyps. 1190 randomised to TC CVS and 1163 to TA CVS.			
Interventions	TA or TC CVS. TC being performed with a plastic catheter and TA with an 18 to 22 G spinal needle.			
Outcomes	Sampling success, pregnancy outcome.			
Notes	Initial cohort of 2353 women presented who delivered before July 1 1989.			
Risk of bias				
Item	Authors' judgement	Description		
Allocation concealment?	Yes	A - Adequate		
AC: amniocentesis CRL: crown rump length CVS: chorionic villus samp EA: early amniocentesis G: gauge TA: transabdominal TC: transcervical vs: versus	bling			

Characteristics of excluded studies [ordered by study ID]

ARIA Trial 2006	This study evaluated the impact of providing early results in altering maternal anxiety during the waiting period, compared with a policy of telling parents that the result will be issued "when available" (i.e. variable date). This study will be included in the Cochrane review that addresses the issue of anxiety reduction during prenatal diagnostic tests.
Chang 1994	This study evaluated the feasibility of midtrimester placental biopsy as an alternative technique of prenatal cytogenetic diagnosis. Midtrimester amniocentesis and placental biopsies were performed simultaneously in 92 cases. According to our protocol this type of study design is not included.
Corrado 2002	This study compared a short prophylactic treatment with progesterone after amniocentesis with untreated controls. It did not compare 2 different methods of invasive testing.
Fischer 2000a	This study evaluated the role of local anaesthesia in reducing pain during and immediately after the procedure. This study will be included in the Cochrane review that addresses the issue of pain relief during prenatal diagnostic tests.
Fischer 2000b	This study evaluated the effect of leg rubbing by the assisting nurse during genetic amniocentesis with regard to pain perception and patient anxiety. 200 women were randomised using sealed envelopes, but the number of women per randomised group was not stated in the abstract. This study will be included in the Cochrane review that addresses the issue of pain relief during prenatal diagnostic tests.
Gordon 2007	This study evaluated the role of local anaesthesia (1% lidocaine) with no anaesthesia before amniocentesis in a diverse population. Immediately after the procedure, subjects were asked to assess their pain using both a Visual Analogue Scale and a 101-point Numerical Rating Scale. This study will be included in the Cochrane review that addresses the issue of pain relief during prenatal diagnostic tests.
Horovitz 1994	This study compared transabdominal CVS with amniocentesis in 56 multiple pregnancies. It is not clear from the abstract whether this was a randomised study or not.
Ketupanya 1997	This study compared early amniocentesis (12 to 14 weeks) performed with or without amniofiltration technique (29 women in each group). The culture failure was 13.8% in the amniofiltration group compared with 10.3% in the control group. However, the method of randomisation was not described.
Leach 1978	In this study amniocentesis was performed to assess fetal lung maturity with only 10.2% of the procedures carried out before 36 weeks' gestation.
Leung 2002	This study evaluated the impact of early reporting of the results obtained from polymerase chain reaction on amniotic fluid cells (amnio-PCR) on anxiety levels in women with positive biochemical screening for Down syndrome. This study will be included in the Cochrane review that addresses the issue of anxiety reduction during prenatal diagnostic tests.

Levine 1977	This study evaluated the role of ultrasound immediately before genetic amniocentesis. The patients were "alternately assigned" to the "with ultrasound" and "without ultrasound" groups. According to our protocol quasi-randomised protocols such as alternative allocations are not included.
Pistorius 1998	In this study amniocentesis was performed later in pregnancy in women with proteinuric hypertension.
Shalev 1994	This is an abstract of the study that compared the clinical and laboratory result of first trimester transvaginal amniocentesis with those of CVS and mid-trimester amniocentesis. It had a matched case-control study design. It did not meet inclusion criteria of this review.
Shulman 1990	This study reported comparison between 15 transcervical and 15 transabdominal CVS procedures in terms of the specimen size and change in maternal serum alpha-feto-protein levels. Some women were selected by 'choice' and others took part in the NICH study comparing CVS and amniocentesis (Rhoads GG, Jackson LG, Schlesselman SE, de la Cruz FF, Desnick RJ, Golbus MS et al. The safety and efficacy of chorionic villus sampling for early prenatal diagnosis of cytogenetic abnormalities. New England Journal of Medicine 1989;320(10):609-17). This study, therefore, does not fulfil our criteria for randomised study.
SIlver 2003	This study was a part of a randomised control study performed by NICHD EATA Trial Group. It evaluated the relationship between placental penetration during amniocentesis or chorionic villus sampling and the development of gestational hypertension/pre-eclampsia. It did not report prespecified outcomes included in this review.
Uppsala 1997	The trial from Uppsala, Sweden by Cederholm and Axelsson (Uppsala 1997) randomised 86 women to early amniocentesis or CVS. The data for 86 randomised women are 'lumped together' with the data for 235 women who selected the procedure 'by choice'. We are therefore, at present, unable to include the randomised data set in the 'intention-to-treat' analysis.
Van Schoubroeck 2000	This study evaluated the role of therapeutic massage in reducing pain during and immediately after the procedure. This study will be included in the Cochrane review that addresses the issue of pain relief during prenatal diagnostic tests.
Wax 2005	This study determined whether pain associated with second trimester genetic amniocentesis is decreased by using subfreezing rather than room temperature needles. This study will be included in the Cochrane review that addresses the issue of pain relief during prenatal diagnostic tests.
Zwinger 1994	This study evaluated the efficiency and safety of individual invasive methods of prenatal diagnosis. This study was not a randomised controlled study but based on a population cohort of Institute for Mother and Child Care in Czech Republic. Data were represented in an abstract form for the conference proceeding.

CVS: chorionic villus sampling

DATA AND ANALYSES

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Not complied with allocated procedure	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	1.73 [1.03, 2.91]
3 Multiple insertions	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	91.08 [5.61, 1477.53]
4 Second test performed	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	41.04 [2.48, 678.07]
5 Laboratory failure	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	27.02 [1.61, 454.31]
6 All non-mosaic abnormalities	1	4593	Risk Ratio (M-H, Fixed, 95% CI)	30.85 [1.85, 515.31]
13 Vaginal bleeding after test	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	0.95 [0.66, 1.37]
14 Amniotic leakage after test	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	3.90 [1.95, 7.80]
20 All known pregnancy loss (including termination of pregnancy)	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [0.99, 2.00]
21 Termination of pregnancy (all)	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	2.50 [0.97, 6.44]
24 Spontaneous miscarriage	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	1.60 [1.02, 2.52]
26 Perinatal deaths	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	0.63 [0.28, 1.38]
27 Stillbirths	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.36, 1.93]
28 Neonatal deaths	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	0.11 [0.01, 2.06]
29 All recorded deaths after viability	1	4606	Risk Ratio (M-H, Fixed, 95% CI)	0.63 [0.28, 1.38]
30 Anomalies (all recorded)	1	4507	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.62, 1.39]
31 Talipes	1	4507	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.37, 1.22]
35 Neonatal respiratory distress syndrome	1	4507	Risk Ratio (M-H, Fixed, 95% CI)	2.11 [1.06, 4.19]

Comparison 1. Second trimester amniocentesis versus control

Comparison 2. Early versus second trimester amniocentesis

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Not complied with allocated procedure	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	0.65 [0.57, 0.75]
2 Sampling failure	1	629	Risk Ratio (M-H, Fixed, 95% CI)	4.53 [0.53, 38.56]
3 Multiple insertions	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	2.79 [1.92, 4.04]
4 Second test performed	1	4107	Risk Ratio (M-H, Fixed, 95% CI)	8.72 [3.47, 21.91]
5 Laboratory failure	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	9.76 [3.49, 27.26]
6 All non-mosaic abnormalities	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [0.75, 1.66]
7 True mosaics	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.25, 4.00]
9 Maternal contamination	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	2.00 [0.37, 10.92]
11 False negative chromosomal diagnosis	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

11.1 False negative chromosomal results (excluding sex determination)	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	3.00 [0.12, 73.67]
11.2 Incorrect sex determination	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	5.00 [0.24, 104.18]
12 Reporting time	1	4107	Mean Difference (IV, Fixed, 95% CI)	1.20 [0.89, 1.51]
14 Amniotic leakage after test	1	4368	Risk Ratio (M-H, Fixed, 95% CI)	2.05 [1.43, 2.94]
20 All known pregnancy loss	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	1.29 [1.03, 1.61]
(including termination of pregnancy)				
21 Termination of pregnancy (all)	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	1.26 [0.89, 1.77]
24 Spontaneous miscarriage	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	1.41 [1.00, 1.98]
25 Spontaneous miscarriage after test	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	3.22 [1.88, 5.53]
27 Stillbirths	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	0.73 [0.34, 1.59]
28 Neonatal deaths	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	4.98 [0.58, 42.56]
29 All recorded deaths after viability	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	1.00 [0.50, 1.99]
30 Anomalies (all recorded)	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	1.73 [1.26, 2.38]
31 Talipes	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
31.1 Talipes (all)	0	0	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
31.2 Talipes equinovarus	1	4334	Risk Ratio (M-H, Fixed, 95% CI)	14.43 [3.45, 60.41]

Comparison 3. Chorionic villus sampling versus second trimester amniocentesis

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Not complied with allocated procedure	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
1.1 Transcervical CVS versus amniocentesis	3	4595	Risk Ratio (M-H, Random, 95% CI)	0.50 [0.18, 1.36]
1.3 CVS (any route) versus amniocentesis	1	3197	Risk Ratio (M-H, Random, 95% CI)	0.66 [0.52, 0.83]
2 Sampling failure	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
2.1 Transervical CVS versus amniocentesis	1	797	Risk Ratio (M-H, Fixed, 95% CI)	0.55 [0.26, 1.19]
2.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	3.09 [1.98, 4.82]
3 Multiple insertions	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
3.1 Transcervical CVS versus amniocentesis	1	794	Risk Ratio (M-H, Fixed, 95% CI)	3.93 [2.72, 5.68]
3.3 CVS (any route) versus amniocentesis	1	2917	Risk Ratio (M-H, Fixed, 95% CI)	4.85 [3.92, 6.01]
4 Second test performed	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
4.1 Transcervical CVS versus amniocentesis	3	4256	Risk Ratio (M-H, Random, 95% CI)	19.63 [1.24, 309.90]
4.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Random, 95% CI)	2.83 [1.94, 4.13]

5 Laboratory failure	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5.1 Transcervical CVS versus amniocentesis	2	2792	Risk Ratio (M-H, Fixed, 95% CI)	22.62 [3.07, 166.89]
5.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	0.77 [0.29, 2.06]
6 All non-mosaic abnormalities	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
6.1 Transcervical CVS versus amniocentesis	2	2667	Risk Ratio (M-H, Fixed, 95% CI)	1.12 [0.73, 1.72]
7 True mosaics	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
7.1 Transcervical CVS versus amniocentesis	1	672	Risk Ratio (M-H, Fixed, 95% CI)	3.42 [0.14, 83.63]
8 Confined mosaics	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
8.1 Transcervical CVS versus amniocentesis	1	1995	Risk Ratio (M-H, Fixed, 95% CI)	5.66 [1.97, 16.24]
9 Maternal contamination	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
9.1 Transcervical CVS versus amniocentesis	1	1991	Risk Ratio (M-H, Fixed, 95% CI)	12.30 [3.81, 39.67]
9.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	8.90 [0.48, 165.26]
10 Known false positive after birth	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
10.1 Transcervical CVS versus amniocentesis	2	2627	Risk Ratio (M-H, Fixed, 95% CI)	7.30 [2.20, 24.25]
10.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.06, 15.80]
11 Known false negative after birth	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
11.1 Transcervical CVS versus amniocentesis	2	2627	Risk Ratio (M-H, Fixed, 95% CI)	7.84 [0.41, 151.61]
11.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	2.97 [0.12, 72.81]
13 Vaginal bleeding after test	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
13.1 Transcervical CVS versus amniocentesis	2	3193	Risk Ratio (M-H, Random, 95% CI)	11.48 [2.58, 51.08]
14 Amniotic leakage after test	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
14.1 Transabdominal CVS vs amniocentesis	1	1485	Risk Ratio (M-H, Fixed, 95% CI)	2.53 [0.81, 7.92]
14.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	0.55 [0.18, 1.64]
15 Vaginal bleeding after 20 weeks	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
15.1 Transcervical CVS versus amniocentesis	1	797	Risk Ratio (M-H, Fixed, 95% CI)	1.44 [0.62, 3.33]
15.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	0.99 [0.69, 1.42]
16 PROM before 28 weeks	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
16.1 Transcervical CVS versus amniocentesis	1	722	Risk Ratio (M-H, Fixed, 95% CI)	4.97 [1.45, 17.03]
16.3 CVS (any route) versus amniocentesis	1	2765	Risk Ratio (M-H, Fixed, 95% CI)	1.60 [0.80, 3.17]
17 Antenatal hospital admission	2		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
17.1 Transcervical CVS versus amniocentesis	1	780	Risk Ratio (M-H, Fixed, 95% CI)	1.47 [0.81, 2.68]

17.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	0.90 [0.75, 1.08]
18 Delivery before 37 weeks	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
18.1 Transcervical CVS versus amniocentesis	2	2506	Risk Ratio (M-H, Random, 95% CI)	1.29 [0.67, 2.47]
18.3 CVS (any route) versus amniocentesis	1	3189	Risk Ratio (M-H, Random, 95% CI)	1.33 [1.13, 1.57]
19 Delivery before 33 weeks	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
19.1 Transcervical CVS versus amniocentesis	1	768	Risk Ratio (M-H, Fixed, 95% CI)	2.16 [0.94, 4.94]
20 All known pregnancy loss (including termination of pregnancy)	5		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
20.1 Transcervical CVS versus amniocentesis	4	6527	Risk Ratio (M-H, Random, 95% CI)	1.40 [1.09, 1.81]
20.2 Transabdominal CVS versus amniocentesis	1	2234	Risk Ratio (M-H, Random, 95% CI)	0.90 [0.66, 1.23]
20.3 CVS (any route) versus amniocentesis	2	6503	Risk Ratio (M-H, Random, 95% CI)	1.43 [1.22, 1.67]
21 Termination of pregnancy (all)	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
21.1 Transcervical CVS versus amniocentesis	2	3454	Risk Ratio (M-H, Fixed, 95% CI)	0.88 [0.58, 1.34]
21.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	1.42 [0.96, 2.11]
24 Spontaneous miscarriage	4		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
24.1 Transcervical CVS versus amniocentesis	3	5506	Risk Ratio (M-H, Random, 95% CI)	1.50 [1.07, 2.11]
24.2 Transabdominal CVS versus amniocentesis	1	2069	Risk Ratio (M-H, Random, 95% CI)	0.77 [0.49, 1.21]
24.3 CVS (any route) versus amniocentesis	2	6280	Risk Ratio (M-H, Random, 95% CI)	1.51 [1.23, 1.85]
25 Spontaneous miscarriage after test	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
25.1 Transcervical CVS versus amniocentesis	2	1579	Risk Ratio (M-H, Random, 95% CI)	1.77 [0.28, 11.00]
25.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Random, 95% CI)	3.46 [2.21, 5.42]
26 Perinatal deaths	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
26.1 Transcervical CVS versus amniocentesis	3	5521	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [0.73, 3.84]
26.2 Transabdominal CVS versus amniocentesis	1	2069	Risk Ratio (M-H, Fixed, 95% CI)	1.18 [0.40, 3.51]
26.3 CVS (any route) versus amniocentesis	2	6280	Risk Ratio (M-H, Fixed, 95% CI)	1.21 [0.65, 2.24]
27 Stillbirths	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
27.1 Transcervical CVS versus amniocentesis	2	3454	Risk Ratio (M-H, Random, 95% CI)	0.94 [0.02, 45.31]
27.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Random, 95% CI)	0.99 [0.35, 2.81]
28 Neonatal deaths	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

28.1 Transcervical CVS versus amniocentesis	3	4251	Risk Ratio (M-H, Fixed, 95% CI)	1.58 [0.41, 6.06]
28.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	2.64 [0.70, 9.93]
29 All recorded deaths after viability	3		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
29.1 Transcervical CVS versus amniocentesis	2	1579	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.24, 2.93]
29.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	1.44 [0.67, 3.09]
30 Congenital anomalies (all recorded)	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
30.1 Transcervical CVS versus amniocentesis	2	1408	Risk Ratio (M-H, Fixed, 95% CI)	0.62 [0.24, 1.56]
30.3 CVS (any route) versus amniocentesis	2	3338	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.66, 0.96]
31 Talipes	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
31.1 Transcervical CVS versus amniocentesis	1	797	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
32 Hemangiomas (localised vascular lesions of the skin and subcutaneous tissue)	1	182	Risk Ratio (M-H, Fixed, 95% CI)	1.35 [0.81, 2.24]
33 Limb reduction defects	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	4.95 [0.24, 102.97]
33.3 CVS (any route) versus amniocentesis	1	3201	Risk Ratio (M-H, Fixed, 95% CI)	4.95 [0.24, 102.97]
38 Result given in less than 7 days (not prespecified)	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
38.3 CVS (any route) versus amniocentesis	1	3099	Risk Ratio (M-H, Fixed, 95% CI)	23.52 [12.54, 44.10]
39 Result given in less than 14 days (not prespecified)	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
39.3 CVS (any route) versus amniocentesis	1	3099	Risk Ratio (M-H, Fixed, 95% CI)	3.96 [3.17, 4.95]
40 Result given in less than 21 days (not prespecified)	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
40.3 CVS (any route) versus amniocentesis	1	3099	Risk Ratio (M-H, Fixed, 95% CI)	0.72 [0.63, 0.82]
41 Result given in more than 21 days (not prespecified)	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
41.3 CVS (any route) versus amniocentesis	1	3099	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.28, 0.39]
42 Not wanting another baby at 22 weeks' gestation (not prespecified)	1		Odds Ratio (M-H, Fixed, 95% CI)	Subtotals only
42.1 Transcervical CVS versus amniocentesis	1	51	Odds Ratio (M-H, Fixed, 95% CI)	0.34 [0.11, 1.09]

Comparison 4.	Transcervical	versus	transabdominal	CVS
----------------------	---------------	--------	----------------	-----

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Not complied with allocated procedure	3	5187	Risk Ratio (M-H, Random, 95% CI)	1.68 [0.59, 4.76]
2 Sampling failure	4	5231	Risk Ratio (M-H, Fixed, 95% CI)	1.82 [1.15, 2.86]
3 Multiple insertions	2	1314	Risk Ratio (M-H, Fixed, 95% CI)	2.73 [1.78, 4.17]
4 Second test performed	1	1194	Risk Ratio (M-H, Fixed, 95% CI)	1.24 [0.65, 2.37]
5 Laboratory failure	1	1194	Risk Ratio (M-H, Fixed, 95% CI)	2.23 [0.69, 7.22]
6 All non-mosaic abnormalities	1	2862	Risk Ratio (M-H, Fixed, 95% CI)	1.23 [0.87, 1.75]
7 True mosaics	1	2862	Risk Ratio (M-H, Fixed, 95% CI)	0.92 [0.39, 2.17]
8 Confined mosaics	1	2862	Risk Ratio (M-H, Fixed, 95% CI)	0.85 [0.26, 2.77]
13 Vaginal bleeding after test	3	1358	Risk Ratio (M-H, Random, 95% CI)	6.93 [0.77, 62.83]
14 Amniotic leakage after test	1	44	Risk Ratio (M-H, Fixed, 95% CI)	0.29 [0.01, 6.52]
20 All known pregnancy loss (including termination of pregnancy)	5	7978	Risk Ratio (M-H, Random, 95% CI)	1.16 [0.81, 1.65]
21 Termination of pregnancy (all)	2	1303	Risk Ratio (M-H, Fixed, 95% CI)	0.83 [0.56, 1.22]
24 Spontaneous miscarriage	4	3384	Risk Ratio (M-H, Random, 95% CI)	1.68 [0.79, 3.58]
25 Spontaneous miscarriage after test	3	1347	Risk Ratio (M-H, Fixed, 95% CI)	1.25 [0.76, 2.06]
26 Perinatal deaths	1	2037	Risk Ratio (M-H, Fixed, 95% CI)	0.44 [0.11, 1.68]
27 Stillbirths	2	1227	Risk Ratio (M-H, Fixed, 95% CI)	1.69 [0.38, 7.62]
28 Neonatal deaths	2	4845	Risk Ratio (M-H, Fixed, 95% CI)	0.60 [0.14, 2.49]
30 Anomalies (all recorded)	2	3622	Risk Ratio (M-H, Fixed, 95% CI)	0.68 [0.41, 1.12]
31 Talipes	1	2624	Risk Ratio (M-H, Fixed, 95% CI)	3.21 [0.33, 30.80]

Comparison 5. Early amniocentesis versus transabdominal CVS

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Not complied with allocated procedure	4	5566	Risk Ratio (M-H, Fixed, 95% CI)	0.22 [0.08, 0.60]
2 Sampling failure	4	5566	Risk Ratio (M-H, Fixed, 95% CI)	0.59 [0.30, 1.14]
3 Multiple insertions	3	4445	Risk Ratio (M-H, Fixed, 95% CI)	0.47 [0.29, 0.74]
4 Second test performed	4	5566	Risk Ratio (M-H, Fixed, 95% CI)	0.59 [0.36, 0.98]
5 Laboratory failure	4	5566	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.34, 1.49]
6 All non-mosaic abnormalities	4	5566	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.70, 1.55]
7 True mosaics	3	5451	Risk Ratio (M-H, Fixed, 95% CI)	0.46 [0.10, 2.06]
8 Abnormalities confined to non- fetal tissues	4	5566	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.56, 1.55]
9 Maternal contamination	2	4330	Risk Ratio (M-H, Fixed, 95% CI)	3.04 [0.83, 11.14]
10 Known false positive after birth	2	670	Risk Ratio (M-H, Fixed, 95% CI)	0.36 [0.02, 8.73]
11 Known false negative after birth	1	555	Risk Ratio (M-H, Fixed, 95% CI)	Not estimable
12 Reporting time	1	3775	Mean Difference (IV, Fixed, 95% CI)	4.00 [3.82, 4.18]
13 Vaginal bleeding after test	3	4934	Risk Ratio (M-H, Fixed, 95% CI)	0.67 [0.45, 1.01]

14 Amniotic leakage after test	3	4934	Risk Ratio (M-H, Random, 95% CI)	3.35 [0.37, 30.09]
15 Vaginal bleeding after 20 weeks	1	3698	Risk Ratio (M-H, Fixed, 95% CI)	0.71 [0.35, 1.43]
16 Prelabour ruptured membranes	1	3698	Risk Ratio (M-H, Fixed, 95% CI)	0.50 [0.27, 0.92]
less than 28 weeks				
18 Delivery before 37 weeks	3	1755	Risk Ratio (M-H, Fixed, 95% CI)	1.16 [0.78, 1.74]
19 Delivery before 33 weeks	1	1121	Risk Ratio (M-H, Fixed, 95% CI)	0.50 [0.09, 2.73]
20 All known pregnancy loss	4	5491	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [0.86, 1.54]
(including termination of				
pregnancy)				
21 Termination of pregnancy (all)	4	5489	Risk Ratio (M-H, Fixed, 95% CI)	0.74 [0.45, 1.24]
24 Spontaneous miscarriage	4	5491	Risk Ratio (M-H, Fixed, 95% CI)	1.76 [1.17, 2.64]
25 Spontaneous miscarriage after	4	5489	Risk Ratio (M-H, Fixed, 95% CI)	1.74 [1.14, 2.64]
test				
26 Perinatal deaths	4	5428	Risk Ratio (M-H, Fixed, 95% CI)	1.10 [0.53, 2.28]
27 Stillbirths	4	5428	Risk Ratio (M-H, Fixed, 95% CI)	1.11 [0.52, 2.36]
28 Neonatal deaths	4	5455	Risk Ratio (M-H, Fixed, 95% CI)	0.34 [0.05, 2.17]
29 All recorded deaths after	4	5453	Risk Ratio (M-H, Fixed, 95% CI)	1.18 [0.43, 3.23]
viability				
30 Anomalies (all recorded)	4	5305	Risk Ratio (M-H, Random, 95% CI)	1.14 [0.57, 2.30]
32 Talipes equinovarus	4	5305	Risk Ratio (M-H, Fixed, 95% CI)	4.61 [1.82, 11.66]
33 Haemangioma	4	5305	Risk Ratio (M-H, Fixed, 95% CI)	0.87 [0.69, 1.10]
35 Neonatal respiratory distress syndrome	4	4725	Risk Ratio (M-H, Fixed, 95% CI)	0.80 [0.34, 1.89]
36 Birthweight below 10th centile	1	3618	Risk Ratio (M-H, Fixed, 95% CI)	0.84 [0.66, 1.06]
37 Birthweight below 5th centile	2	629	Risk Ratio (M-H, Fixed, 95% CI)	1.04 [0.43, 2.56]

Comparison 6. Ultrasound versus no ultrasound before second trimester amniocentesis

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2 Sampling failure	1	223	Risk Ratio (M-H, Fixed, 95% CI)	10.90 [0.61, 194.85]
3 Multiple insertions	1	223	Risk Ratio (M-H, Fixed, 95% CI)	0.67 [0.41, 1.09]
20 All known pregnancy loss (including termination of pregnancy)	1	223	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.01, 8.02]
24 Spontaneous miscarriage	1	223	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.01, 8.02]
25 Spontaneous miscarriage after test	1	223	Risk Ratio (M-H, Fixed, 95% CI)	0.33 [0.01, 8.02]
38 Bloody tap (not prespecified)	1	223	Odds Ratio (M-H, Fixed, 95% CI)	2.03 [0.86, 4.77]

Analysis I.I. Comparison I Second trimester amniocentesis versus control, Outcome I Not complied with allocated procedure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: I Not complied with allocated procedure

Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
	11/1 N	11/1 N	11-1 I, I Xed, 75% CI		11-1 I, I Xed, 75% CI
Tabor 1986	38/2302	22/2304		100.0 %	1.73 [1.03, 2.91]
Total (95% CI)	2302	2304	•	100.0 %	1.73 [1.03, 2.91]
Total events: 38 (Amnioc	centesis), 22 (Control)				
Heterogeneity: not applie	cable				
Test for overall effect: Z	= 2.06 (P = 0.040)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis I.3. Comparison I Second trimester amniocentesis versus control, Outcome 3 Multiple insertions.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 3 Multiple insertions

Study or subgroup	Amniocentesis	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
Tabor 1986	45/2302	0/2304		100.0 %	91.08 [5.61, 1477.53]
Total (95% CI)	2302	2304	-	100.0 %	91.08 [5.61, 1477.53]
Total events: 45 (Amnioc	centesis), 0 (Control)				
Heterogeneity: not applie	cable				
Test for overall effect: Z	= 3.17 (P = 0.0015)				
			<u> </u>		
			0.0010 0.1 1.0 10.0 1000.0		

Favours treatment Favours control

Analysis I.4. Comparison I Second trimester amniocentesis versus control, Outcome 4 Second test performed.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 4 Second test performed

Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	20/2302	0/2304		100.0 %	41.04 [2.48, 678.07]
Total (95% CI) Total events: 20 (Amnioc Heterogeneity: not applic Test for overall effect: Z	cable	2304		100.0 %	41.04 [2.48, 678.07]
			0.0010 0.1 1.0 10.0 1000.0 Favours treatment Favours control)	

Analysis I.5. Comparison I Second trimester amniocentesis versus control, Outcome 5 Laboratory failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: I Second trimester amniocentesis versus control Outcome: 5 Laboratory failure Weight Risk Ratio Study or subgroup Amniocentesis Control Risk Ratio n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% Cl Tabor 1986 13/2302 0/2304 100.0 % 27.02 [1.61, 454.31] 2304 100.0 % Total (95% CI) 2302 27.02 [1.61, 454.31] Total events: 13 (Amniocentesis), 0 (Control) Heterogeneity: not applicable Test for overall effect: Z = 2.29 (P = 0.022) 0.0010 0.1 1.0 10.0 1000.0 Favours control Favours treatment

Analysis I.6. Comparison I Second trimester amniocentesis versus control, Outcome 6 All non-mosaic abnormalities.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 6 All non-mosaic abnormalities

Study or subgroup	Amniocentesis n/N	Control n/N	Risk R: M-H,Fixed,95	8 1	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	15/2302	0/2291		100.0 %	30.85 [1.85, 515.31]
Total (95% CI)	2302	2291		100.0 %	30.85 [1.85, 515.31]
Total events: 15 (Amniod	centesis), 0 (Control)				
Heterogeneity: not applie	cable				
Test for overall effect: Z	= 2.39 (P = 0.017)				
			0.0010 0.1 1.0 10.	0 1000.0	
			Favours treatment Favo	purs control	

Analysis 1.13. Comparison I Second trimester amniocentesis versus control, Outcome 13 Vaginal bleeding after test.

Review: Amniocentesis	and chorionic villus sampl	ing for prenatal diagno	osis		
Comparison: I Second	trimester amniocentesis v	ersus control			
Outcome: 13 Vaginal bl	leeding after test				
Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	55/2302	58/2304		100.0 %	0.95 [0.66, 1.37]
Total (95% CI) Total events: 55 (Amnioce Heterogeneity: not applica Test for overall effect: Z =	able	2304		100.0 %	0.95 [0.66, 1.37]
			0.5 0.7 1.0 1.5 2.0		
		Favou	urs treatment Favours control		
Amniocentesis and cho	rionic villus sampling	for prenatal diagno	sis (Review)		3

Analysis 1.14. Comparison I Second trimester amniocentesis versus control, Outcome 14 Amniotic leakage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 14 Amniotic leakage after test

Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	39/2302	10/2304		100.0 %	3.90 [1.95, 7.80]
Total (95% CI)	2302	2304	-	100.0 %	3.90 [1.95, 7.80]
Total events: 39 (Amnioc	entesis), 10 (Control)				
Heterogeneity: not applic	able				
Test for overall effect: Z =	= 3.86 (P = 0.00012)				
			0.2 0.5 1.0 2.0 5.0		

Favours treatment Favours control

Analysis 1.20. Comparison I Second trimester amniocentesis versus control, Outcome 20 All known pregnancy loss (including termination of pregnancy).

Review: Amniocentesis	and chorionic villus sampl	ing for prenatal dia	gnosis		
Comparison: I Second	trimester amniocentesis v	ersus control			
Outcome: 20 All know	n pregnancy loss (including	g termination of pr	egnancy)		
Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	73/2302	52/2304		100.0 %	1.41 [0.99, 2.00]
Total (95% CI) Total events: 73 (Amnioce Heterogeneity: not applica Test for overall effect: Z =	able	2304	•	100.0 %	1.41 [0.99, 2.00]
			0.1 0.2 0.5 1.0 2.0 5.0 1	0.0	
			Favours treatment Favours contr	ol	

Analysis 1.21. Comparison I Second trimester amniocentesis versus control, Outcome 21 Termination of pregnancy (all).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 21 Termination of pregnancy (all)

Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	15/2302	6/2304		100.0 %	2.50 [0.97, 6.44]
Total (95% CI)	2302	2304		100.0 %	2.50 [0.97, 6.44]
Total events: 15 (Amnioc	entesis), 6 (Control)				
Heterogeneity: not applic	able				
Test for overall effect: Z =	= 1.90 (P = 0.057)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis I.24. Comparison I Second trimester amniocentesis versus control, Outcome 24 Spontaneous miscarriage.

Review: Amniocentesis	s and chorionic villus sampli	ing for prenatal di	agnosis		
Comparison: I Second	l trimester amniocentesis v	ersus control			
Outcome: 24 Spontan	eous miscarriage				
Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	48/2302	30/2304		100.0 %	1.60 [1.02, 2.52]
Total (95% CI) Total events: 48 (Amnioce Heterogeneity: not applic Test for overall effect: Z =	able	2304	•	100.0 %	1.60 [1.02, 2.52]
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Analysis 1.26. Comparison I Second trimester amniocentesis versus control, Outcome 26 Perinatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 26 Perinatal deaths

Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	10/2302	16/2304		100.0 %	0.63 [0.28, 1.38]
Total (95% CI) Total events: 10 (Amnioc Heterogeneity: not applic	able	2304	-	100.0 %	0.63 [0.28, 1.38]
Test for overall effect: Z =	= 1.17 (P = 0.24)		0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control		

Analysis I.27. Comparison I Second trimester amniocentesis versus control, Outcome 27 Stillbirths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: I Second trimester amniocentesis versus control Outcome: 27 Stillbirths Risk Ratio Study or subgroup Amniocentesis Control Risk Ratio Weight M-H,Fixed,95% Cl n/N n/N M-H,Fixed,95% CI 0.83 [0.36, 1.93] Tabor 1986 10/2302 12/2304 100.0 % Total (95% CI) 2304 0.83 [0.36, 1.93] 2302 100.0 % Total events: 10 (Amniocentesis), 12 (Control) Heterogeneity: not applicable Test for overall effect: Z = 0.42 (P = 0.67) 0.1 0.2 0.5 1 0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 1.28. Comparison I Second trimester amniocentesis versus control, Outcome 28 Neonatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 28 Neonatal deaths

Study or subgroup	Amniocentesis n/N	Control n/N		Risk Ratio xed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	0/2302	4/2304	•		100.0 %	0.11 [0.01, 2.06]
Total (95% CI)	2302	2304			100.0 %	0.11 [0.01, 2.06]
Total events: 0 (Amniocer	ntesis), 4 (Control)					
Heterogeneity: not applic	able					
Test for overall effect: Z =	= 1.47 (P = 0.14)					
			0.1 0.2 0.5	1.0 2.0 5.0 10.0		
			Favours treatment	Favours control		

Analysis 1.29. Comparison I Second trimester amniocentesis versus control, Outcome 29 All recorded deaths after viability.

Review: Amniocentesis	and chorionic villus sampl	ing for prenatal dia	gnosis		
Comparison: I Second	l trimester amniocentesis v	ersus control			
Outcome: 29 All recor	ded deaths after viability				
Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	10/2302	16/2304		100.0 %	0.63 [0.28, 1.38]
Total (95% CI)	2302	2304	-	100.0 %	0.63 [0.28, 1.38]
			0.1 0.2 0.5 1 0 2.0 5.0 10.0		
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Analysis 1.30. Comparison I Second trimester amniocentesis versus control, Outcome 30 Anomalies (all recorded).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 30 Anomalies (all recorded)

Study or subgroup	Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tabor 1986	45/2239	49/2268	-	100.0 %	0.93 [0.62, 1.39]
Total (95% CI)	2239	2268	•	100.0 %	0.93 [0.62, 1.39]
Total events: 45 (Amnioce	entesis), 49 (Control)				
Heterogeneity: not applica	able				
Test for overall effect: Z =	= 0.35 (P = 0.72)				
(J					
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		

Favours treatment Favours control

Analysis 1.31. Comparison I Second trimester amniocentesis versus control, Outcome 31 Talipes.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: I Second trimester amniocentesis versus control Outcome: 31 Talipes Risk Ratio Study or subgroup Amniocentesis Control Risk Ratio Weight n/N n/N M-H,Fixed,95% Cl M-H,Fixed,95% Cl Tabor 1986 18/2239 27/2268 100.0 % 0.68 [0.37, 1.22] 2268 100.0 % 0.68 [0.37, 1.22] Total (95% CI) 2239 Total events: 18 (Amniocentesis), 27 (Control) Heterogeneity: not applicable Test for overall effect: Z = 1.30 (P = 0.19) 0.1 0.2 0.5 1 0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 1.35. Comparison I Second trimester amniocentesis versus control, Outcome 35 Neonatal respiratory distress syndrome.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: I Second trimester amniocentesis versus control

Outcome: 35 Neonatal respiratory distress syndrome

Amniocentesis n/N	Control n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
25/2239	12/2268		100.0 %	2.11 [1.06, 4.19]
2239	2268	-	100.0 %	2.11 [1.06, 4.19]
entesis), 12 (Control)				
able				
2.13 (P = 0.033)				
	n/N 25/2239 2239 Intesis), 12 (Control) Ible	n/N n/N 25/2239 12/2268 2239 2268 Intesis), 12 (Control) ible	n/N n/N M-H,Fixed,95% Cl 25/2239 12/2268 2239 2268 Intesis), 12 (Control) ible	n/N n/N M-H,Fixed,95% Cl 25/2239 12/2268 100.0 % 2239 2268 100.0 % intesis), 12 (Control) ible

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 2.1. Comparison 2 Early versus second trimester amniocentesis, Outcome 1 Not complied with allocated procedure.

Review: Amniocente	sis and chorionic villus sampl	ing for prenatal diagnosis					
Comparison: 2 Early versus second trimester amniocentesis							
Outcome: I Not cor	mplied with allocated procec	lure					
Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	٢		iisk Ratio ed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	267/2183	410/2185		+		100.0 %	0.65 [0.57, 0.75]
Total (95% CI)	2183	2185		٠		100.0 %	0.65 [0.57, 0.75]
Total events: 267 (Early	amniocentesis), 410 (Mid-tr	imester amnio)					
Heterogeneity: not app	licable						
Test for overall effect: Z	Z = 5.90 (P < 0.00001)						
			0.1 0.2	0.5 I.	0 2.0 5.0 10.0		
			Favours treat	ment	Favours control		

Analysis 2.2. Comparison 2 Early versus second trimester amniocentesis, Outcome 2 Sampling failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 2 Sampling failure

Study or subgroup	Early amniocentesis	Mid-trimester amnio	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
CEMAT 1998	5/330	1/299		100.0 %	4.53 [0.53, 38.56]
Total (95% CI)	330	299		100.0 %	4.53 [0.53, 38.56]
Total events: 5 (Early ar	nniocentesis), I (Mid-trimes	ter amnio)			
Heterogeneity: not app	licable				
Test for overall effect: Z	Z = 1.38 (P = 0.17)				
		C	0.05 0.2 1.0 5.0 20.0		
		Favours	treatment Favours control		

Analysis 2.3. Comparison 2 Early versus second trimester amniocentesis, Outcome 3 Multiple insertions.

Review: Amniocentes	sis and chorionic villus sampl	ing for prenatal diagnosis			
Comparison: 2 Early	versus second trimester amr	niocentesis			
Outcome: 3 Multiple	insertions				
Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	103/2183	37/2185		100.0 %	2.79 [1.92, 4.04]
Total (95% CI) Total events: 103 (Early Heterogeneity: not appl Test for overall effect: Z		2185 nester amnio)	•	100.0 %	2.79 [1.92, 4.04]
			0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control		

Analysis 2.4. Comparison 2 Early versus second trimester amniocentesis, Outcome 4 Second test performed.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 4 Second test performed

Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N		Risk Ratio xed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	46/2108	5/1999		— <mark>—</mark> —	100.0 %	8.72 [3.47, 21.91]
Total (95% CI)	2108	1999		•	100.0 %	8.72 [3.47, 21.91]
Total events: 46 (Early a	amniocentesis), 5 (Mid-trime	ster amnio)				
Heterogeneity: not app	licable					
Test for overall effect: Z	Z = 4.61 (P < 0.00001)					
		1				
		0.0	5 0.2 I.	0 5.0 20.0		
		Favours	treatment	Favours control		

Analysis 2.5. Comparison 2 Early versus second trimester amniocentesis, Outcome 5 Laboratory failure.

Review: Amniocentes	sis and chorionic villus samp	ling for prenatal diagnosis			
Comparison: 2 Early	versus second trimester am	niocentesis			
Outcome: 5 Laborate	ory failure				
Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	Risk Ratio M-H,Fixed,95% CI	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	39/2183	4/2185		100.0 %	9.76 [3.49, 27.26]
Total (95% CI)	2183	2185	-	100.0 %	9.76 [3.49, 27.26]
Heterogeneity: not appl Test for overall effect: Z		0	.05 0.2 1.0 5.0 20.0 treatment Favours control		

Analysis 2.6. Comparison 2 Early versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 6 All non-mosaic abnormalities

Study or subgroup	Early amniocentesis	Mid-trimester amnio	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
CEMAT 1998	50/2183	45/2185		100.0 %	1.11 [0.75, 1.66]
Total (95% CI)	2183	2185	-	100.0 %	1.11 [0.75, 1.66]
Total events: 50 (Early a	amniocentesis), 45 (Mid-trim	ester amnio)			
Heterogeneity: not appl	licable				
Test for overall effect: Z	Z = 0.52 (P = 0.60)				

0.5 0.7 1.0 1.52.0 Favours treatment Favours control

Analysis 2.7. Comparison 2 Early versus second trimester amniocentesis, Outcome 7 True mosaics.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 2 Early versus second trimester amniocentesis Outcome: 7 True mosaics Study or subgroup Early amniocentesis Mid-trimester amnio Risk Ratio Weight Risk Ratio M-H,Fixed,95% CI M-H,Fixed,95% Cl n/N n/N CEMAT 1998 4/2183 4/2185 100.0 % 1.00 [0.25, 4.00] Total (95% CI) 2183 2185 100.0 % 1.00 [0.25, 4.00] Total events: 4 (Early amniocentesis), 4 (Mid-trimester amnio) Heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.0)0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 2.9. Comparison 2 Early versus second trimester amniocentesis, Outcome 9 Maternal contamination.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 9 Maternal contamination

Study or subgroup	Early amniocentesis	Mid-trimester amnio		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,F	ixed,95% Cl		M-H,Fixed,95% CI
CEMAT 1998	4/2183	2/2185			100.0 %	2.00 [0.37, 10.92]
Total (95% CI)	2183	2185			100.0 %	2.00 [0.37, 10.92]
Total events: 4 (Early ar	mniocentesis), 2 (Mid-trimes	ter amnio)				
Heterogeneity: not app	licable					
Test for overall effect: Z	Z = 0.80 (P = 0.42)					
			0.1 0.2 0.5 1	.0 2.0 5.0 10.0		
		Favo	ours treatment	Favours control		

Analysis 2.11. Comparison 2 Early versus second trimester amniocentesis, Outcome 11 False negative chromosomal diagnosis.

Review: Amniocentesis a	nd chorionic villus sampling	g for prenatal diagnosis				
Comparison: 2 Early vers	sus second trimester amnic	ocentesis				
Outcome: II False negat	ive chromosomal diagnosis	5				
Study or subgroup	Early amniocentesis	Mid-trimester amnio		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,ł	ixed,95% Cl		M-H,Fixed,95% CI
I False negative chromoson	nal results (excluding sex d	etermination)				
CEMAT 1998	1/2183	0/2185			100.0 %	3.00 [0.12, 73.67]
Subtotal (95% CI)	2183	2185			100.0 %	3.00 [0.12, 73.67]
Total events: I (Early amnio	centesis), 0 (Mid-trimester	amnio)				
Heterogeneity: not applicab						
Test for overall effect: $Z = 0$	· · · ·					
2 Incorrect sex determination CEMAT 1998	on 2/2183	0/2185			100.0 %	5.00 [0.24, 104.18]
Subtotal (95% CI)	2183	2185			100.0 %	5.00 [0.24, 104.18]
Total events: 2 (Early amnio	, (amnio)				
Heterogeneity: not applicab						
Test for overall effect: $Z = 1$	1.04 (P – 0.30)					
			0.01 0.1	1.0 10.0 100.0		
		Favo	ours treatment	Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 2 Early versus second trimester amniocentesis

Outcome: II False negative chromosomal diagnosis

Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I False negative chromosom	nal results (excluding sex d	letermination)			
CEMAT 1998	1/2183	0/2185		100.0 %	3.00 [0.12, 73.67
Subtotal (95% CI)	2183	2185		100.0 %	3.00 [0.12, 73.67
Total events: 1 (Early amnior Heterogeneity: not applicabl Test for overall effect: Z = 0	e	amnio)			
			01 0.1 1,0 10.0 100.0 rs treatment Favours control		
Review: Amniocentesis ar	nd chorionic villus sampling	g for prenatal diagnosis			
Review: Amniocentesis ar Comparison: 2 Early verse					
	us second trimester amnic	ocentesis			
Comparison: 2 Early vers	us second trimester amnic	ocentesis	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% CI
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N	ocentesis s Mid-trimester amnio		Weight	
Comparison: 2 Early vers Outcome: 11 False negati	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N	ocentesis s Mid-trimester amnio		Weight 100.0 %	M-H,Fixed,95% CI
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnion Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185			M-H,Fixed,95% Cl 5.00 [0.24, 104.18
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnion Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185	M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 5.00 [0.24, 104.18
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185 amnio)	M-H,Fixed,95% Cl	100.0 %	
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnioon Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185 amnio)	M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 5.00 [0.24, 104.18
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnioon Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185 amnio)	M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 5.00 [0.24, 104.18
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnioon Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185 amnio)	M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 5.00 [0.24, 104.18
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnioon Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185 amnio)	M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 5.00 [0.24, 104.18
Comparison: 2 Early verse Outcome: 11 False negati Study or subgroup 2 Incorrect sex determination CEMAT 1998 Subtotal (95% CI) Total events: 2 (Early amnion Heterogeneity: not applicable	us second trimester amnic ive chromosomal diagnosis Early amniocentesis n/N 2/2183 2183 centesis), 0 (Mid-trimester le	Mid-trimester amnio n/N 0/2185 2185 amnio)	M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 5.00 [0.24, 104.18

Analysis 2.12. Comparison 2 Early versus second trimester amniocentesis, Outcome 12 Reporting time.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 12 Reporting time

-

Study or subgroup	Early amniocentesis		Mid-trimester amnio		Mea	n Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	IV,Fixe	d,95% Cl		IV,Fixed,95% CI
CEMAT 1998	2108	17.7 (4.9)	1999	16.5 (5.3)			100.0 %	1.20 [0.89, 1.51]
Total (95% CI)	2108		1999			•	100.0 %	1.20 [0.89, 1.51]
Heterogeneity: not a	applicable							
Test for overall effect	t: Z = 7.52 (P < 0.0000	I)						
				-1	2 - 1 () I	2	
				Favou	irs treatment	Favours con	ntrol	

Analysis 2.14. Comparison 2 Early versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.

Ratio 5% Cl
, 2.94]
2.94]
9 <u>.</u> 3,

Analysis 2.20. Comparison 2 Early versus second trimester amniocentesis, Outcome 20 All known pregnancy loss (including termination of pregnancy).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	166/2172	128/2162		100.0 %	1.29 [1.03, 1.61]
Total (95% CI)	2172	2162	•	100.0 %	1.29 [1.03, 1.61]
Total events: 166 (Early	amniocentesis), 128 (Mid-tr	imester amnio)			
Heterogeneity: not app	licable				
Test for overall effect: Z	Z = 2.25 (P = 0.025)				
			0.5 0.7 1.0 1.5 2.0		

Favours treatment Favours control

Analysis 2.21. Comparison 2 Early versus second trimester amniocentesis, Outcome 21 Termination of pregnancy (all).

Review: Amniocente	sis and chorionic villus sampl	ing for prenatal diagnosis			
Comparison: 2 Early	versus second trimester am	niocentesis			
Outcome: 21 Termin	ation of pregnancy (all)				
Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	72/2172	57/2162		100.0 %	1.26 [0.89, 1.77]
Total (95% CI)	2172	2162	-	100.0 %	1.26 [0.89, 1.77]
Heterogeneity: not appl Test for overall effect: Z					
		(0.5 0.7 1.0 1.5 2.0		
		Favours tre	eatment Favours control		

Analysis 2.24. Comparison 2 Early versus second trimester amniocentesis, Outcome 24 Spontaneous miscarriage.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 24 Spontaneous miscarriage

Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	78/2172	55/2162	—— <mark>—</mark> —	100.0 %	.4 [.00, .98]
Total (95% CI)	2172	2162		100.0 %	1.41 [1.00, 1.98]
Total events: 78 (Early a	amniocentesis), 55 (Mid-trime	ester amnio)			
Heterogeneity: not app	licable				
Test for overall effect: Z	Z = 1.99 (P = 0.047)				
		(0.5 0.7 1.0 1.5 2.0		
		Favours	treatment Favours control		

Analysis 2.25. Comparison 2 Early versus second trimester amniocentesis, Outcome 25 Spontaneous miscarriage after test.

Review: Amniocente	sis and chorionic villus sampl	ing for prenatal diagnosis				
Comparison: 2 Early	versus second trimester am	niocentesis				
Outcome: 25 Sponta	neous miscarriage after test					
Study or subgroup	Early amniocentesis n/N	Mid-trimester amnio n/N	M-H,F	Risk Ratio Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
CEMAT 1998	55/2172	17/2162			100.0 %	3.22 [1.88, 5.53
Total (95% CI)	2172	2162		•	100.0 %	3.22 [1.88, 5.53
			01 02 05			
			0.1 0.2 0.5 Favours treatment	1.0 2.0 5.0 10.0 Favours control		

Analysis 2.27. Comparison 2 Early versus second trimester amniocentesis, Outcome 27 Stillbirths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 27 Stillbirths

Study or subgroup	Early amniocentesis	Mid-trimester amnio	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
CEMAT 1998	11/2172	15/2162		100.0 %	0.73 [0.34, 1.59]
Total (95% CI)	2172	2162		100.0 %	0.73 [0.34, 1.59]
Total events: (Early a	amniocentesis), I5 (Mid-trim	ester amnio)			
Heterogeneity: not app	licable				
Test for overall effect: Z	L = 0.80 (P = 0.43)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0)	
		Fa	vours treatment Favours control		

Analysis 2.28. Comparison 2 Early versus second trimester amniocentesis, Outcome 28 Neonatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 2 Early versus second trimester amniocentesis Outcome: 28 Neonatal deaths Risk Ratio Study or subgroup Early amniocentesis Mid-trimester amnio Risk Ratio Weight M-H,Fixed,95% CI M-H,Fixed,95% CI n/N n/N CEMAT 1998 5/2172 1/2162 100.0 % 4.98 [0.58, 42.56] Total (95% CI) 4.98 [0.58, 42.56] 2172 2162 100.0 % Total events: 5 (Early amniocentesis), I (Mid-trimester amnio) Heterogeneity: not applicable Test for overall effect: Z = 1.47 (P = 0.14) 0.02 0.1 1.0 10.0 50.0 Favours treatment Favours control

Analysis 2.29. Comparison 2 Early versus second trimester amniocentesis, Outcome 29 All recorded deaths after viability.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 29 All recorded deaths after viability

Study or subgroup	Early amniocentesis	Mid-trimester amnio	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
CEMAT 1998	16/2172	16/2162		100.0 %	1.00 [0.50, 1.99]
Total (95% CI)	2172	2162	-	100.0 %	1.00 [0.50, 1.99]
Total events: 16 (Early a	amniocentesis), 16 (Mid-trim	ester amnio)			
Heterogeneity: not app	licable				
Test for overall effect: Z	<u>Z</u> = 0.01 (P = 0.99)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 2.30. Comparison 2 Early versus second trimester amniocentesis, Outcome 30 Anomalies (all recorded).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 30 Anomalies (all recorded)

Study or subgroup	Early amniocentesis	Mid-trimester amnio	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
CEMAT 1998	101/2172	58/2162		100.0 %	1.73 [1.26, 2.38]
Total (95% CI)	2172	2162	•	100.0 %	1.73 [1.26, 2.38]
Total events: 101 (Early	amniocentesis), 58 (Mid-trin	nester amnio)			
Heterogeneity: not appl	licable				
Test for overall effect: Z	Z = 3.40 (P = 0.00068)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 2.31. Comparison 2 Early versus second trimester amniocentesis, Outcome 31 Talipes.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 2 Early versus second trimester amniocentesis

Outcome: 31 Talipes

Study or subgroup	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Talipes (all)					
Subtotal (95% CI)	0	0		0.0 %	0.0 [0.0, 0.0
Total events: 0 (Early amni	ocentesis), 0 (Mid-trimester	amnio)			
Heterogeneity: not applica	ble				
Test for overall effect: not	applicable				
2 Talipes equinovarus					
CEMAT 1998	29/2172	2/2162		100.0 %	4.43 [3.45, 60.4
Subtotal (95% CI)	2172	2162	•	100.0 %	14.43 [3.45, 60.41
Total events: 29 (Early am	niocentesis), 2 (Mid-trimeste	er amnio)			
Heterogeneity: not applica					
Test for overall effect: $Z =$	3.65 (P = 0.00026)				
			0.01 0.1 1.0 10.0 10.0		
		Favours	s treatment Favours control		
	and chorionic villus sampling				
Comparison: 2 Early ver			Risk Ratio	Weight	Risk Ratio
Comparison: 2 Early ver Outcome: 31 Talipes	rsus second trimester amnic	pcentesis	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup	rsus second trimester amnic Early amniocentesis	Dicentesis Mid-trimester amnio		Weight	
Comparison: 2 Early ver Outcome: 31 Talipes	rsus second trimester amnic Early amniocentesis	Dicentesis Mid-trimester amnio		Weight 100.0 %	M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup 2 Talipes equinovarus CEMAT 1998	rsus second trimester amnic Early amniocentesis n/N 29/2172	Mid-trimester amnio n/N 2/2162		100.0 %	M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup 2 Talipes equinovarus CEMAT 1998 Subtotal (95% CI)	rsus second trimester amnic Early amniocentesis n/N	Mid-trimester amnio n/N 2/2162 2162			M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup 2 Talipes equinovarus CEMAT 1998 Subtotal (95% CI)	rsus second trimester amnic Early amniocentesis n/N 29/2172 2172 niocentesis), 2 (Mid-trimeste	Mid-trimester amnio n/N 2/2162 2162		100.0 %	M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup 2 Talipes equinovarus CEMAT 1998 Subtotal (95% CI) Total events: 29 (Early am Heterogeneity: not applica	Early amniocentesis n/N 29/2172 2172 niocentesis), 2 (Mid-trimeste	Mid-trimester amnio n/N 2/2162 2162		100.0 %	M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup 2 Talipes equinovarus CEMAT 1998 Subtotal (95% CI) Total events: 29 (Early am	Early amniocentesis n/N 29/2172 2172 niocentesis), 2 (Mid-trimeste	Mid-trimester amnio n/N 2/2162 2162 er amnio)	M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl
Comparison: 2 Early ver Outcome: 31 Talipes Study or subgroup 2 Talipes equinovarus CEMAT 1998 Subtotal (95% CI) Total events: 29 (Early am Heterogeneity: not applica	Early amniocentesis n/N 29/2172 2172 niocentesis), 2 (Mid-trimeste	Mid-trimester amnio n/N 2/2162 2162 er amnio)		100.0 %	

Analysis 3.1. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome I Not complied with allocated procedure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: I Not complied with allocated procedure

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
					,, ,
I Transcervical CVS versus an			_		
Borrell 1999	185/503	145/508	-	44.0 %	1.29 [1.08, 1.54]
Canada 1992	200/1391	455/1396	•	44.3 %	0.44 [0.38, 0.51]
MRC (Finland) 1993	1/399	18/398		11.7 %	0.06 [0.01, 0.41]
Subtotal (95% CI)	2293	2302	-	100.0 %	0.50 [0.18, 1.36]
Total events: 386 (CVS), 618	(Amniocentesis)				
Heterogeneity: $Tau^2 = 0.61$; C	Chi ² = 89.14, df = 2	(P<0.00001); I ² =98%			
Test for overall effect: $Z = 1.3$	6 (P = 0.17)				
3 CVS (any route) versus amr	niocentesis				
MRC 1991	2/ 608	168/1589	+	100.0 %	0.66 [0.52, 0.83]
Subtotal (95% CI)	1608	1589	•	100.0 %	0.66 [0.52, 0.83]
Total events: 112 (CVS), 168	(Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 3.5$	7 (P = 0.00035)				

0.01 0.1 1.0 10.0 100.0

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: I Not complied with allocated procedure

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% C
I Transcervical CVS versus ar	nniocentesis				
Borrell 1999	185/503	145/508	•	44.0 %	1.29 [1.08, 1.54]
Canada 1992	200/1391	455/1396	•	44.3 %	0.44 [0.38, 0.5]
MRC (Finland) 1993	1/399	18/398		11.7 %	0.06 [0.01, 0.41]
Subtotal (95% CI)	2293	2302	•	100.0 %	0.50 [0.18, 1.36]
Total events: 386 (CVS), 618 Heterogeneity: Tau ² = 0.61; C Test for overall effect: Z = 1.3	$Chi^2 = 89.14, df = 2$	(P<0.00001); l ² =98%			
		Favo	0.01 0.1 1.0 10.0 100.0 Purs treatment Favours control		
Review: Amniocentesis and	I chorionic villus sam	pling for prenatal diagnosis			
Review: Amniocentesis and Comparison: 3 Chorionic v			tesis		
	villus sampling versus	second trimester amniocer	tesis		
Comparison: 3 Chorionic v	villus sampling versus	second trimester amniocer	ıtesis		
Comparison: 3 Chorionic v	villus sampling versus with allocated proce CVS	second trimester amniocer edure Amniocentesis	Risk Ratio	Weight	Risk Ratio
Comparison: 3 Chorionic v Outcome: I Not complied	villus sampling versus	second trimester amniocer edure		Weight	
Comparison: 3 Chorionic v Outcome: I Not complied Study or subgroup 3 CVS (any route) versus ame	villus sampling versus with allocated proce CVS n/N niocentesis	second trimester amniocer edure Amniocentesis n/N	Risk Ratio		M-H,Random,95% C
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608	second trimester amniocer edure Amniocentesis n/N 168/1589	Risk Ratio	100.0 %	M-H,Random,95% C 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI)	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608	second trimester amniocer edure Amniocentesis n/N	Risk Ratio		M-H,Random,95% C
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589	Risk Ratio	100.0 %	M-H,Random,95% C 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589	Risk Ratio	100.0 %	M-H,Random,95% C 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589	Risk Ratio	100.0 %	M-H,Random,95% Cl 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589 1589	Risk Ratio	100.0 %	M-H,Random,95% Cl 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589 1589	Risk Ratio M-H,Random,95% Cl	100.0 %	M-H,Random,95% Cl 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589 1589	Risk Ratio M-H,Random,95% Cl	100.0 %	M-H,Random,95% Cl 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589 1589	Risk Ratio M-H,Random,95% Cl	100.0 %	M-H,Random,95% C 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589 1589	Risk Ratio M-H,Random,95% Cl	100.0 %	M-H,Random,95% C 0.66 [0.52, 0.83]
Comparison: 3 Chorionic v Outcome: 1 Not complied Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 112 (CVS), 168 Heterogeneity: not applicable	villus sampling versus with allocated proce CVS n/N niocentesis 112/1608 1608 (Amniocentesis)	second trimester amniocer edure Amniocentesis n/N 168/1589 1589	Risk Ratio M-H,Random,95% Cl	100.0 %	M-H,Random,95% Cl 0.66 [0.52, 0.83]

Analysis 3.2. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 2 Sampling failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 2 Sampling failure

I Transervical CVS versus amnioo MRC (Finland) 1993 Subtotal (95% CI) Total events: 10 (CVS), 18 (Amni Heterogeneity: not applicable Test for overall effect: Z = 1.52 (F	n/N centesis 10/399 399	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
MRC (Finland) 1993 Subtotal (95% CI) Total events: 10 (CVS), 18 (Amni Heterogeneity: not applicable	10/399				
Total events: 10 (CVS), 18 (Amni Heterogeneity: not applicable	399	18/398		100.0 %	0.55 [0.26, 1.19
Heterogeneity: not applicable	-	398	-	100.0 %	0.55 [0.26, 1.19
	ocentesis)				
10311010001an Check Z = 1.3Z (1)	P = 0.13				
3 CVS (any route) versus amnioc	,				
MRC 1991	78/1609	25/1592		100.0 %	3.09 [1.98, 4.82
Subtotal (95% CI) Total events: 78 (CVS), 25 (Amni	1609	1592	•	100.0 %	3.09 [1.98, 4.82
Heterogeneity: not applicable					
Test for overall effect: $Z = 4.96$ (F	³ < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		Fa	avours treatment Favours control		
Review: Amniocentesis and cho	orionic villus sar	npling for prenatal diagnosis			
Comparison: 3 Chorionic villus	s sampling versu	s second trimester amniocer	ntesis		
Outcome: 2 Sampling failure					
Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	
Transervical CVS versus amnio	n/N centesis	n/N			M-H,Fixed,95% C
I Transervical CVS versus amnioo MRC (Finland) 1993	n/N centesis 10/399	n/N 18/398		100.0 %	M-H,Fixed,95% C
I Transervical CVS versus amnioo MRC (Finland) 1993 Subtotal (95% CI)	n/N centesis 10/399 399	n/N			M-H,Fixed,95% C
I Transervical CVS versus amnioc MRC (Finland) 1993 Subtotal (95% CI) Total events: 10 (CVS), 18 (Amni	n/N centesis 10/399 399	n/N 18/398		100.0 %	M-H,Fixed,95% C
I Transervical CVS versus amnioo MRC (Finland) 1993 Subtotal (95% CI) Total events: 10 (CVS), 18 (Amni Heterogeneity: not applicable	n/N centesis 10/399 399 iocentesis)	n/N 18/398		100.0 %	M-H,Fixed,95% C
I Transervical CVS versus amnioo MRC (Finland) 1993 Subtotal (95% CI)	n/N centesis 10/399 399 iocentesis)	n/N 18/398 398		100.0 %	Risk Ratio M-H,Fixed,95% C 0.55 [0.26, 1.19 0.55 [0.26, 1.19

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 2 Sampling failure

-

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amn MRC 1991	iocentesis 78/1609	25/1592	-	100.0 %	3.09 [1.98, 4.82]
Subtotal (95% CI) Total events: 78 (CVS), 25 (Ar Heterogeneity: not applicable Test for overall effect: Z = 4.9/	,	1592	•	100.0 %	3.09 [1.98, 4.82]
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		

Favours treatment Favours control

Analysis 3.3. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 3 Multiple insertions.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 3 Multiple insertions

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus am	nniocentesis				
MRC (Finland) 1993	123/399	31/395		100.0 %	3.93 [2.72, 5.68]
Subtotal (95% CI)	399	395	•	100.0 %	3.93 [2.72, 5.68]
Total events: 123 (CVS), 31 (A	Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 7.26$	8 (P < 0.00001)				
3 CVS (any route) versus amn	niocentesis				
MRC 1991	460/1496	90/1421		100.0 %	4.85 [3.92, 6.01]
Subtotal (95% CI)	1496	1421	•	100.0 %	4.85 [3.92, 6.01]
Total events: 460 (CVS), 90 (A	Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 14.4$	48 (P < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 3 Multiple insertions

11 Transcervical CVS versus annicoentesis 12339 31/395 ■ 100.0 % 393 [2.72, 5.68 Stubbeal (95% CI) 3 99 395 395 100.0 % 3.93 [2.72, 5.68 Transcervical CVS versus annicoentesis ■ 100.0 % 3.93 [2.72, 5.68 Transcervical CVS versus annicoentesis ■ 100.0 % 3.93 [2.72, 5.68 Transcervical CVS versus annicoentesis ■ 100.0 % 3.93 [2.72, 5.68 Transcervical CVS versus annicoentesis ■ 100.0 % 3.93 [2.72, 5.68 Transcervical CVS versus annicoentesis ■ 100.0 % 3.93 [2.72, 5.68 Transcervical CVS versus annicoentesis ■ 100.0 % 3.93 [2.72, 5.68 Pervices: Annicoentesis and chorionic villus sampling for prenatal diagnosis ■ 100.0 % 3.93 [2.72, 5.68 Comparison: 3 Chorionic villus sampling for prenatal diagnosis ■ ■ 100.0 % MitHised State Study or subgroup CVS Armicoentesis Risk Ratio Weight MitHised State Study or subgroup CVS Armicoentesis Risk Ratio Weight MitHised State Transcerist: 460 (CVS), 90 (Armicoen	Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Subord (95% CI) 399 395 Total events: 123 (CVS), 31 (Amniccentesis) 100.0 % 3.93 [2.72, 5.68 Test events: 123 (CVS), 31 (Amniccentesis) 100.0 % 3.93 [2.72, 5.68 Test for overall effect: Z = 7.28 (P < 0.00001) 100.0 % 3.93 [2.72, 5.68 Review: Anniocentesis and chorionic villus sampling for prenatal diagnosis Facours treatment Facours control Review: Anniocentesis and chorionic villus sampling versus second trimester anniocentesis Risk Ratio Weight Risk Ratio Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis Risk Ratio Weight Risk Ratio 3 CVS (any route) versus anniocentesis m/N m/N M-H-Fixed.95% CI M-H.Fixed.95% CI M-H.Fixed.95% CI 3 CVS (any route) versus anniocentesis Milc 1991 460/1496 90/1421 Image: State of the state of	I Transcervical CVS versus ar	mniocentesis				
Total events: 123 (CVS), 31 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 7.28 (P < 0.00001)	MRC (Finland) 1993	123/399	31/395		100.0 %	3.93 [2.72, 5.68
Heterogeneity: not applicable Test for overall effect: Z = 7.28 (P < 0.00001)	Subtotal (95% CI)	399	395	•	100.0 %	3.93 [2.72, 5.68
Test for overall effect: Z = 7.28 (P < 0.00001)						
0.1 0.2 0.5 10 20 50 100 Favours treatment Favours treatment Favours control Review. Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS MN n/N MH-H.Fixed,95% Cl MRC 1991 460/1496 90/1421 Subtotal (95% Cl) 1496 1421 Total events: 460 (CVS), 90 (Anniocentesis) Heterogeneity: not applicable Test or overall effect: Z = 11448 (P < 0.00001)						
Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Out come: 3 Multiple insertions Study or subgroup CVS Amniocentesis Review: Miniocentesis Study or subgroup CVS Amniocentesis Review: Risk Ratio Weight Risk Ratio Weight Risk Ratio MC 1991 460/1496 90/1421 Intervents: 460/1496 90/1421 Subtocal (05% CI) 1496 1421 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable 1000,0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Anniocentesis) Heterogeneity: not applicable 0.1 0.2 0.5 0.00	Test for overall effect. Z = 7.2	0 (1 < 0.00001)				
Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis Risk Ratio Weight Risk Ratio n/N n/N M-H.Fixed,95% Cl M-H.Fixed,95\% Cl M-H.Fixed,95\% Cl M-H.Fixed,95\% Cl M-H.Fixed,95\% Cl				0.1 0.2 0.5 1.0 2.0 5.0 10.0		
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N/H,Fixed,95% Cl M-H,Fixed,95% Cl M-H,Fixed,95% C 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)				Favours treatment Favours control		
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N/H,Fixed,95% Cl M-H,Fixed,95% Cl M-H,Fixed,95% C 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N/H,Fixed,95% Cl M-H,Fixed,95% Cl M-H,Fixed,95% C 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N/H,Fixed,95% Cl M-H,Fixed,95% Cl M-H,Fixed,95% C 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N/H,Fixed,95% Cl M-H,Fixed,95% Cl M-H,Fixed,95% Cl 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 • 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 • 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N/H,Fixed,95% Cl M-H,Fixed,95% Cl M-H,Fixed,95% Cl 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 • 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 • 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N M-H,Fixed,95% CI M-H,Fixed,95% CI M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N N-H,Fixed,95% CI M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 Subtotal (95% CI) 1496 1421 Subtotal (95% CI) 1496 1421 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001) 0.1 0.2 0.5 0 2.0 5.0 100						
Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis NN n/N M-H,Fixed,95% CI M-H,Fixed,95% CI M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						
Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis Risk Ratio Weight Risk Ratio n/N n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI M-H,Fixed,95% CI M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 I I 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 I<	Review: Amniocentesis and	d chorionic villus sam	pling for prenatal diagnosi	s		
Outcome: 3 Multiple insertions Study or subgroup CVS Amniocentesis Risk Ratio Weight Risk Ratio n/N n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI M-H,Fixed,95% CI M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 I I 00.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 I </td <td>Comparison: 3 Chorionic v</td> <td>villus sampling versus</td> <td>second trimester amnioc</td> <td>entesis</td> <td></td> <td></td>	Comparison: 3 Chorionic v	villus sampling versus	second trimester amnioc	entesis		
Study or subgroup CVS n/N Amniocentesis n/N Risk Ratio M-H,Fixed,95% CI Weight Risk Ratio M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 I00.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 I00.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable 100.0 % 4.85 [3.92, 6.01 Test for overall effect: Z = 14.48 (P < 0.00001)						
n/N n/N M-H,Fixed,95% Cl M-H,Fixed,95% Cl 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 I00.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable 100.0 % 4.85 [3.92, 6.01 Test for overall effect: Z = 14.48 (P < 0.00001) 0.1 0.2 0.5 10 20 50 10.0 0.0 10.0	Outcome: 3 Pluitiple Insert	lions				
n/N n/N M-H,Fixed,95% Cl M-H,Fixed,95% Cl 3 CVS (any route) versus amniocentesis MRC 1991 460/1496 90/1421 I00.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable 100.0 % 4.85 [3.92, 6.01 Test for overall effect: Z = 14.48 (P < 0.00001) 0.1 0.2 0.5 10 20 50 10.0 0.0 10.0	Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
MRC 1991 460/1496 90/1421 ■ 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 ● 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable ● 100.0 % 4.85 [3.92, 6.01 Test for overall effect: Z = 14.48 (P < 0.00001)	5000 01 50051000				, voigne	
MRC 1991 460/1496 90/1421 ■ 100.0 % 4.85 [3.92, 6.01 Subtotal (95% CI) 1496 1421 ● 100.0 % 4.85 [3.92, 6.01 Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable ● 100.0 % 4.85 [3.92, 6.01 Test for overall effect: Z = 14.48 (P < 0.00001)	2 CVS (any muto) vortus am	niocontocic				
Subtotal (95% CI) 1496 1421 Total events: 460 (CVS), 90 (Amniocentesis) + 100.0 % 4.85 [3.92, 6.01 Heterogeneity: not applicable - - - - Test for overall effect: Z = 14.48 (P < 0.00001)	, , ,		90/1421		100.0 %	4.85 [3.92, 6.0]
Total events: 460 (CVS), 90 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)						-
Heterogeneity: not applicable Test for overall effect: Z = 14.48 (P < 0.00001)			1421	•	100.0 %	4.85 [3.92, 6.01
Test for overall effect: Z = 14.48 (P < 0.00001) 0.1 0.2 0.5 1.0 2.0 5.0 10.0						
0.1 0.2 0.5 1.0 2.0 5.0 10.0						
		,				
Favours treatment Favours control				0.1 0.2 0.5 1.0 2.0 5.0 10.0		
				Favours treatment Favours control		
mniocentesis and chorionic villus sampling for prenatal diagnosis (Review)						

Analysis 3.4. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 4 Second test performed.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 4 Second test performed

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Transcervical CVS versus ar	nniocentesis				
Borrell 1999	3/3 4	1/358		32.4 %	4.82 [.95, 2.66]
Canada 1992	103/1391	0/1396	∎→	25.1 %	207.74 [12.92, 3340.27]
MRC (Finland) 1993	17/399	4/398	-	42.5 %	4.24 [1.44, 12.49]
Subtotal (95% CI)	2104	2152	-	100.0 %	19.63 [1.24, 309.90]
Total events: 133 (CVS), 5 (A	mniocentesis)				
Heterogeneity: $Tau^2 = 4.90$; (,	2 (P = 0.002); I ² =84%			
Test for overall effect: $Z = 2.1$					
3 CVS (any route) versus amr	· /				
MRC 1991	100/1609	35/1592	•	100.0 %	2.83 [1.94, 4.13]
Subtotal (95% CI)	1609	1592	•	100.0 %	2.83 [1.94, 4.13]
Total events: 100 (CVS), 35 (/	Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: Z = 5.3	88 (P < 0.00001)				

0.0010 0.1 1.0 10.0 1000.0

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 4 Second test performed

	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
I Transcervical CVS versus am					
Borrell 1999	13/314	1/358		32.4 %	4.82 [.95, 2.66]
Canada 1992	103/1391	0/1396	∎ →	25.1 %	207.74 [12.92, 3340.27]
MRC (Finland) 1993	17/399	4/398	-	42.5 %	4.24 [1.44, 12.49]
Subtotal (95% CI)	2104	2152	-	100.0 %	19.63 [1.24, 309.90]
Total events: 133 (CVS), 5 (Ar Heterogeneity: Tau ² = 4.90; C Test for overall effect: Z = 2.1	Chi ² = 12.74, df = 2	. (P = 0.002); I ² =84%			
			0.0010 0.1 1 0 10.0 1000.0		
			Favours treatment Favours control		
Review: Amniocentesis and Comparison: 3 Chorionic vi					
Outcome: 4 Second test pe	erformed				
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% C
	niocentesis				
3 CVS (any route) versus amn			-+-	100.0 %	
3 CVS (any route) versus amn MRC 1991	100/1609	35/1592		100.0 %	2.83 [1.94, 4.13]
. , ,	1609 Amniocentesis)	35/1592 1592	•	100.0 %	2.83 [1.94, 4.13]

Analysis 3.5. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 5 Laboratory failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 5 Laboratory failure

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
			,,		
I Transcervical CVS versus an	nniocentesis		_		
Canada 1992	24/1027	1/968		100.0 %	22.62 [3.07, 166.89]
MRC (Finland) 1993	0/399	0/398	•	0.0 %	0.0 [0.0, 0.0]
Subtotal (95% CI)	1426	1366	-	100.0 %	22.62 [3.07, 166.89]
Total events: 24 (CVS), I (Am	niocentesis)				
Heterogeneity: $Chi^2 = 0.0$, df	$= 0 (P = 1.00); I^2$	=0.0%			
Test for overall effect: $Z = 3.0$	6 (P = 0.0022)				
3 CVS (any route) versus amr	niocentesis				
MRC 1991	7/1609	9/1592	-	100.0 %	0.77 [0.29, 2.06]
Subtotal (95% CI)	1609	1592	•	100.0 %	0.77 [0.29, 2.06]
Total events: 7 (CVS), 9 (Amn	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.5$	2 (P = 0.60)				

0.0010 0.1 1.0 10.0 1000.0

Favours treatment Favours control

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 5 Laboratory failure

Study or subgroup	CVS	Amniocentesis		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fi	xed,95% Cl		M-H,Fixed,95% Cl
I Transcervical CVS versus ar	nniocentesis					
Canada 1992	24/1027	1/968			100.0 %	22.62 [3.07, 166.89]
MRC (Finland) 1993	0/399	0/398	4		0.0 %	0.0 [0.0, 0.0]
Subtotal (95% CI)	1426	1366		-	100.0 %	22.62 [3.07, 166.89]
Total events: 24 (CVS), 1 (An	nniocentesis)					
Heterogeneity: $Chi^2 = 0.0$, df	$P = 0 (P = 1.00); ^2$	=0.0%				
Test for overall effect: Z = 3.0	06 (P = 0.0022)					
				<u> </u>		
			0.0010 0.1	1.0 10.0 1000.0		
			Favours treatment	Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 5 Laboratory failure

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus am	niocentesis				
MRC 1991	7/1609	9/1592	-	100.0 %	0.77 [0.29, 2.06]
Subtotal (95% CI)	1609	1592	•	100.0 %	0.77 [0.29, 2.06]
Total events: 7 (CVS), 9 (Am	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.5$	52 (P = 0.60)				
			<u> </u>	ı	
			0.0010 0.1 1.0 10.0 10	00.0	
		F	avours treatment Favours contr	ol	

Analysis 3.6. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 6 All non-mosaic abnormalities.

Review: Amniocentesis and	l chorionic villus sar	mpling for prenatal diagnosis			
Comparison: 3 Chorionic v	villus sampling versu	s second trimester amnioce	ntesis		
Outcome: 6 All non-mosai	c abnormalities				
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
l Transcervical CVS versus ar	nniocentesis				
Borrell 1999	10/314	10/358		24.5 %	1.14 [0.48, 2.70]
Canada 1992	33/1027	28/968	-	75.5 %	. [0.68, .82]
Subtotal (95% CI) Total events: 43 (CVS), 38 (A	1341 mniocentesis)	1326	-	100.0 %	1.12 [0.73, 1.72]
Heterogeneity: $Chi^2 = 0.00$, c	$ff = 1 (P = 0.96); I^2$	=0.0%			
Test for overall effect: $Z = 0.5$	61 (P = 0.61)				
		F	0.1 0.2 0.5 1.0 2.0 5.0 10.0 avours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 6 All non-mosaic abnormalities

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	10/314	10/358		24.5 %	1.14 [0.48, 2.70]
Canada 1992	33/1027	28/968	-	75.5 %	. [0.68, .82]
Subtotal (95% CI)	1341	1326	+	100.0 %	1.12 [0.73, 1.72]
Total events: 43 (CVS), 38 (A	mniocentesis)				
Heterogeneity: $Chi^2 = 0.00$, d	$ff = 1 (P = 0.96); I^2$	=0.0%			
Test for overall effect: Z = 0.5	61 (P = 0.61)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 3.7. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 7 True mosaics.

Review: Amniocentesis and	chorionic villus s	ampling for prenatal diagnos	is		
Comparison: 3 Chorionic vi	llus sampling vers	sus second trimester amnioc	entesis		
Outcome: 7 True mosaics					
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Transcervical CVS versus am	niocentesis				
Borrell 1999	1/314	0/358		100.0 %	3.42 [0.14, 83.63]
Subtotal (95% CI)	314	358		100.0 %	3.42 [0.14, 83.63]
Total events: I (CVS), 0 (Amni	iocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.75$	5 (P = 0.45)				
		(0.0050 0.1 1.0 10.0 200.0		
		Fav	ours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 7 True mosaics

-

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus am	niocentesis				
Borrell 1999	1/314	0/358		100.0 %	3.42 [0.14, 83.63]
Subtotal (95% CI)	314	358		100.0 %	3.42 [0.14, 83.63]
Total events: I (CVS), 0 (Amn	iocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.75$	5 (P = 0.45)				
			<u> </u>		
			0.0050 0.1 1.0 10.0 200.0		

Favours treatment Favours control

Analysis 3.8. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 8 Confined mosaics.

Review: Amniocentesis and	d chorionic villus sa	mpling for prenatal diagnosis	5		
Comparison: 3 Chorionic	villus sampling versu	is second trimester amnioce	entesis		
Outcome: 8 Confined mos	saics				
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus ar	mniocentesis				
Canada 1992	24/1027	4/968		100.0 %	5.66 [1.97, 16.24]
Subtotal (95% CI) Total events: 24 (CVS), 4 (An Heterogeneity: not applicable Test for overall effect: Z = 3.2	;	968	-	100.0 %	5.66 [1.97, 16.24]
			0.05 0.2 1.0 5.0 20.0		
		Favour	rs treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 8 Confined mosaics

-

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus an	nniocentesis				
Canada 1992	24/1027	4/968		100.0 %	5.66 [1.97, 16.24]
Subtotal (95% CI)	1027	968	-	100.0 %	5.66 [1.97, 16.24]
Total events: 24 (CVS), 4 (Am	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 3.2$	2 (P = 0.0013)				
		(D.05 0.2 I.0 5.0 20.0		
		Favours	s treatment Favours control		

Analysis 3.9. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 9 Maternal contamination.

Review: Amniocentesis and	d chorionic villus sa	mpling for prenatal diagn	osis		
Comparison: 3 Chorionic	villus sampling vers	us second trimester amni	ocentesis		
Outcome: 9 Maternal cont	amination				
Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
I Transcervical CVS versus ar	mniocentesis				
Canada 1992	39/1023	3/968		100.0 %	12.30 [3.81, 39.67]
Subtotal (95% CI)	1023	968	•	100.0 %	12.30 [3.81, 39.67]
Total events: 39 (CVS), 3 (An	nniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 4.2$	20 (P = 0.000027)				
3 CVS (any route) versus am	niocentesis				
MRC 1991	4/1609	0/1592		100.0 %	8.90 [0.48, 165.26]
Subtotal (95% CI)	1609	1592		100.0 %	8.90 [0.48, 165.26]
Total events: 4 (CVS), 0 (Amr	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.4$	47 (P = 0.14)				
			<u> </u>		
			0.0010 0.1 1.0 10.0 1000.0)	
			Favours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 9 Maternal contamination

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Transcervical CVS versus ar	mniocentesis				
Canada 1992	39/1023	3/968		100.0 %	12.30 [3.81, 39.67
Subtotal (95% CI)	1023	968	•	100.0 %	12.30 [3.81, 39.67
Total events: 39 (CVS), 3 (Am Heterogeneity: not applicable	2				
Test for overall effect: $Z = 4.2$	20 (P = 0.000027))			
			0.0010 0.1 1.0 10.0 1000.0)	
			Favours treatment Favours control		
Review: Amniocentesis and	d chorionic villus s	ampling for prenatal diagn	osis		
Review: Amniocentesis and Comparison: 3 Chorionic v					
Comparison: 3 Chorionic v	villus sampling ver				
	villus sampling ver				
Comparison: 3 Chorionic v Outcome: 9 Maternal cont	villus sampling ver			Weight	Risk Ratio
Comparison: 3 Chorionic v	villus sampling vers	sus second trimester amni	ocentesis Risk Ratio	Weight	Risk Ratio M-H,Fixed,95% CI
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup	villus sampling vers tamination CVS n/N	sus second trimester amni Amniocentesis	ocentesis	Weight	
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr	villus sampling vers tamination CVS n/N niocentesis	Amniocentesis n/N	ocentesis Risk Ratio		M-H,Fixed,95% CI
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr MRC 1991	villus sampling vers tamination CVS n/N niocentesis 4/1609	Amniocentesis n/N 0/1592	ocentesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 8.90 [0.48, 165.26
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI)	villus sampling vers tamination CVS n/N niocentesis 4/1609 1609	Amniocentesis n/N	ocentesis Risk Ratio		M-H,Fixed,95% Cl 8.90 [0.48, 165.26
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 4 (CVS), 0 (Amr	villus sampling vers tamination CVS n/N niocentesis 4/1609 1609 niocentesis)	Amniocentesis n/N 0/1592	ocentesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 8.90 [0.48, 165.26
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 4 (CVS), 0 (Amr Heterogeneity: not applicable	villus sampling vers tamination CVS n/N niocentesis 4/1609 1609 niocentesis)	Amniocentesis n/N 0/1592	ocentesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 8.90 [0.48, 165.26
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 4 (CVS), 0 (Amr	villus sampling vers tamination CVS n/N niocentesis 4/1609 1609 niocentesis)	Amniocentesis n/N 0/1592	ocentesis Risk Ratio	100.0 %	
Comparison: 3 Chorionic v Outcome: 9 Maternal cont Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 4 (CVS), 0 (Amr Heterogeneity: not applicable	villus sampling vers tamination CVS n/N niocentesis 4/1609 1609 niocentesis)	Amniocentesis n/N 0/1592	ocentesis Risk Ratio	100.0 % 100.0 %	M-H,Fixed,95% Cl 8.90 [0.48, 165.26

Analysis 3.10. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 10 Known false positive after birth.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 10 Known false positive after birth

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus am	niocentesis				
Canada 1992	19/863	2/967		65.3 %	10.64 [2.49, 45.57]
MRC (Finland) 1993	1/399	1/398	e	34.7 %	1.00 [0.06, 15.89]
Subtotal (95% CI)	1262	1365	•	100.0 %	7.30 [2.20, 24.25]
Total events: 20 (CVS), 3 (Am	niocentesis)				
Heterogeneity: Chi ² = 2.24, df	f = (P = 0.13);	² =55%			
Test for overall effect: $Z = 3.24$	4 (P = 0.0012)				
3 CVS (any route) versus amn	iocentesis				
MRC 1991	1/1609	1/1592		100.0 %	0.99 [0.06, 15.80]
Subtotal (95% CI)	1609	1592		100.0 %	0.99 [0.06, 15.80]
Total events: I (CVS), I (Amn	iocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	I (P = 0.99)				

0.0050 0.1 1.0 10.0 200.0 Favours treatment Favours control

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 10 Known false positive after birth

Study or subgroup	CVS	Amniocentesis	I	Risk Ratio		Weight	Risk Ratio
	n/N	n/N	M-H,Fi	ked,95% C	I		M-H,Fixed,95% Cl
I Transcervical CVS versus am	niocentesis						
Canada 1992	19/863	2/967			-	65.3 %	10.64 [2.49, 45.57]
MRC (Finland) 1993	1/399	1/398				34.7 %	1.00 [0.06, 15.89]
Subtotal (95% CI)	1262	1365		-		100.0 %	7.30 [2.20, 24.25]
Total events: 20 (CVS), 3 (Am	niocentesis)						
Heterogeneity: Chi ² = 2.24, d	$f = (P = 0. 3); ^2$	=55%					
Test for overall effect: $Z = 3.24$	4 (P = 0.0012)						
					ī		
			0.0050 0.1 1	.0 10.0	200.0		
		F	Favours treatment	Favours	control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 10 Known false positive after birth

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% C	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC 1991	1/1609	1/1592		100.0 %	0.99 [0.06, 15.80]
Subtotal (95% CI)	1609	1592		100.0 %	0.99 [0.06, 15.80]
Total events: (CVS), (Amr	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	I (P = 0.99)				
				L	
		().0050 0.1 1.0 10.0	200.0	
		Fav	ours treatment Favours	control	

Analysis 3.11. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 11 Known false negative after birth.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: II Known false negative after birth

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Transcervical CVS versus an		10111			i, i xeu, 23% Cl
Canada 1992	3/863	0/967		100.0 %	7.84 [0.41, 151.61]
MRC (Finland) 1993	0/399	0/398		0.0 %	0.0 [0.0, 0.0]
Subtotal (95% CI)	1262	1365		100.0 %	7.84 [0.41, 151.61]
Total events: 3 (CVS), 0 (Amr Heterogeneity: $Chi^2 = 0.0$, df Test for overall effect: $Z = 1.3$ 3 CVS (any route) versus amr	$P = 0 (P = 1.00); I^{2}$ 86 (P = 0.17)	2 =0.0%			
MRC 1991	1/1609	0/1592		100.0 %	2.97 [0.12, 72.81]
Subtotal (95% CI)	1609	1592		100.0 %	2.97 [0.12, 72.81]
Total events: 1 (CVS), 0 (Amr Heterogeneity: not applicable Test for overall effect: $Z = 0.6$					
			0050 0.1 1.0 10.0 200.0		
Review: Amniocentesis and Comparison: 3 Chorionic v					
Outcome: II Known false	negative after birt	h			
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus an	nniocentesis				
Canada 1992	3/863	0/967		100.0 %	7.84 [0.41, 151.61]
MRC (Finland) 1993	0/399	0/398	•	0.0 %	0.0 [0.0, 0.0]
Subtotal (95% CI) Total events: 3 (CVS), 0 (Amr Heterogeneity: Chi ² = 0.0, df Test for overall effect: Z = 1.3	= 0 (P = 1.00); I ²	1365 2 =0.0%		100.0 %	7.84 [0.41, 151.61]
			0050 0.1 1.0 10.0 200.0 urs treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: II Known false negative after birth

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
3 CVS (any route) versus amr	niocentesis				
MRC 1991	1/1609	0/1592		100.0 %	2.97 [0.12, 72.81]
Subtotal (95% CI)	1609	1592		100.0 %	2.97 [0.12, 72.81]
Total events: I (CVS), 0 (Amr	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.6$	67 (P = 0.51)				
		1	0.0050 0.1 1.0 10.0 200.0		
		Fav	ours treatment Favours control		

Analysis 3.13. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 13 Vaginal bleeding after test.

Review: Amniocentesis and	d chorionic villus sar	mpling for prenatal dia	gnosis			
Comparison: 3 Chorionic	villus sampling versu	s second trimester an	nniocentesis			
Outcome: 13 Vaginal bleed	ding after test					
Study or subgroup	CVS n/N	Amniocentesis n/N	M-H,Ra	Risk Ratio ndom,95% Cl	Weight	Risk Ratio M-H,Random,95% CI
I Transcervical CVS versus a	mniocentesis					
Canada 1992	206/1196	35/1200		-	54.8 %	5.91 [4.16, 8.37]
MRC (Finland) 1993	103/399	4/398			45.2 %	25.69 [9.55, 69.07]
Subtotal (95% CI) Total events: 309 (CVS), 39 (,	1598		-	100.0 %	11.48 [2.58, 51.08]
Heterogeneity: $Tau^2 = 1.03$; Test for overall effect: $Z = 3.2$		(P = 0.004); I ² =88%				
			0.01 0.1 Favours treatment	1.0 10.0 100.0 Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 13 Vaginal bleeding after test

-

-

Study or subgroup	CVS	Amniocentesis		F	isk Ratio		Weight	Risk Ratio
	n/N	n/N		M-H,Ran	dom,95% C	1		M-H,Random,95% Cl
I Transcervical CVS versus ar	nniocentesis							
Canada 1992	206/1196	35/1200					54.8 %	5.91 [4.16, 8.37]
MRC (Finland) 1993	103/399	4/398				_	45.2 %	25.69 [9.55, 69.07]
Subtotal (95% CI)	1595	1598			-		100.0 %	11.48 [2.58, 51.08]
Total events: 309 (CVS), 39 (/	Amniocentesis)							
Heterogeneity: $Tau^2 = 1.03$; C	$Chi^2 = 8.17, df = 1$	$(P = 0.004); ^2 = 88\%$						
Test for overall effect: $Z = 3.2$	(P = 0.0013)							
			I		I			
			0.01	0.1 1.0	0.01	00.0		

Favours treatment Favours control

Analysis 3.14. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 14 Amniotic leakage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 14 Amniotic leakage after test

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
I Transabdominal CVS vs amr	niocentesis				
Canada 1992	11/773	4/712		100.0 %	2.53 [0.81, 7.92]
Subtotal (95% CI)	773	712		100.0 %	2.53 [0.81, 7.92]
Total events: 11 (CVS), 4 (Am	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.6$	0 (P = 0.11)				
3 CVS (any route) versus amr	niocentesis				
MRC 1991	5/1609	9/1592		100.0 %	0.55 [0.18, 1.64]
Subtotal (95% CI)	1609	1592		100.0 %	0.55 [0.18, 1.64]
Total events: 5 (CVS), 9 (Amn	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.0$	8 (P = 0.28)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 14 Amniotic leakage after test

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transabdominal CVS vs am	niocentesis				
Canada 1992	11/773	4/712		100.0 %	2.53 [0.81, 7.92
Subtotal (95% CI)	773	712		100.0 %	2.53 [0.81, 7.92
Total events: 11 (CVS), 4 (An	nniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.6$	50 (P = 0.11)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		Fav	vours treatment Favours control		
Review: Amniocentesis and	t chorionic villus sa	mpling for prenatal diagnosis			
Review: Amniocentesis and					
		mpling for prenatal diagnosis us second trimester amniocen	tesis		
	<i>v</i> illus sampling versu		tesis		
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea	villus sampling versu kage after test	us second trimester amniocen		Weight	Risk Ratio
Comparison: 3 Chorionic v	<i>v</i> illus sampling versu		tesis Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup	villus sampling versu kage after test CVS n/N	us second trimester amniocen	Risk Ratio	Weight	
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup	villus sampling versu kage after test CVS n/N	us second trimester amniocen	Risk Ratio	Weight 100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991	villus sampling versu kage after test CVS n/N	Amniocentesis n/N 9/1592	Risk Ratio		M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI)	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609	us second trimester amniocen Amniocentesis n/N	Risk Ratio	100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI) Total events: 5 (CVS), 9 (Amr	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592	Risk Ratio	100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI) Total events: 5 (CVS), 9 (Amr Heterogeneity: not applicable	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592	Risk Ratio	100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI) Total events: 5 (CVS), 9 (Amr Heterogeneity: not applicable	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus am	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI) Total events: 5 (CVS), 9 (Amr Heterogeneity: not applicable	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI) Total events: 5 (CVS), 9 (Amr Heterogeneity: not applicable	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% C
Comparison: 3 Chorionic v Outcome: 14 Amniotic lea Study or subgroup 3 CVS (any route) versus amn MRC 1991 Subtotal (95% CI) Total events: 5 (CVS), 9 (Amr Heterogeneity: not applicable	villus sampling versu kage after test CVS n/N niocentesis 5/1609 1609 niocentesis)	Amniocentesis n/N 9/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% C

Analysis 3.15. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 15 Vaginal bleeding after 20 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 15 Vaginal bleeding after 20 weeks

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus am	nniocentesis		_		
MRC (Finland) 1993	13/399	9/398		100.0 %	1.44 [0.62, 3.33]
Subtotal (95% CI)	399	398	-	100.0 %	1.44 [0.62, 3.33]
Total events: 13 (CVS), 9 (Am Heterogeneity: not applicable	niocentesis)				
Test for overall effect: $Z = 0.85$	5 (P = 0.39)				
3 CVS (any route) versus amn			_		
MRC 1991	56/1609	56/1592		100.0 %	0.99 [0.69, 1.42
Subtotal (95% CI)	1609	1592	+	100.0 %	0.99 [0.69, 1.42
Total events: 56 (CVS), 56 (Ar	nniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.06$	6 (P = 0.95)				
Review: Amniocentesis and					
Review: Amniocentesis and Comparison: 3 Chorionic vi			tesis		
	llus sampling versu		tesis		
Comparison: 3 Chorionic vi	llus sampling versu		ıtesis Risk Ratio	Weight	Risk Ratio
Comparison: 3 Chorionic vi Outcome: 15 Vaginal bleedi	llus sampling versu ng after 20 weeks	s second trimester amniocer		Weight	Risk Ratio M-H,Fixed,95% CI
Comparison: 3 Chorionic vi Outcome: 15 Vaginal bleedi Study or subgroup	llus sampling versu ng after 20 weeks CVS n/N	s second trimester amniocer Amniocentesis	Risk Ratio	Weight	
Comparison: 3 Chorionic vi Outcome: 15 Vaginal bleedi	llus sampling versu ng after 20 weeks CVS n/N	s second trimester amniocer Amniocentesis	Risk Ratio	Weight 100.0 %	
Comparison: 3 Chorionic vi Outcome: 15 Vaginal bleedi Study or subgroup I Transcervical CVS versus am	Ilus sampling versu ng after 20 weeks CVS n/N niocentesis	s second trimester amniocer Amniocentesis n/N	Risk Ratio		M-H,Fixed,95% Cl
Comparison: 3 Chorionic vi Outcome: 15 Vaginal bleedi Study or subgroup I Transcervical CVS versus an MRC (Finland) 1993	Ilus sampling versu ng after 20 weeks CVS n/N nniocentesis 13/399 399	Amniocentesis n/N 9/398	Risk Ratio	100.0 %	M-H,Fixed,95% Cl
Comparison: 3 Chorionic vi Outcome: 15 Vaginal bleedi Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI)	Ilus sampling versu ng after 20 weeks CVS n/N nniocentesis 13/399 399	Amniocentesis n/N 9/398	Risk Ratio	100.0 %	M-H,Fixed,95% C

0.1 0.2 0.5 1.0 2.0 5.0 10.0

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 15 Vaginal bleeding after 20 weeks

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
3 CVS (any route) versus amn	iocentesis				
MRC 1991	56/1609	56/1592		100.0 %	0.99 [0.69, 1.42]
Subtotal (95% CI)	1609	1592	•	100.0 %	0.99 [0.69, 1.42]
Total events: 56 (CVS), 56 (Ar	nniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	6 (P = 0.95)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		F	avours treatment Favours control		

Analysis 3.16. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 16 PROM before 28 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 16 PROM before 28 weeks Study or subgroup CVS Amniocentesis Risk Ratio Weight M-H,Fixed,95% CI n/N n/N I Transcervical CVS versus amniocentesis MRC (Finland) 1993 3/360 100.0 % 15/362 Subtotal (95% CI) 100.0 % 4.97 [1.45, 17.03] 362 360 Total events: 15 (CVS), 3 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 2.55 (P = 0.011) 3 CVS (any route) versus amniocentesis MRC 1991 21/1391 13/1374 100.0 % Subtotal (95% CI) 1391 1374 100.0 % 1.60 [0.80, 3.17] Total events: 21 (CVS), 13 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 1.33 (P = 0.18) 0.05 0.2 1.0 5.0 20.0

> Favours treatment Favours control

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Risk Ratio

M-H,Fixed,95% CI

4.97 [1.45, 17.03]

1.60 [0.80, 3.17]

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 16 PROM before 28 weeks

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus an	nniocentesis				
MRC (Finland) 1993	15/362	3/360		100.0 %	4.97 [1.45, 17.03]
Subtotal (95% CI) Total events: 15 (CVS), 3 (Am Heterogeneity: not applicable Test for overall effect: Z = 2.5		360		100.0 %	4.97 [1.45, 17.03]
			0.05 0.2 1.0 5.0 20.0		
		Fav	vours treatment Favours control		
Review: Amniocentesis and	chorionic villus sar	mpling for prenatal diagno	sis		
Comparison: 3 Chorionic v	illus sampling versu	s second trimester amnio	centesis		
Outcome: 16 PROM before	e 28 weeks				
Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
3 CVS (any route) versus amr				100.0.0/	
MRC 1991	21/1391	3/ 374		100.0 %	1.60 [0.80, 3.17]
Subtotal (95% CI) Total events: 21 (CVS), 13 (Ar Heterogeneity: not applicable Test for overall effect: Z = 1.3		1374	•	100.0 %	1.60 [0.80, 3.17]
		r	0.05 0.2 1.0 5.0 20.0		
		F	avours treatment Favours control		

Analysis 3.17. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 17 Antenatal hospital admission.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 17 Antenatal hospital admission

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
I Transcervical CVS versus am	iniocentesis				
MRC (Finland) 1993	25/390	17/390		100.0 %	1.47 [0.81, 2.68]
Subtotal (95% CI)	390	390	-	100.0 %	1.47 [0.81, 2.68]
Total events: 25 (CVS), 17 (An	nniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.26$	6 (P = 0.21)				
3 CVS (any route) versus amn	iocentesis				
MRC 1991	199/1609	219/1592		100.0 %	0.90 [0.75, 1.08]
Subtotal (95% CI)	1609	1592	•	100.0 %	0.90 [0.75, 1.08]
Total events: 199 (CVS), 219 (Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.16$	6 (P = 0.24)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 17 Antenatal hospital admission

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Transcervical CVS versus ar	nniocentesis				
MRC (Finland) 1993	25/390	17/390	+	100.0 %	1.47 [0.81, 2.68]
Subtotal (95% CI) Total events: 25 (CVS), 17 (A Heterogeneity: not applicable Test for overall effect: Z = 1.2	,	390	-	100.0 %	1.47 [0.81, 2.68]
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 17 Antenatal hospital admission

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC 1991	199/1609	219/1592		100.0 %	0.90 [0.75, 1.08]
Subtotal (95% CI)	1609	1592	•	100.0 %	0.90 [0.75, 1.08]
Total events: 199 (CVS), 219	(Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.1$	6 (P = 0.24)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		F	avours treatment Favours control		

Analysis 3.18. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 18 Delivery before 37 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 18 Delivery before 37 weeks

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
l Transcervical CVS versus ar	nniocentesis				
Canada 1992	56/905	54/833	+	62.5 %	0.95 [0.66, 1.37]
MRC (Finland) 1993	33/381	18/387		37.5 %	1.86 [1.07, 3.25]
Subtotal (95% CI)	1286	1220	-	100.0 %	1.29 [0.67, 2.47]
Total events: 89 (CVS), 72 (A	mniocentesis)				
Heterogeneity: Tau ² = 0.17; C	$Chi^2 = 3.90, df = 1$ (1	P = 0.05); I ² =74%			
Test for overall effect: $Z = 0.7$	76 (P = 0.45)				
3 CVS (any route) versus amr	niocentesis				
MRC 1991	293/1601	218/1588		100.0 %	1.33 [1.13, 1.57]
Subtotal (95% CI)	1601	1588	•	100.0 %	1.33 [1.13, 1.57]
Total events: 293 (CVS), 218	(Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 3.5$	50 (P = 0.00046)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 18 Delivery before 37 weeks


Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95%
		11/1 N			,Nandom,7378
I Transcervical CVS versus a Canada 1992	mniocentesis 56/905	54/833		62.5 %	0.95 [0.66, 1.37
MRC (Finland) 1993	33/381	18/387		37.5 %	1.86 [1.07, 3.25
Subtotal (95% CI)	1286	1220		100.0 %	1.29 [0.67, 2.47
Total events: 89 (CVS), 72 (A		1220		100.0 %	1.29 [0.0/, 2.4/
Heterogeneity: $Tau^2 = 0.17$; (,	$(P = 0.05); I^2 = 74\%$			
Test for overall effect: $Z = 0.7$	76 (P = 0.45)				
			<u> </u>		
		F	0.1 0.2 0.5 1.0 2.0 5.0 10.0 avours treatment Favours control		
		I			
Review: Amniocentesis and	d chorionic villus san	npling for prenatal diagnosis	5		
Review: Amniocentesis and Comparison: 3 Chorionic v					
	villus sampling versus				
Comparison: 3 Chorionic	villus sampling versus				
Comparison: 3 Chorionic	villus sampling versus ore 37 weeks CVS	s second trimester amnioce Amniocentesis	entesis Risk Ratio	Weight	Risk Ratio
Comparison: 3 Chorionic Outcome: 18 Delivery bef	villus sampling versus	s second trimester amnioce	entesis	Weight	Risk Ratio M-H,Random,95%
Comparison: 3 Chorionic Outcome: 18 Delivery bef	villus sampling versus fore 37 weeks CVS n/N	s second trimester amnioce Amniocentesis	entesis Risk Ratio	Weight	
Comparison: 3 Chorionic of Outcome: 18 Delivery bef Study or subgroup	villus sampling versus fore 37 weeks CVS n/N	s second trimester amnioce Amniocentesis	entesis Risk Ratio	Weight 100.0 %	M-H,Random,95%
Comparison: 3 Chorionic of Outcome: 18 Delivery bef Study or subgroup 3 CVS (any route) versus am	villus sampling versus ore 37 weeks CVS n/N niocentesis	s second trimester amnioce Amniocentesis n/N	entesis Risk Ratio	-	M-H,Random,95%
Comparison: 3 Chorionic o Outcome: 18 Delivery bef Study or subgroup 3 CVS (any route) versus am MRC 1991	villus sampling versus fore 37 weeks CVS n/N niocentesis 293/1601 1601	Amniocentesis n/N 218/1588	entesis Risk Ratio	100.0 %	M-H,Random,95%
Comparison: 3 Chorionic of Outcome: 18 Delivery bef Study or subgroup 3 CVS (any route) versus am MRC 1991 Subtotal (95% CI)	villus sampling versus core 37 weeks CVS n/N niocentesis 293/1601 1601 (Amniocentesis)	Amniocentesis n/N 218/1588	entesis Risk Ratio	100.0 %	M-H,Random,95%
Comparison: 3 Chorionic of Outcome: 18 Delivery bef Study or subgroup 3 CVS (any route) versus am MRC 1991 Subtotal (95% CI) Total events: 293 (CVS), 218 Heterogeneity: not applicable	villus sampling versus core 37 weeks CVS n/N niocentesis 293/1601 1601 (Amniocentesis)	Amniocentesis n/N 218/1588	entesis Risk Ratio	100.0 %	M-H,Random,95%
Comparison: 3 Chorionic of Outcome: 18 Delivery bef Study or subgroup 3 CVS (any route) versus am MRC 1991 Subtotal (95% CI) Total events: 293 (CVS), 218	villus sampling versus core 37 weeks CVS n/N niocentesis 293/1601 1601 (Amniocentesis)	Amniocentesis n/N 218/1588	Risk Ratio M-H,Random,95% Cl	100.0 %	M-H,Random,95%
Comparison: 3 Chorionic of Outcome: 18 Delivery bef Study or subgroup 3 CVS (any route) versus am MRC 1991 Subtotal (95% CI) Total events: 293 (CVS), 218 Heterogeneity: not applicable	villus sampling versus core 37 weeks CVS n/N niocentesis 293/1601 1601 (Amniocentesis)	Amniocentesis n/N 218/1588 1588	entesis Risk Ratio	100.0 %	

Analysis 3.19. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 19 Delivery before 33 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 19 Delivery before 33 weeks



Analysis 3.20. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 20 All known pregnancy loss (including termination of pregnancy).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	83/425	57/407		24.8 %	1.39 [1.02, 1.90]
Canada 1992	232/1348	208/1324	-	36.0 %	1.10 [0.92, 1.30]
Denmark 1992	127/1068	81/1158		28.0 %	1.70 [1.30, 2.22]
MRC (Finland) 1993	29/399	6/398		11.2 %	1.81 [1.00, 3.28]
Subtotal (95% CI)	3240	3287	•	100.0 %	1.40 [1.09, 1.81]
Total events: 471 (CVS), 362	(Amniocentesis)				
Heterogeneity: $Tau^2 = 0.04$; C		$P = 0.03$; $I^2 = 67\%$			
Test for overall effect: $Z = 2.5$	9 (P = 0.0095)				
2 Transabdominal CVS versus					
Denmark 1992	68/1076	81/1158		100.0 %	0.90 [0.66, 1.23]
Subtotal (95% CI)	1076	1158	•	100.0 %	0.90 [0.66, 1.23]
Total events: 68 (CVS), 81 (A	mniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.6$	4 (P = 0.52)				
3 CVS (any route) versus amr	niocentesis				
Denmark 1992	195/2144	81/1158		46.6 %	1.30 [1.01, 1.67]
MRC 1991	220/1609	144/1592	-	53.4 %	1.51 [1.24, 1.84]
Subtotal (95% CI)	3753	2750	•	100.0 %	1.43 [1.22, 1.67]
Total events: 415 (CVS), 225	(Amniocentesis)				
Heterogeneity: $Tau^2 = 0.0$; Ch		= 0.35); l ² =0.0%			
Test for overall effect: $Z = 4.4$	8 (P < 0.00001)				

0.5 0.7 1.0 1.5 2.0

Favours treatment | Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% CI
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	83/425	57/407		24.8 %	1.39 [1.02, 1.90]
Canada 1992	232/1348	208/1324	-	36.0 %	1.10 [0.92, 1.30]
Denmark 1992	127/1068	81/1158		28.0 %	1.70 [1.30, 2.22]
MRC (Finland) 1993	29/399	16/398		11.2 %	1.81 [1.00, 3.28]
Subtotal (95% CI)	3240	3287	•	100.0 %	1.40 [1.09, 1.81]
Total events: 471 (CVS), 362	(Amniocentesis)				
Heterogeneity: Tau ² = 0.04; C	$Chi^2 = 9.15, df = 3$ (P = 0.03); I ² =67%			
Test for overall effect: Z = 2.5	9 (P = 0.0095)				

0.5 0.7 1.0 1.5 2.0

Favours treatment Favours control

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
2 Transabdominal CVS versus	amniocentesis				
Denmark 1992	68/1076	81/1158		100.0 %	0.90 [0.66, 1.23]
Subtotal (95% CI)	1076	1158	-	100.0 %	0.90 [0.66, 1.23]
Total events: 68 (CVS), 81 (Ar	mniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.6$	4 (P = 0.52)				
			0.5 0.7 1.0 1.5 2.0		

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
3 CVS (any route) versus ami	niocentesis				
Denmark 1992	195/2144	81/1158	-	46.6 %	1.30 [1.01, 1.67]
MRC 1991	220/1609	144/1592	-	53.4 %	1.51 [1.24, 1.84]
Subtotal (95% CI)	3753	2750	*	100.0 %	1.43 [1.22, 1.67]
Total events: 415 (CVS), 225	(Amniocentesis)				
Heterogeneity: Tau ² = 0.0; Cł	$hi^2 = 0.86, df = 1$ (P	= 0.35); l ² =0.0%			
Test for overall effect: $Z = 4.4$	18 (P < 0.00001)				

0.5 0.7 1.0 1.5 2.0

Favours treatment Favours control

Analysis 3.21. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 21 Termination of pregnancy (all).

Review: Amniocentesis and	l chorionic villus sar	npling for prenatal diagnosis			
Comparison: 3 Chorionic v	villus sampling versu	s second trimester amnioce	ntesis		
Outcome: 21 Termination	of pregnancy (all)				
Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	7/382	5/400		10.6 %	1.47 [0.47, 4.58
Canada 1992	34/1348	41/1324	-	89.4 %	0.81 [0.52, 1.28
Subtotal (95% CI)	1730	1724	•	100.0 %	0.88 [0.58, 1.34
Total events: 41 (CVS), 46 (A	mniocentesis)				
Heterogeneity: $Chi^2 = 0.89$, d	$ff = 1 (P = 0.35); I^2$	=0.0%			
Test for overall effect: $Z = 0.5$	9 (P = 0.56)				
3 CVS (any route) versus amr	niocentesis				
MRC 1991	59/1609	41/1592		100.0 %	1.42 [0.96, 2.11
Subtotal (95% CI)	1609	1592	•	100.0 %	1.42 [0.96, 2.11
Total events: 59 (CVS), 41 (A	mniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.7$	76 (P = 0.078)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		F	avours treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 21 Termination of pregnancy (all)

	n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
		n/IN	IM-H,FIXEd,95% CI		I*I-H,FIXed,95% CI
I Transcervical CVS versus a		E (400			
Borrell 1999	7/382	5/400		10.6 %	1.47 [0.47, 4.58
Canada 1992	34/1348	41/1324		89.4 %	0.81 [0.52, 1.28
Subtotal (95% CI)	1730	1724	•	100.0 %	0.88 [0.58, 1.34
Total events: 41 (CVS), 46 (A	,				
Heterogeneity: $Chi^2 = 0.89$,		=0.0%			
Test for overall effect: $Z = 0$.	.59 (P = 0.56)				
			<u></u>		
		-	0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		Fa	avours treatment Favours control		
Review: Amniocentesis an	nd chorionic villus san	npling for prenatal diagnosis			
Comparison 2 Charianis					
	villus sampling versu	s second trimester amniocer	ntesis		
		s second trimester amniocer	ntesis		
Outcome: 21 Termination		s second trimester amniocer	ntesis		
Outcome: 21 Termination	n of pregnancy (all)			Weight	Rick Batio
	n of pregnancy (all) CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio M-H Fixed 95% (71
Outcome: 21 Termination Study or subgroup	n of pregnancy (all) CVS n/N			Weight	
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an	n of pregnancy (all) CVS n/N	Amniocentesis n/N	Risk Ratio		M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup	n of pregnancy (all) CVS n/N	Amniocentesis	Risk Ratio	Weight 100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991	n of pregnancy (all) CVS n/N	Amniocentesis n/N	Risk Ratio		M-H,Fixed,95% C
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI)	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609	Amniocentesis n/N 41/1592	Risk Ratio	100.0 %	M-H,Fixed,95% C
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI) Total events: 59 (CVS), 41 (<i>A</i>	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis)	Amniocentesis n/N 41/1592	Risk Ratio	100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI) Total events: 59 (CVS), 41 (/ Heterogeneity: not applicable	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis) le	Amniocentesis n/N 41/1592	Risk Ratio	100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI) Total events: 59 (CVS), 41 (/ Heterogeneity: not applicable	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis) le	Amniocentesis n/N 41/1592	Risk Ratio	100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI) Total events: 59 (CVS), 41 (/ Heterogeneity: not applicable	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis) le	Amniocentesis n/N 41/1592	Risk Ratio	100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI) Total events: 59 (CVS), 41 (/ Heterogeneity: not applicable	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis) le	Amniocentesis n/N 41/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an MRC 1991 Subtotal (95% CI) Total events: 59 (CVS), 41 (/ Heterogeneity: not applicable	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis) le	Amniocentesis n/N 41/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl
Outcome: 21 Termination Study or subgroup 3 CVS (any route) versus an	n of pregnancy (all) CVS n/N nniocentesis 59/1609 1609 Amniocentesis) le	Amniocentesis n/N 41/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	Risk Ratio M-H,Fixed,95% CI 1.42 [0.96, 2.11] 1.42 [0.96, 2.11]

Analysis 3.24. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 24 Spontaneous miscarriage.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 24 Spontaneous miscarriage

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	75/382	52/400	-	31.1 %	1.51 [1.09, 2.09]
Canada 1992	196/1348	166/1324	-	40.5 %	1.16 [0.96, 1.41]
Denmark 1992	83/1010	41/1042	-	28.4 %	2.09 [1.45, 3.01]
Subtotal (95% CI)	2740	2766	•	100.0 %	1.50 [1.07, 2.11]
Total events: 354 (CVS), 259 Heterogeneity: $Tau^2 = 0.07$; C	Chi ² = 8.39, df = 2 (P = 0.02); I ² =76%			
Test for overall effect: $Z = 2.3$	```				
2 Transabdominal CVS versus Denmark 1992	amniocentesis 31/1027	41/1042	_ _ _	100.0 %	0.77 [0.49, 1.21]
Subtotal (95% CI)	1027	1042	-	100.0 %	0.77 [0.49, 1.21]
Total events: 31 (CVS), 41 (A				10000 /0	,
Heterogeneity: not applicable	,				
Test for overall effect: $Z = 1.1$	3 (P = 0.26)				
3 CVS (any route) versus amr	niocentesis				
Denmark 1992	114/2037	41/1042	-	44.8 %	1.42 [1.00, 2.02]
MRC 1991	145/1609	92/1592	-	55.2 %	1.56 [1.21, 2.01]
Subtotal (95% CI)	3646	2634	•	100.0 %	1.51 [1.23, 1.85]
Total events: 259 (CVS), 133	(Amniocentesis)				
Heterogeneity: $Tau^2 = 0.0$; Cł	$mi^2 = 0.18, df = 1$ (P	= 0.67); l ² =0.0%			
Test for overall effect: $Z = 3.9$	6 (P = 0.000075)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 24 Spontaneous miscarriage

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% CI
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	75/382	52/400	-	31.1 %	1.51 [1.09, 2.09]
Canada 1992	196/1348	166/1324	-	40.5 %	1.16 [0.96, 1.41]
Denmark 1992	83/1010	41/1042		28.4 %	2.09 [1.45, 3.01]
Subtotal (95% CI)	2740	2766	◆	100.0 %	1.50 [1.07, 2.11]
Total events: 354 (CVS), 259 ((Amniocentesis)				
Heterogeneity: $Tau^2 = 0.07$; C	Chi ² = 8.39, df = 2 ($P = 0.02$; $I^2 = 76\%$			
Test for overall effect: $Z = 2.3$	2 (P = 0.020)				

^{0.1 0.2 0.5 1.0 2.0 5.0 10.0} Favours treatment Favours control

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 24 Spontaneous miscarriage

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% CI
2 Transabdominal CVS versus	amniocentesis				
Denmark 1992	31/1027	41/1042		100.0 %	0.77 [0.49, 1.21]
Subtotal (95% CI)	1027	1042	•	100.0 %	0.77 [0.49, 1.21]
Total events: 31 (CVS), 41 (Ar	mniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.1$	3 (P = 0.26)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 24 Spontaneous miscarriage

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
3 CVS (any route) versus amr	niocentesis				
Denmark 1992	114/2037	41/1042	-	44.8 %	.42 [.00, 2.02]
MRC 1991	145/1609	92/1592	-	55.2 %	1.56 [1.21, 2.01]
Subtotal (95% CI)	3646	2634	•	100.0 %	1.51 [1.23, 1.85]
Total events: 259 (CVS), 133	(Amniocentesis)				
Heterogeneity: $Tau^2 = 0.0$; Ch	$hi^2 = 0.18, df = 1$ (P	= 0.67); l ² =0.0%			
Test for overall effect: Z = 3.9	6 (P = 0.000075)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		

Favours treatment Favours control

Analysis 3.25. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 25 Spontaneous miscarriage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 25 Spontaneous miscarriage after test

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	7/382	10/400		54.1 %	0.73 [0.28, 1.91]
MRC (Finland) 1993	14/399	3/398		45.9 %	4.65 [1.35, 16.07]
Subtotal (95% CI)	781	798		100.0 %	1.77 [0.28, 11.00]
Total events: 21 (CVS), 13 (A	mniocentesis)				
Heterogeneity: $Tau^2 = 1.42$; C	$Chi^2 = 5.47, df = 1$	(P = 0.02); l ² =82%			
Test for overall effect: $Z = 0.6$	I (P = 0.54)				
3 CVS (any route) versus amr	niocentesis				
MRC 1991	84/1609	24/1592		100.0 %	3.46 [2.21, 5.42]
Subtotal (95% CI)	1609	1592	•	100.0 %	3.46 [2.21, 5.42]
Total events: 84 (CVS), 24 (A	mniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 5.4$	-3 (P < 0.00001)				
			0.05 0.2 1.0 5.0 20.0		
			Favours treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 25 Spontaneous miscarriage after test

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% C
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	7/382	10/400		54.1 %	0.73 [0.28, 1.91
MRC (Finland) 1993	14/399	3/398		45.9 %	4.65 [1.35, 16.07
Subtotal (95% CI)	781	798		100.0 %	1.77 [0.28, 11.00
Total events: 21 (CVS), 13 (A	mniocentesis)				
Heterogeneity: $Tau^2 = 1.42$; C		(P = 0.02); I ² =82%			
Test for overall effect: $Z = 0.6$	I (P = 0.54)				
		En	0.05 0.2 1.0 5.0 20.0 vours treatment Favours control		
		Fa	vours treatment Favours control		
De inc. Annie onteriore					
Review: Amniocentesis and	chorionic villus sa	mpling for prenatal diagno	sis		
Review: Amniocentesis and Comparison: 3 Chorionic v					
	illus sampling versi	us second trimester amnio			
Comparison: 3 Chorionic v Outcome: 25 Spontaneous	illus sampling versu miscarriage after t	us second trimester amnio test	centesis	Woight	Rick Patio
Comparison: 3 Chorionic v	illus sampling versu miscarriage after 1 CVS	us second trimester amnio test Amniocentesis	centesis Risk Ratio	Weight	Risk Ratio M-H.Random 95%
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup	illus sampling verso miscarriage after t CVS n/N	us second trimester amnio test	centesis	Weight	Risk Ratio M-H,Random,95%
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup 3 CVS (any route) versus amr	illus sampling verso miscarriage after t CVS n/N	us second trimester amnio test Amniocentesis n/N	centesis Risk Ratio		M-H,Random,95%
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup	illus sampling verso miscarriage after t CVS n/N	us second trimester amnio test Amniocentesis	centesis Risk Ratio	Weight 100.0 %	
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup 3 CVS (any route) versus amr	illus sampling verso miscarriage after t CVS n/N	us second trimester amnio test Amniocentesis n/N	centesis Risk Ratio		M-H,Random,95%
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup 3 CVS (any route) versus amr MRC 1991	illus sampling versu miscarriage after r CVS n/N niocentesis 84/1609 1609	us second trimester amnio test Amniocentesis n/N 24/1592	centesis Risk Ratio	100.0 %	M-H,Random,95% 3.46 [2.21, 5.42
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI)	illus sampling versu miscarriage after r CVS n/N niocentesis 84/1609 1609	us second trimester amnio test Amniocentesis n/N 24/1592	centesis Risk Ratio	100.0 %	M-H,Random,95% 3.46 [2.21, 5.42
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 84 (CVS), 24 (Ai Heterogeneity: not applicable	illus sampling versu miscarriage after t CVS n/N niocentesis 84/1609 1609 mniocentesis)	us second trimester amnio test Amniocentesis n/N 24/1592	centesis Risk Ratio	100.0 %	M-H,Random,95% 3.46 [2.21, 5.42
Comparison: 3 Chorionic v Outcome: 25 Spontaneous Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 84 (CVS), 24 (Au	illus sampling versu miscarriage after t CVS n/N niocentesis 84/1609 1609 mniocentesis)	us second trimester amnio test Amniocentesis n/N 24/1592	centesis Risk Ratio	100.0 %	M-H,Random,95% 3.46 [2.21, 5.42

Favours treatment Favours control

Analysis 3.26. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 26 Perinatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 26 Perinatal deaths

Study or subgroup			Weight	Risk Ratio		
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl	
I Transcervical CVS versus an	nniocentesis					
Canada 1992	8/1348	2/1324		22.6 %	3.93 [0.84, 18.47]	
Denmark 1992	3/1010	6/1042		66.2 %	0.52 [0.13, 2.06]	
MRC (Finland) 1993	4/399	1/398		11.2 %	3.99 [0.45, 35.54]	
Subtotal (95% CI)	2757	2764	-	100.0 %	1.68 [0.73, 3.84]	
Total events: 15 (CVS), 9 (Am	niocentesis)					
Heterogeneity: Chi ² = 4.56, d	$f = 2 (P = 0.10); I^2$	=56%				
Test for overall effect: $Z = 1.2$	2 (P = 0.22)					
2 Transabdominal CVS versus	amniocentesis					
Denmark 1992	7/1027	6/1042		100.0 %	1.18 [0.40, 3.51]	
Subtotal (95% CI)	1027	1042	-	100.0 %	1.18 [0.40, 3.51]	
Total events: 7 (CVS), 6 (Amn	iocentesis)					
Heterogeneity: not applicable						
Test for overall effect: $Z = 0.3$	0 (P = 0.76)					
3 CVS (any route) versus amr	niocentesis					
Denmark 1992	10/2037	6/1042		44.1 %	0.85 [0.31, 2.34]	
MRC 1991	15/1609	10/1592		55.9 %	1.48 [0.67, 3.29]	
Subtotal (95% CI)	3646	2634	*	100.0 %	1.21 [0.65, 2.24]	
Total events: 25 (CVS), 16 (Ar	nniocentesis)					
Heterogeneity: $Chi^2 = 0.71$, d	$f = (P = 0.40); ^2$	=0.0%				
Test for overall effect: $Z = 0.5$	9 (P = 0.55)					
			<u> </u>			

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 26 Perinatal deaths

	n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% CI
I Transcervical CVS versus a	mniocentesis				
Canada 1992	8/1348	2/1324		22.6 %	3.93 [0.84, 18.47
Denmark 1992	3/1010	6/1042		66.2 %	0.52 [0.13, 2.06
MRC (Finland) 1993	4/399	1/398		11.2 %	3.99 [0.45, 35.54
Subtotal (95% CI) Total events: 15 (CVS), 9 (Ar Heterogeneity: $Chi^2 = 4.56$, Test for overall effect: $Z = 1$.	df = 2 (P = 0.10); I^2	2764 =56%	-	100.0 %	1.68 [0.73, 3.84
			0.05 0.2 1.0 5.0 20.0 rs treatment Favours control		
Review: Amniocentesis an Comparison: 3 Chorionic					
	villus sampling versu aths CVS	s second trimester amnioce Amniocentesis	ntesis Risk Ratio	Weight	Risk Ratio
Comparison: 3 Chorionic Outcome: 26 Perinatal dea	villus sampling versu aths	s second trimester amnioce	ntesis	Weight	
Comparison: 3 Chorionic Outcome: 26 Perinatal des Study or subgroup 2 Transabdominal CVS versu	villus sampling versu aths CVS n/N is amniocentesis	s second trimester amnioce Amniocentesis n/N	ntesis Risk Ratio		M-H,Fixed,95% CI
Comparison: 3 Chorionic Outcome: 26 Perinatal dea Study or subgroup	villus sampling versu aths CVS n/N is amniocentesis 7/1027 1027 iniocentesis) e	s second trimester amnioce Amniocentesis	ntesis Risk Ratio	Weight 100.0 % 100.0 %	

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 26 Perinatal deaths

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
Denmark 1992	10/2037	6/1042		44.1 %	0.85 [0.31, 2.34]
MRC 1991	15/1609	10/1592		55.9 %	1.48 [0.67, 3.29]
Subtotal (95% CI)	3646	2634	•	100.0 %	1.21 [0.65, 2.24]
Total events: 25 (CVS), 16 (Ar	mniocentesis)				
Heterogeneity: Chi ² = 0.71, d	$f = (P = 0.40); ^2$	=0.0%			
Test for overall effect: $Z = 0.5$	9 (P = 0.55)				
			0.05 0.2 1.0 5.0 20.0		

Favours treatment Favours control

Analysis 3.27. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 27 Stillbirths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 27 Stillbirths

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl	
Transcervical CVS versus ar	nniocentesis					
Borrell 1999	0/382	4/400		41.3 %	0.12[0.01, 2.15]	
Canada 1992	6/1348	1/1324		58.7 %	5.89 [0.71, 48.88]	
Subtotal (95% CI)	1730	1724		100.0 %	0.94 [0.02, 45.31]	
Total events: 6 (CVS), 5 (Amr	niocentesis)					
Heterogeneity: $Tau^2 = 6.14$; (Chi ² = 4.63, df =	I (P = 0.03); I ² =78%				
Test for overall effect: $Z = 0.0$)3 (P = 0.98)					
3 CVS (any route) versus ami	niocentesis					
MRC 1991	7/1609	7/1592	-	100.0 %	0.99 [0.35, 2.81]	
Subtotal (95% CI)	1609	1592	+	100.0 %	0.99 [0.35, 2.81]	
Total events: 7 (CVS), 7 (Amr	niocentesis)					
Heterogeneity: not applicable						
Test for overall effect: $Z = 0.0$)2 (P = 0.98)					
			0.0050 0.1 1.0 10.0 200.0			
			Favours treatment Favours control			

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 27 Stillbirths

Study or subgroup	CVS n/N	Amniocentesis n/N		M-H,F		isk Ratio Iom,95%	CI	Weight	Risk Ratio M-H,Random,95% Cl
l Transcervical CVS versus ar	mniocentesis								
Borrell 1999	0/382	4/400	_	-		_		41.3 %	0.12 [0.01, 2.15]
Canada 1992	6/1348	1/1324			+	•	-	58.7 %	5.89 [0.71, 48.88]
Subtotal (95% CI)	1730	1724						100.0 %	0.94 [0.02, 45.31]
Total events: 6 (CVS), 5 (Amr	niocentesis)								
Heterogeneity: Tau ² = 6.14; C	$Chi^2 = 4.63, df =$	I (P = 0.03); I ² =78%							
Test for overall effect: $Z = 0.0$	03 (P = 0.98)								
			0.0050	0.1	1.0	0.01	200.0		
			Favours 1	treatment		Favours	control		

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 27 Stillbirths

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC 1991	7/1609	7/1592		100.0 %	0.99 [0.35, 2.81]
Subtotal (95% CI)	1609	1592	+	100.0 %	0.99 [0.35, 2.81]
Total events: 7 (CVS), 7 (Amr	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	02 (P = 0.98)				
			0.0050 0.1 1.0 10.0 200.0		
		F	avours treatment Favours control		

Analysis 3.28. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 28 Neonatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 28 Neonatal deaths

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio	
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI	
I Transcervical CVS versus an	nniocentesis					
Borrell 1999	0/382	1/400		42.2 %	0.35 [0.01, 8.54]	
Canada 1992	2/1348	1/1324		29.0 %	1.96 [0.18, 21.64]	
MRC (Finland) 1993	3/399	1/398		28.8 %	2.99 [0.31, 28.65]	
Subtotal (95% CI)	2129	2122	-	100.0 %	1.58 [0.41, 6.06]	
Total events: 5 (CVS), 3 (Amr	iocentesis)					
Heterogeneity: Chi ² = 1.20, d	$f = 2 (P = 0.55); I^2$	2 =0.0%				
Test for overall effect: $Z = 0.6$	7 (P = 0.51)					
3 CVS (any route) versus amr	niocentesis					
MRC 1991	8/1609	3/1592		100.0 %	2.64 [0.70, 9.93]	
Subtotal (95% CI)	1609	1592	-	100.0 %	2.64 [0.70, 9.93]	
Total events: 8 (CVS), 3 (Amr	iocentesis)					
Heterogeneity: not applicable						

Favours treatment

Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 28 Neonatal deaths

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% CI
I Transcervical CVS versus an	nniocentesis				
Borrell 1999	0/382	1/400		42.2 %	0.35 [0.01, 8.54]
Canada 1992	2/1348	1/1324		29.0 %	1.96 [0.18, 21.64]
MRC (Finland) 1993	3/399	1/398		28.8 %	2.99 [0.31, 28.65]
Subtotal (95% CI)	2129	2122	-	100.0 %	1.58 [0.41, 6.06]
Total events: 5 (CVS), 3 (Amn Heterogeneity: $Chi^2 = 1.20$, d Test for overall effect: Z = 0.6	f = 2 (P = 0.55); l ²	2 =0.0%			
			0.02 0.1 1.0 10.0 50.0		
		Favou	rs treatment Favours control		
Review: Amniocentesis and	chorionic villus sa	mpling for prenatal diagnosis			
Review: Amniocentesis and Comparison: 3 Chorionic v					
	illus sampling versu				
Comparison: 3 Chorionic v	illus sampling versu				
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea	illus sampling versu		ntesis		
Comparison: 3 Chorionic v	illus sampling versu			Weight	Risk Ratio
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea	illus sampling versu aths CVS	us second trimester amniocer Amniocentesis	ntesis Risk Ratio	Weight	
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea	illus sampling versu aths	us second trimester amnioce	ntesis	Weight	Risk Ratio M-H,Fixed,95% CI
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup	illus sampling versu aths CVS n/N	us second trimester amniocer Amniocentesis	ntesis Risk Ratio	Weight	
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr	illus sampling versu aths CVS n/N	us second trimester amniocer Amniocentesis n/N	ntesis Risk Ratio		M-H,Fixed,95% Cl
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup	illus sampling versu aths CVS n/N	us second trimester amniocer Amniocentesis	ntesis Risk Ratio	Weight 100.0 %	M-H,Fixed,95% Cl
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr	illus sampling versu aths CVS n/N	us second trimester amniocer Amniocentesis n/N	ntesis Risk Ratio		M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI)	illus sampling versu aths CVS n/N niocentesis 8/1609 1609	us second trimester amniocer Amniocentesis n/N 3/1592	ntesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn	illus sampling versu cVS n/N niocentesis 8/1609 1609 niocentesis)	us second trimester amniocer Amniocentesis n/N 3/1592	ntesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI)	illus sampling versu cVS n/N niocentesis 8/1609 1609 niocentesis)	us second trimester amniocer Amniocentesis n/N 3/1592	ntesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	us second trimester amniocer Amniocentesis n/N 3/1592	ntesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	us second trimester amniocer Amniocentesis n/N 3/1592	ntesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	ntesis Risk Ratio	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% Cl	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93]
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93
Comparison: 3 Chorionic v Outcome: 28 Neonatal dea Study or subgroup 3 CVS (any route) versus amr MRC 1991 Subtotal (95% CI) Total events: 8 (CVS), 3 (Amn Heterogeneity: not applicable	illus sampling versu aths CVS n/N niocentesis 8/1609 1609 niocentesis)	Amniocentesis n/N 3/1592 1592	Risk Ratio M-H,Fixed,95% CI	100.0 %	M-H,Fixed,95% Cl 2.64 [0.70, 9.93

Analysis 3.29. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 29 All recorded deaths after viability.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 29 All recorded deaths after viability

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
	11/1 N	11/1N	TIFLI, I Ked, 7378 CI		T I-I I,I IXEU,7578 CI
I Transcervical CVS versus am	niocentesis				
Borrell 1999	0/382	4/400		81.5 %	0.12 [0.01, 2.15]
MRC (Finland) 1993	4/399	1/398		18.5 %	3.99 [0.45, 35.54]
Subtotal (95% CI)	781	798	•	100.0 %	0.83 [0.24, 2.93]
Total events: 4 (CVS), 5 (Amnio	ocentesis)				
Heterogeneity: Chi ² = 3.72, df	$= (P = 0.05); ^2$	=73%			
Test for overall effect: Z = 0.28	(P = 0.78)				
3 CVS (any route) versus amnie	ocentesis				
MRC 1991	16/1609	11/1592		100.0 %	1.44 [0.67, 3.09]
Subtotal (95% CI)	1609	1592	•	100.0 %	1.44 [0.67, 3.09]
Total events: 16 (CVS), 11 (Am	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.93$	(P = 0.35)				

0.01 0.1 1.0 10.0 100.0 Favours treatment Favours control

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 29 All recorded deaths after viability

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk M-H,Fixed,	Ratio 95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus am	niocentesis					
Borrell 1999	0/382	4/400			81.5 %	0.12 [0.01, 2.15]
MRC (Finland) 1993	4/399	1/398		•	18.5 %	3.99 [0.45, 35.54]
Subtotal (95% CI)	781	798	-		100.0 %	0.83 [0.24, 2.93]
Total events: 4 (CVS), 5 (Amn	iocentesis)					
Heterogeneity: Chi ² = 3.72, d	f = I (P = 0.05);	l ² =73%				
Test for overall effect: $Z = 0.23$	8 (P = 0.78)					
				. i		
			0.01 0.1 1.0	10.0 100.0		
		Fav	ours treatment Fa	avours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 29 All recorded deaths after viability

Study or subgroup	CVS n/N	Amniocentesis n/N					Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis						
MRC 1991	16/1609	11/1592				100.0 %	1.44 [0.67, 3.09]
Subtotal (95% CI)	1609	1592			•	100.0 %	1.44 [0.67, 3.09]
Total events: 16 (CVS), 11 (Ar	mniocentesis)						
Heterogeneity: not applicable							
Test for overall effect: $Z = 0.9$	3 (P = 0.35)						
				ı			
			0.01	0.1	1.0 10.0 10	0.0	

Favours treatment Favours control

Analysis 3.30. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 30 Congenital anomalies (all recorded).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 30 Congenital anomalies (all recorded)

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
I Transcervical CVS versus am	nniocentesis				
Borrell 1999	2/314	5/358		40.2 %	0.46 [0.09, 2.33]
MRC (Finland) 1993	5/365	7/371		59.8 %	0.73 [0.23, 2.27]
Subtotal (95% CI)	679	729	-	100.0 %	0.62 [0.24, 1.56]
Total events: 7 (CVS), 12 (Am	niocentesis)				
Heterogeneity: Chi ² = 0.21, d	$f = I (P = 0.65); I^2$	=0.0%			
Test for overall effect: $Z = 1.02$	2 (P = 0.31)				
3 CVS (any route) versus amn	iocentesis				
Canada 1992	63/95	77/87	-	65.8 %	0.75 [0.64, 0.88]
MRC 1991	38/1609	41/1547	-	34.2 %	0.89 [0.58, 1.38]
Subtotal (95% CI)	1704	1634	•	100.0 %	0.80 [0.66, 0.96]
Total events: 101 (CVS), 118 (Amniocentesis)				
Heterogeneity: Chi ² = 0.82, d	$f = (P = 0.36); ^2$	=0.0%			
Test for overall effect: $Z = 2.3$	5 (P = 0.019)				
			0.05 0.2 1.0 5.0 20.0		

Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 30 Congenital anomalies (all recorded)

	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
1 Transcervical CVS versus ar Borrell 1999	mniocentesis 2/314	5/358		40.2 %	0.46 [0.09, 2.33]
MRC (Finland) 1993	5/365	7/371		59.8 %	0.73 [0.23, 2.27]
Subtotal (95% CI) Total events: 7 (CVS), 12 (An	679	729		100.0 %	0.62 [0.24, 1.56]
Heterogeneity: $Chi^2 = 0.21$, c	,	=0.0%			
Test for overall effect: $Z = 1.0$	02 (P = 0.31)				
			0.05 0.2 1.0 5.0 20.0		
			U.05 U.2 I.0 5.0 20.0		
Review: Amniocentesis and	d chorionic villus sa	mpling for proposal diagnosis			
Comparison: 3 Chorionic	villus sampling versu	is second trimester amnioce	ntesis		
Outcome: 30 Congenital a					
-	nomalies (all record	ded)			
Study or subgroup	·	,	Risk Ratio	Weight	Risk Ratio
Study or subgroup	nomalies (all record CVS n/N	ded) Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
	CVS n/N	Amniocentesis		Weight	
Study or subgroup 3 CVS (any route) versus am Canada 1992	CVS n/N	Amniocentesis		Weight 65.8 %	
3 CVS (any route) versus am	CVS n/N niocentesis	Amniocentesis n/N			M-H,Fixed,95% Cl 0.75 [0.64, 0.88]
3 CVS (any route) versus am Canada 1992 MRC 1991	CVS n/N niocentesis 63/95	Amniocentesis n/N 77/87		65.8 % 34.2 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]
3 CVS (any route) versus am Canada 1992 MRC 1991 Subtotal (95% CI)	CVS n/N niocentesis 63/95 38/1609 1704	Amniocentesis n/N 77/87 41/1547		65.8 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]
3 CVS (any route) versus am Canada 1992 MRC 1991 Subtotal (95% CI) Total events: 101 (CVS), 118	CVS n/N niocentesis 63/95 38/1609 1704 (Amniocentesis)	Amniocentesis n/N 77/87 41/1547 1634		65.8 % 34.2 %	M-H,Fixed,95% Cl
3 CVS (any route) versus am Canada 1992 MRC 1991 Subtotal (95% CI) Total events: 101 (CVS), 118 Heterogeneity: Chi ² = 0.82, o	CVS n/N niocentesis 63/95 38/1609 1704 (Amniocentesis) df = 1 (P = 0.36); 1 ²	Amniocentesis n/N 77/87 41/1547 1634		65.8 % 34.2 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]
3 CVS (any route) versus am Canada 1992 MRC 1991 Subtotal (95% CI) Total events: 101 (CVS), 118 Heterogeneity: Chi ² = 0.82, o	CVS n/N niocentesis 63/95 38/1609 1704 (Amniocentesis) df = 1 (P = 0.36); 1 ²	Amniocentesis n/N 77/87 41/1547 1634	M-H,Fixed,95% Cl	65.8 % 34.2 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]
3 CVS (any route) versus am Canada 1992 MRC 1991 Subtotal (95% CI) Total events: 101 (CVS), 118 Heterogeneity: Chi ² = 0.82, o	CVS n/N niocentesis 63/95 38/1609 1704 (Amniocentesis) df = 1 (P = 0.36); 1 ²	Amniocentesis n/N 77/87 41/1547 1634	M-H,Fixed,95% Cl	65.8 % 34.2 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]
3 CVS (any route) versus am Canada 1992 MRC 1991 Subtotal (95% CI) Total events: 101 (CVS), 118 Heterogeneity: Chi ² = 0.82, c	CVS n/N niocentesis 63/95 38/1609 1704 (Amniocentesis) df = 1 (P = 0.36); 1 ²	Amniocentesis n/N 77/87 41/1547 1634	M-H,Fixed,95% Cl	65.8 % 34.2 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]
3 CVS (any route) versus am Canada 1992	CVS n/N niocentesis 63/95 38/1609 1704 (Amniocentesis) df = 1 (P = 0.36); 1 ²	Amniocentesis n/N 77/87 41/1547 1634	M-H,Fixed,95% Cl	65.8 % 34.2 %	M-H,Fixed,95% Cl 0.75 [0.64, 0.88] 0.89 [0.58, 1.38]

Analysis 3.31. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 31 Talipes.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 31 Talipes

Study or subgroup	CVS	Amniocentesis	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95%
I Transcervical CVS versus am					
MRC (Finland) 1993	0/399	0/398	•	0.0 %	0.0 [0.0, 0.0
Subtotal (95% CI)	399	398		0.0 %	0.0 [0.0, 0.0]
Total events: 0 (CVS), 0 (Amni	iocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 0.0$	(P < 0.0001)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		
Review: Amniocentesis and	chorionic villus sam	Inling for prenatal diagnosis			
Review: Amniocentesis and	chorionic villus sam	pling for prenatal diagnosis			
		pling for prenatal diagnosis second trimester amniocentes	sis		
			sis		
Comparison: 3 Chorionic vi			sis		
Comparison: 3 Chorionic vi			sis Risk Ratio	Weight	Risk Ratio
Comparison: 3 Chorionic vi Outcome: 31 Talipes	Ilus sampling versus	second trimester amniocente:		Weight	Risk Ratio M-H,Fixed,95% (
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup	llus sampling versus CVS n/N	second trimester amniocente: Amniocentesis	Risk Ratio	Weight	
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup	Ilus sampling versus CVS n/N	second trimester amniocentes Amniocentesis n/N	Risk Ratio		M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993	Ilus sampling versus CVS n/N miocentesis 0/399	Second trimester amniocentes Amniocentesis n/N 0/398	Risk Ratio	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI)	Ilus sampling versus CVS n/N nniocentesis 0/399 399	second trimester amniocentes Amniocentesis n/N	Risk Ratio		M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni	Ilus sampling versus CVS n/N nniocentesis 0/399 399	Second trimester amniocentes Amniocentesis n/N 0/398	Risk Ratio	0.0 %	M-H,Fixed,95% 0.0 [0.0, 0.0
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	Second trimester amniocentes Amniocentesis n/N 0/398	Risk Ratio	0.0 %	M-H,Fixed,95% 0.0 [0.0, 0.0
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	Second trimester amniocentes Amniocentesis n/N 0/398	Risk Ratio	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	Second trimester amniocentes Amniocentesis n/N 0/398	Risk Ratio M-H,Fixed,95% Cl	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	second trimester amniocentes Amniocentesis n/N 0/398 398	Risk Ratio M-H,Fixed,95% CI	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	second trimester amniocentes Amniocentesis n/N 0/398 398	Risk Ratio M-H,Fixed,95% Cl	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	second trimester amniocentes Amniocentesis n/N 0/398 398	Risk Ratio M-H,Fixed,95% CI	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	second trimester amniocentes Amniocentesis n/N 0/398 398	Risk Ratio M-H,Fixed,95% CI	0.0 %	
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	second trimester amniocentes Amniocentesis n/N 0/398 398	Risk Ratio M-H,Fixed,95% CI	0.0 %	M-H,Fixed,95%
Comparison: 3 Chorionic vi Outcome: 31 Talipes Study or subgroup I Transcervical CVS versus am MRC (Finland) 1993 Subtotal (95% CI) Total events: 0 (CVS), 0 (Amni Heterogeneity: not applicable	Ilus sampling versus CVS n/N nniocentesis 0/399 399 iocentesis)	second trimester amniocentes Amniocentesis n/N 0/398 398	Risk Ratio M-H,Fixed,95% CI	0.0 %	M-H,Fixed,95%

Analysis 3.32. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 32 Hemangiomas (localised vascular lesions of the skin and subcutaneous tissue).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 32 Hemangiomas (localised vascular lesions of the skin and subcutaneous tissue)

Study or subgroup	CVS	AC	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
Canada 1992	28/95	19/87		100.0 %	1.35 [0.81, 2.24]
Total (95% CI)	95	87	-	100.0 %	1.35 [0.81, 2.24]
Total events: 28 (CVS), 19	(AC)				
Heterogeneity: not applica	ble				
Test for overall effect: $Z =$	I.I6 (P = 0.24)				


0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 3.33. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 33 Limb reduction defects.

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis Outcome: 33 Limb reduction defects Study or subgroup CVS Amniocentesis Risk Ratio Weight Risk Ratio n/N n/N M-H,Fixed,95% Cl M-H,Fixed,95% CI 3 CVS (any route) versus amniocentesis MRC 1991 2/1609 0/1592 100.0 % 4.95 [0.24, 102.97] Total (95% CI) 1609 1592 100.0 % 4.95 [0.24, 102.97] Total events: 2 (CVS), 0 (Amniocentesis) Heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) 0.0010 01 10 100 1000.0 Favours treatment Favours control

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 33 Limb reduction defects



Analysis 3.38. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 38 Result given in less than 7 days (not prespecified).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 38 Result given in less than 7 days (not prespecified)

Study or subgroup	CVS	Amniocentesis				ik Rati	-	Weight	Risk Ratio
	n/N	n/N		M-H	I,Fixe	d,95%	CI		M-H,Fixed,95% Cl
3 CVS (any route) versus am	niocentesis								
MRC 1991	235/1549	10/1550				•	-	100.0 %	23.52 [12.54, 44.10]
Subtotal (95% CI)	1549	1550				•		100.0 %	23.52 [12.54, 44.10]
Total events: 235 (CVS), 10 (A	Amniocentesis)								
Heterogeneity: not applicable									
Test for overall effect: $Z = 9.8$	84 (P < 0.00001)								
			0.0050	0.1	1.0	10.0	200.0		

Favours treatment Favours control

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review) Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 38 Result given in less than 7 days (not prespecified)

-

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk F M-H,Fixed,9		Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus am	niocentesis					
MRC 1991	235/1549	10/1550			100.0 %	23.52 [12.54, 44.10]
Subtotal (95% CI)	1549	1550		•	100.0 %	23.52 [12.54, 44.10]
Total events: 235 (CVS), 10 (/	Amniocentesis)					
Heterogeneity: not applicable						
Test for overall effect: $Z = 9.8$	84 (P < 0.00001)					
			0.0050 0.1 1.0 10	.0 200.0		

Favours treatment Favours control

Analysis 3.39. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 39 Result given in less than 14 days (not prespecified).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 39 Result given in less than 14 days (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	M-H	Risk Ratio 1-H,Fixed,95% Cl		Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus am	niocentesis						
MRC (Finland) 1993	348/1549	88/1550				100.0 %	3.96 [3.17, 4.95]
Subtotal (95% CI)	1549	1550			•	100.0 %	3.96 [3.17, 4.95]
Total events: 348 (CVS), 88 (A	Amniocentesis)						
Heterogeneity: not applicable							
Test for overall effect: $Z = 12$.09 (P < 0.00001)						
			0.1 0.2 0.5	5 1.0 2.0	5.0 10.0		
			Favours treatme	nt Favou	irs control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 39 Result given in less than 14 days (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC (Finland) 1993	348/1549	88/1550		100.0 %	3.96 [3.17, 4.95]
Subtotal (95% CI)	1549	1550	•	100.0 %	3.96 [3.17, 4.95]
Total events: 348 (CVS), 88 (/	Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 12$.09 (P < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0	10.0	

Favours treatment Favours control

Analysis 3.40. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 40 Result given in less than 21 days (not prespecified).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 40 Result given in less than 21 days (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus am	niocentesis				
MRC (Finland) 1993	282/1549	392/1550		100.0 %	0.72 [0.63, 0.82]
Subtotal (95% CI)	1549	1550	•	100.0 %	0.72 [0.63, 0.82]
Total events: 282 (CVS), 392	(Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 4.7$	74 (P < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 40 Result given in less than 21 days (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC (Finland) 1993	282/1549	392/1550	-	100.0 %	0.72 [0.63, 0.82]
Subtotal (95% CI)	1549	1550	•	100.0 %	0.72 [0.63, 0.82]
Total events: 282 (CVS), 392					
Heterogeneity: not applicable					
Test for overall effect: $Z = 4.7$	74 (P < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		

Favours treatment Favours control

Analysis 3.41. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 41 Result given in more than 21 days (not prespecified).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 41 Result given in more than 21 days (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC 1991	167/1549	505/1550	+	100.0 %	0.33 [0.28, 0.39]
Subtotal (95% CI)	1549	1550	•	100.0 %	0.33 [0.28, 0.39]
Total events: 167 (CVS), 505	(Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 13$.	.53 (P < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 41 Result given in more than 21 days (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
3 CVS (any route) versus amr	niocentesis				
MRC 1991	167/1549	505/1550	-	100.0 %	0.33 [0.28, 0.39]
Subtotal (95% CI)	1549	1550	•	100.0 %	0.33 [0.28, 0.39]
Total events: 167 (CVS), 505	(Amniocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 13$.	.53 (P < 0.00001)				
			0.1 0.2 0.5 1.0 2.0 5.0 1	0.0	

Favours treatment Favours control

Analysis 3.42. Comparison 3 Chorionic villus sampling versus second trimester amniocentesis, Outcome 42 Not wanting another baby at 22 weeks' gestation (not prespecified).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis


Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 42 Not wanting another baby at 22 weeks' gestation (not prespecified)

Study or subgroup	CVS n/N	Amniocentesis n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
I Transcervical CVS versus am	iniocentesis				
Canada 1992	7/26	13/25		100.0 %	0.34 [0.11, 1.09]
Subtotal (95% CI)	26	25		100.0 %	0.34 [0.11, 1.09]
Total events: 7 (CVS), 13 (Amr	niocentesis)				
Heterogeneity: not applicable					
Test for overall effect: $Z = 1.81$	(P = 0.071)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		Fave	ours treatment Favours control		

Comparison: 3 Chorionic villus sampling versus second trimester amniocentesis

Outcome: 42 Not wanting another baby at 22 weeks' gestation (not prespecified)



Favours treatment Favours control

Analysis 4.1. Comparison 4 Transcervical versus transabdominal CVS, Outcome 1 Not complied with allocated procedure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: I Not complied with allocated procedure

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	M	R -H,Ranc	isk Rati dom,959	-	Weight	Risk Ratio M-H,Random,95% Cl
Bovicelli 1986	0/60	0/60	4				0.0 %	0.0 [0.0, 0.0]
Brambati 1991	110/599	38/595				F	49.2 %	2.88 [2.02, 4.08]
USNICHD 1992	130/1944	130/1929		-			50.8 %	0.99 [0.78, 1.25]
Total (95% CI)	2603	2584				-	100.0 %	1.68 [0.59, 4.76]
Total events: 240 (Transo	cervical CVS), 168 (Transat	odominal CVS)						
Heterogeneity: Tau ² = 0	.54; Chi ² = 24.47, df = 1 (P<0.00001); I ² =96%						
Test for overall effect: Z	= 0.97 (P = 0.33)							
			0.1 0.2	0.5 I.	0 2.0	5.0 10.0		
			Favours trea	tment	Favour	s control		

Analysis 4.2. Comparison 4 Transcervical versus transabdominal CVS, Outcome 2 Sampling failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 2 Sampling failure

Study or subgroup	Transcervical CVS	Transabdominal CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Bovicelli 1986	1/60	1/60		3.5 %	1.00 [0.06, 15.62]
Brambati 1991	1/599	1/595		3.5 %	0.99 [0.06, 15.84]
Tomassini 1988	3/24	0/20		1.9 %	5.88 [0.32, 107.49]
USNICHD 1992	47/1944	26/1929	-	91.1 %	1.79 [1.12, 2.88]
Total (95% CI)	2627	2604	•	100.0 %	1.82 [1.15, 2.86]
Total events: 52 (Transc	ervical CVS), 28 (Transabd	ominal CVS)			
Heterogeneity: Chi ² = (0.99, df = 3 (P = 0.80); l ² =	=0.0%			
Test for overall effect: Z	Z = 2.58 (P = 0.0098)				

0.01 0.1 1.0 10.0 100.0 Favours treatment Favours control

Analysis 4.3. Comparison 4 Transcervical versus transabdominal CVS, Outcome 3 Multiple insertions.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 3 Multiple insertions

Study or subgroup	Transcervical CVS	Transabdominal CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% CI
Bovicelli 1986	14/60	8/60		29.6 %	1.75 [0.79, 3.86]
Brambati 1991	60/599	19/595		70.4 %	3.14 [1.90, 5.19]
Total (95% CI)	659	655	•	100.0 %	2.73 [1.78, 4.17]
Total events: 74 (Transc	ervical CVS), 27 (Transabdo	ominal CVS)			
Heterogeneity: $Chi^2 =$	1.50, df = 1 (P = 0.22); I^2 =	33%			
Test for overall effect: Z	Z = 4.64 (P < 0.00001)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 4.4. Comparison 4 Transcervical versus transabdominal CVS, Outcome 4 Second test performed.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 4 Second test performed

Study or subgroup	Transcervical CVS	Transabdominal CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
Brambati 1991	20/599	16/595		100.0 %	1.24 [0.65, 2.37]
Total (95% CI)	599	595	-	100.0 %	1.24 [0.65, 2.37]
Total events: 20 (Transc	ervical CVS), 16 (Transabd	ominal CVS)			
Heterogeneity: not app	licable				
Test for overall effect: Z	Z = 0.66 (P = 0.51)				
			<u></u>		
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
		Fa	avours treatment Favours control		

Analysis 4.5. Comparison 4 Transcervical versus transabdominal CVS, Outcome 5 Laboratory failure.

Review: Amniocentesi	is and chorionic villus samp	oling for prenatal diagnosis			
Comparison: 4 Transco	ervical versus transabdom	inal CVS			
Outcome: 5 Laborator	ry failure				
Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% C
Brambati 1991	9/599	4/595		100.0 %	2.23 [0.69, 7.22
Total (95% CI)	599	595		100.0 %	2.23 [0.69, 7.22
Heterogeneity: not applic Test for overall effect: Z					
	× ,				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0)	
			Favours treatment Favours control		
mniocontosis and ch	orionic villus sampling	for prenatal diagnosis	(Review)		

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 4.6. Comparison 4 Transcervical versus transabdominal CVS, Outcome 6 All non-mosaic abnormalities.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 6 All non-mosaic abnormalities

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Denmark 1992	68/1419	56/1443		100.0 %	1.23 [0.87, 1.75]
Total (95% CI)	1419	1443	•	100.0 %	1.23 [0.87, 1.75]
Total events: 68 (Transo	cervical CVS), 56 (Transabd	ominal CVS)			
Heterogeneity: not app	licable				
Test for overall effect: Z	Z = 1.19 (P = 0.23)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		

Favours treatment Favours control

Analysis 4.7. Comparison 4 Transcervical versus transabdominal CVS, Outcome 7 True mosaics.

Review: Amniocentesi	is and chorionic villus samp	bling for prenatal diagnosis				
Comparison: 4 Transc	ervical versus transabdom	inal CVS				
Outcome: 7 True mos	saics					
Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk M-H,Fixed,	Ratio 95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Denmark 1992	10/1419	11/1443	-	_	100.0 %	0.92 [0.39, 2.17
Total (95% CI)	1419	1443	-	-	100.0 %	0.92 [0.39, 2.17]
Test for overall effect: Z	= 0.18 (P = 0.86)					
Test for overall effect: Z	= 0.18 (P = 0.86)					
			0.1 0.2 0.5 1.0	2.0 5.0 10.0		
				avours control		
mniocontosis and ch	orionic villus sampling	for prenatal diagnosis	(Review)			

Analysis 4.8. Comparison 4 Transcervical versus transabdominal CVS, Outcome 8 Confined mosaics.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 8 Confined mosaics

Study or subgroup	Transcervical CVS	Transabdominal CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Denmark 1992	5/1419	6/1443		100.0 %	0.85 [0.26, 2.77]
Total (95% CI)	1419	1443		100.0 %	0.85 [0.26, 2.77]
Total events: 5 (Transcer	rvical CVS), 6 (Transabdom	ninal CVS)			
Heterogeneity: not appl	icable				
Test for overall effect: Z	= 0.27 (P = 0.78)				
			0.1 0.2 0.5 1.0 2.0 5.0 10	.0	
			Favours treatment Favours contro	ol	

Analysis 4.13. Comparison 4 Transcervical versus transabdominal CVS, Outcome 13 Vaginal bleeding after test.

Comparison: 4 Transc	ervical versus transabdom	iinal CVS			
Outcome: 13 Vaginal	bleeding after test				
Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H,Random,95% Cl	Weight	Risk Ratio M-H,Random,95% (
Bovicelli 1986	32/60	0/60	∎ →	27.8 %	65.00 [4.07, 1037.74
Brambati 1991	35/599	11/595	-	47.5 %	3.16 [1.62, 6.16
Tomassini 1988	1/24	0/20		24.7 %	2.52 [0.11, 58.67
	683 ervical CVS), 11 (Transabc 55; Chi ² = 6.21, df = 2 (f	,		100.0 %	6.93 [0.77, 62.83
Test for overall effect: Z					

Analysis 4.14. Comparison 4 Transcervical versus transabdominal CVS, Outcome 14 Amniotic leakage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 14 Amniotic leakage after test

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Ris M-H,Fixe	sk Ratio d,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Tomassini 1988	0/24	1/20			100.0 %	0.28 [0.01, 6.52]
Total (95% CI)	24	20			100.0 %	0.28 [0.01, 6.52]
Total events: 0 (Transcer	rvical CVS), I (Transabdom	inal CVS)				
Heterogeneity: not appl	icable					
Test for overall effect: Z	= 0.79 (P = 0.43)					
			_			
			0.01 0.1 1.0	10.0 100.0		
		Fav	ours treatment	Favours control		

Analysis 4.20. Comparison 4 Transcervical versus transabdominal CVS, Outcome 20 All known pregnancy loss (including termination of pregnancy).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 4 Transcervical versus transabdominal CVS Outcome: 20 All known pregnancy loss (including termination of pregnancy) Risk Ratio Study or subgroup Transcervical CVS Transabdominal CVS Risk Ratio Weight n/N M-H,Random,95% CI M-H,Random,95% Cl n/N Bovicelli 1986 1.00 [0.31, 3.28] 5/60 5/60 7.1 % Brambati 1991 95/592 102/591 30.6 % 0.93 [0.72, 1.20] Denmark 1992 188/1514 31.9 % 1.68 [1.34, 2.10] 113/1527 Tomassini 1988 2/24 1/20 2.2 % 1.67 [0.16, 17.06] USNICHD 1992 74/1846 72/1744 28.2 % 0.97 [0.71, 1.33] 3942 Total (95% CI) 4036 100.0 % 1.16 [0.81, 1.65] Total events: 364 (Transcervical CVS), 293 (Transabdominal CVS) Heterogeneity: Tau² = 0.09; Chi² = 14.43, df = 4 (P = 0.01); $|^2 = 72\%$ Test for overall effect: Z = 0.81 (P = 0.42) 0.1 0.2 0.5 1.0 2.0 5.0 10.0

Favours treatment Favours control

Analysis 4.21. Comparison 4 Transcervical versus transabdominal CVS, Outcome 21 Termination of pregnancy (all).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 21 Termination of pregnancy (all)

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Bovicelli 1986	3/60	3/60		5.8 %	1.00 [0.21, 4.76]
Brambati 1991	40/591	49/592		94.2 %	0.82 [0.55, 1.22]
Total (95% CI)	651	652	•	100.0 %	0.83 [0.56, 1.22]
Total events: 43 (Transc	ervical CVS), 52 (Transabdo	ominal CVS)			
Heterogeneity: $Chi^2 = 0$	0.06, df = $ (P = 0.8); ^2 =$	=0.0%			
Test for overall effect: Z	L = 0.95 (P = 0.34)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 4.24. Comparison 4 Transcervical versus transabdominal CVS, Outcome 24 Spontaneous miscarriage.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 24 Spontaneous miscarriage

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H.Random.95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Bovicelli 1986	2/60	2/60		11.5 %	1.00 [0.15, 6.87]
Brambati 1991	47/592	44/591	-	41.5 %	1.07 [0.72, 1.58]
Denmark 1992	83/1010	31/1027	-	41.3 %	2.72 [1.82, 4.07]
Tomassini 1988	2/24	0/20		5.6 %	4.20 [0.21, 82.72]
Total (95% CI)	1686	1698	+	100.0 %	1.68 [0.79, 3.58]
Total events: 134 (Trans	cervical CVS), 77 (Transabo	lominal CVS)			
Heterogeneity: Tau ² = (0.32; Chi ² = 11.30, df = 3 (f	^o = 0.01); l ² =73%			
Test for overall effect: Z	L = 1.35 (P = 0.18)				

0.01 0.1 1.0 10.0 100.0

Favours treatment Favours control

Analysis 4.25. Comparison 4 Transcervical versus transabdominal CVS, Outcome 25 Spontaneous miscarriage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 25 Spontaneous miscarriage after test

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Bovicelli 1986	2/60	2/60		7.5 %	1.00 [0.15, 6.87]
Brambati 1991	29/592	24/591		90.4 %	1.21 [0.71, 2.05]
Tomassini 1988	2/24	0/20		2.0 %	4.20 [0.21, 82.72]
Total (95% CI)	676	671	•	100.0 %	1.25 [0.76, 2.06]
Total events: 33 (Transc	ervical CVS), 26 (Transabdo	ominal CVS)			
Heterogeneity: $Chi^2 = 0$	0.70, df = 2 (P = 0.70); I^2 =	=0.0%			
Test for overall effect: Z	= 0.88 (P = 0.38)				
1					

0.0050 0.1 1.0 10.0 200.0 Favours treatment Favours control

Analysis 4.26. Comparison 4 Transcervical versus transabdominal CVS, Outcome 26 Perinatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 26 Perinatal deaths

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	М-Н.	Risk Ratio Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Denmark 1992	3/1010	7/1027			100.0 %	0.44 [0.11, 1.68]
Total (95% CI)	1010	1027			100.0 %	0.44 [0.11, 1.68]
Total events: 3 (Transce	rvical CVS), 7 (Transabdom	inal CVS)				
Heterogeneity: not appl	icable					
Test for overall effect: Z	= 1.21 (P = 0.23)					
			0.1 0.2 0.5	1.0 2.0 5.0 10.0		
		Fa	vours treatment	Favours control		

Analysis 4.27. Comparison 4 Transcervical versus transabdominal CVS, Outcome 27 Stillbirths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 27 Stillbirths

Study or subgroup	Transcervical CVS	Transabdominal CVS		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H	I,Fixed,95% CI		M-H,Fixed,95% Cl
Brambati 1991	4/592	1/591			38.0 %	3.99 [0.45, 35.62]
Tomassini 1988	0/24	1/20			62.0 %	0.28 [0.01, 6.52]
Total (95% CI)	616	611		-	100.0 %	1.69 [0.38, 7.62]
Total events: 4 (Transce	ervical CVS), 2 (Transabdomi	nal CVS)				
Heterogeneity: Chi ² =	1.85, df = 1 (P = 0.17); l ² =	16%				
Test for overall effect: Z	<u>Z</u> = 0.69 (P = 0.49)					
					1	
			0.01 0.1	1.0 10.0 1	00.0	

Favours treatment Favours control

Analysis 4.28. Comparison 4 Transcervical versus transabdominal CVS, Outcome 28 Neonatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 28 Neonatal deaths

Study or subgroup	Transcervical CVS n/N	Transabdominal CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Brambati 1991	2/592	4/591		79.9 %	0.50 [0.09, 2.71]
USNICHD 1992	1/1846	1/1816		20.1 %	0.98 [0.06, 15.72]
Total (95% CI)	2438	2407		100.0 %	0.60 [0.14, 2.49]
Test for overall effect: Z	E = 0.71 (P = 0.48)		0.05 0.2 1,0 5.0 20.0 rs treatment Favours control		

Analysis 4.30. Comparison 4 Transcervical versus transabdominal CVS, Outcome 30 Anomalies (all recorded).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 4 Transcervical versus transabdominal CVS

Outcome: 30 Anomalies (all recorded)

Study or subgroup	Transcervical CVS	Transabdominal CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Brambati 1991	9/501	3/497		36.0 %	0.69 [0.30, 1.59]
Denmark 1992	15/1268	24/1356		64.0 %	0.67 [0.35, 1.27]
Total (95% CI)	1769	1853	•	100.0 %	0.68 [0.41, 1.12]
Total events: 24 (Transc	ervical CVS), 37 (Transabdo	ominal CVS)			
Heterogeneity: $Chi^2 = 0$	0.00, df = 1 (P = 0.96); I^2 =	0.0%			
Test for overall effect: Z	= 1.51 (P = 0.13)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0

Favours treatment Favours control

Analysis 4.31. Comparison 4 Transcervical versus transabdominal CVS, Outcome 31 Talipes.

Outcome: 31 Talipes						
Study or subgroup	Transcervical CVS	Transabdominal CVS	Risk	Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,	,95% CI		M-H,Fixed,95% Cl
Denmark 1992	3/1268	1/1356			100.0 %	3.21 [0.33, 30.80]
Total (95% CI)	1268	1356			100.0 %	3.21 [0.33, 30.80]
Test for overall effect: Z	= 1.01 (P = 0.31)			2.0 5.0 10.0 Favours control		
mniocentesis and ch	orionic villus sampling	for prenatal diagnosis	(Review)			1

Analysis 5.1. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 1 Not complied with allocated procedure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: I Not complied with allocated procedure

Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
0/559	4/562		21.4 %	0.11[0.01, 2.07]
0/278	0/277	4	0.0 %	0.0 [0.0, 0.0]
1/55	10/60		45.6 %	0.11 [0.01, 0.82]
3/1861	7/1914		32.9 %	0.44 [0.11, 1.70]
2753	2813	•	100.0 %	0.22 [0.08, 0.60]
entesis), 21 (CVS)				
$ff = 2 (P = 0.43); I^2 = 0.0\%$				
94 (P = 0.0032)				
	n/N 0/559 0/278 1/55 3/1861 2753 entesis), 21 (CVS) If = 2 (P = 0.43); I ² =0.0%	n/N n/N 0/559 4/562 0/278 0/277 1/55 10/60 3/1861 7/1914 2753 2813 entesis), 21 (CVS) If = 2 (P = 0.43); I ² = 0.0%	n/N n/N M-H,Fixed,95% Cl 0/559 4/562 0/278 0/277 1/55 10/60 3/1861 7/1914 2753 2813 ← entesis), 21 (CVS) If = 2 (P = 0.43); I ² = 0.0%	n/N n/N M-H,Fixed,95% Cl 0/559 4/562 ● 21.4 % 0/278 0/277 ● 0.0 % 1/55 10/60 ● 45.6 % 3/1861 7/1914 ● 32.9 % 2753 2813 ● 100.0 % entesis), 21 (CVS) # 0.0 %

0.0010 0.1 1.0 10.0 1000.0 Favours treatment Favours control

Analysis 5.2. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 2 Sampling failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 2 Sampling failure

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	3/559	11/562		47.1 %	0.27 [0.08, 0.98]
King's 1996	0/278	2/277	• —	10.8 %	0.20 [0.01, 4.13]
Leiden 1998	1/55	2/60		8.2 %	0.55 [0.05, 5.85]
NICHD EATA 2004	9/1861	8/1914		33.9 %	1.16 [0.45, 2.99]
Total (95% CI)	2753	2813	•	100.0 %	0.59 [0.30, 1.14]
Total events: 13 (Early amn	niocentesis), 23 (CVS)				
Heterogeneity: $Chi^2 = 3.83$	3, df = 3 (P = 0.28); I ² =22%				
Test for overall effect: $Z =$	1.57 (P = 0.12)				
			0.02 0.1 1.0 10.0 50.0		
			Favours treatment Favours control		

Analysis 5.3. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 3 Multiple insertions.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 3 Multiple insertions

-

-

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
King's 1996	4/278	7/277		12.8 %	0.57 [0.17, 1.92]
Leiden 1998	5/55	25/60		43.8 %	0.22 [0.09, 0.53]
NICHD EATA 2004	16/1861	24/1914		43.3 %	0.69 [0.37, 1.29]
Total (95% CI)	2194	2251	•	100.0 %	0.47 [0.29, 0.74]
Total events: 25 (Early amnic	ocentesis), 56 (CVS)				
Heterogeneity: $Chi^2 = 4.36$,	df = 2 (P = 0.11); $I^2 = 54\%$				
Test for overall effect: $Z = 3$.26 (P = 0.0011)				

```
0.05 0.2 1.0 5.0 20.0
Favours treatment Favours control
```

Analysis 5.4. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 4 Second test performed.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 4 Second test performed

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	1/559	3/562		32.8 %	0.08 [0.01, 0.59]
King's 1996	5/278	7/277		17.7 %	0.71 [0.23, 2.22]
Leiden 1998	4/55	4/60	-	9.7 %	1.09 [0.29, 4.15]
NICHD EATA 2004	13/1861	16/1914	+	39.9 %	0.84 [0.40, 1.73]
Total (95% CI)	2753	2813	•	100.0 %	0.59 [0.36, 0.98]
Total events: 23 (Early am	niocentesis), 40 (CVS)				
Heterogeneity: Chi ² = 5.6	64, df = 3 (P = 0.13); l ² =47%				
Test for overall effect: Z =	= 2.04 (P = 0.041)				
			0.0050 0.1 1.0 10.0 200.0		
			Favours treatment Favours control		

Analysis 5.5. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 5 Laboratory failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 5 Laboratory failure

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	1/559	5/562		30.4 %	0.20 [0.02, 1.72]
King's 1996	5/278	7/277		42.7 %	0.71 [0.23, 2.22]
Leiden 1998	1/55	0/60		2.9 %	3.27 [0.14, 78.58]
NICHD EATA 2004	4/1861	4/1914		24.0 %	1.03 [0.26, 4.11]
Total (95% CI)	2753	2813	•	100.0 %	0.71 [0.34, 1.49]
Total events: II (Early amnie	ocentesis), 16 (CVS)				
Heterogeneity: $Chi^2 = 2.49$,	df = 3 (P = 0.48); $I^2 = 0.0\%$				
Test for overall effect: $Z = 0$.91 (P = 0.36)				

0.01 0.1 1.0 10.0 100.0 Favours treatment Favours control

Analysis 5.6. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 6 All non-mosaic abnormalities.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 6 All non-mosaic abnormalities

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	4/559	11/562		23.3 %	0.37 [0.12, 1.14]
King's 1996	5/278	5/277		10.7 %	1.00 [0.29, 3.40]
Leiden 1998	2/55	0/60		1.0 %	5.45 [0.27, 111.01]
NICHD EATA 2004	37/1861	31/1914	-	65.0 %	1.23 [0.76, 1.97]
Total (95% CI)	2753	2813	+	100.0 %	1.04 [0.70, 1.55]
Total events: 48 (Early amr	niocentesis), 47 (CVS)				
Heterogeneity: $Chi^2 = 4.87$	7, df = 3 (P = 0.18); l ² =38%				
Test for overall effect: $Z =$	0.22 (P = 0.83)				
			0.01 0.1 1.0 10.0 100.0		
			Favours treatment Favours control		

Analysis 5.7. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 7 True mosaics.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 7 True mosaics

-

-

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
Copenhagen 1997	1/559	1/562		18.3 %	1.01 [0.06, 16.03]
King's 1996	0/278	1/277		27.5 %	0.33 [0.01, 8.12]
NICHD EATA 2004	1/1861	3/1914		54.2 %	0.34 [0.04, 3.29]
Total (95% CI)	2698	2753	-	100.0 %	0.46 [0.10, 2.06]
Total events: 2 (Early amnio	centesis), 5 (CVS)				
Heterogeneity: $Chi^2 = 0.4I$,	df = 2 (P = 0.8 l); l ² =0.0%				
Test for overall effect: $Z = I$.02 (P = 0.31)				

0.0020 0.1 1.0 10.0 500.0 Favours treatment Favours control

Analysis 5.8. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 8 Abnormalities confined to non-fetal tissues.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 8 Abnormalities confined to non-fetal tissues

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	0/559	3/562		11.6 %	0.14 [0.01, 2.77]
King's 1996	0/278	2/277		8.3 %	0.20 [0.01, 4.13]
Leiden 1998	2/55	0/60		1.6 %	5.45 [0.27, .0]
NICHD EATA 2004	24/1861	24/1914	=	78.5 %	1.03 [0.59, 1.80]
Total (95% CI)	2753	2813	+	100.0 %	0.93 [0.56, 1.55]
Total events: 26 (Early amr	niocentesis), 29 (CVS)				
Heterogeneity: $Chi^2 = 3.97$	7, df = 3 (P = 0.26); l ² =24%				
Test for overall effect: Z =	0.29 (P = 0.77)				
			0.0050 0.1 1.0 10.0 200.0		

Favours treatment Favours control

Analysis 5.9. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 9 Maternal contamination.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 9 Maternal contamination

-

Study or subgroup	Early amniocentesis	CVS		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,F	ixed,95% Cl		M-H,Fixed,95% Cl
King's 1996	0/278	2/277		+	83.6 %	0.20 [0.01, 4.13]
NICHD EATA 2004	8/1861	0/1914			- 16.4 %	17.48 [1.01, 302.70]
Total (95% CI)	2139	2191		-	100.0 %	3.04 [0.83, 11.14]
Total events: 8 (Early amnic	ocentesis), 2 (CVS)					
Heterogeneity: Chi ² = 4.55	5, df = 1 (P = 0.03); l ² =78%					
Test for overall effect: $Z =$	I.68 (P = 0.093)					
					1	
			0.0020 0.1	1.0 10.0	500.0	
			Favours treatment	Favours co	ntrol	

Analysis 5.10. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 10 Known false positive after birth.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 10 Known false positive after birth

Study or subgroup	Early amniocentesis	CVS		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	I*I-Ħ,Fi	xed,95% Cl		M-H,Fixed,95% Cl
King's 1996	0/278	0/277	4		0.0 %	0.0 [0.0, 0.0]
Leiden 1998	0/55	1/60			100.0 %	0.36 [0.02, 8.73]
Total (95% CI)	333	337			100.0 %	0.36 [0.02, 8.73]
Total events: 0 (Early am	niocentesis), I (CVS)					
Heterogeneity: $Chi^2 = 0$.00, df = 0 (P<0.00001); $ ^2 = 00000000000000000000000000000000000$)%				
Test for overall effect: Z	= 0.62 (P = 0.53)					
			0.0050 0.1 1	.0 10.0 200.0		
			Favours treatment	Favours control		

Analysis 5.11. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 11 Known false negative after birth.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: II Known false negative after birth

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
King's 1996	0/277	0/278	•	0.0 %	0.0 [0.0, 0.0]
Total (95% CI)	277	278		0.0 %	0.0 [0.0, 0.0]
Total events: 0 (Early amn	iocentesis), 0 (CVS)				
Heterogeneity: not applica	able				
Test for overall effect: Z =	= 0.0 (P < 0.00001)				
				1	

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 5.12. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 12 Reporting time.

Outcome: 12 Reportin	ig time						
Study or subgroup	EAC N	Mean(SD)	CVS N	Mean(SD)	Mean Difference IV,Fixed,95% Cl	Weight	Mean Differen IV,Fixed,95% Cl
NICHD EATA 2004	1861	10.3 (2.5)	1914	6.3 (3)		100.0 %	4.00 [3.82, 4.18
Total (95% CI) Heterogeneity: not applic Test for overall effect: Z =		0.00001)	1914		•	100.0 %	4.00 [3.82, 4.18
)	
					D -5 0 5 IC)	
)	
)	
)	
)	

Analysis 5.13. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 13 Vaginal bleeding after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 13 Vaginal bleeding after test

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
	1013	101 1	TTT (i Ked) 570 G		
Copenhagen 1997	23/559	40/562	-	71.7 %	0.58 [0.35, 0.95]
Leiden 1998	3/55	1/60		1.7 %	3.27 [0.35, 30.54]
NICHD EATA 2004	11/1820	15/1878		26.5 %	0.76 [0.35, 1.64]
Total (95% CI)	2434	2500	•	100.0 %	0.67 [0.45, 1.01]
Total events: 37 (Early amnic	ocentesis), 56 (CVS)				
Heterogeneity: Chi ² = 2.37,	, , ,				
e ,	. ,				
Test for overall effect: $Z = 1$.	.92 (P = 0.055)				

0.05 0.2 1.0 5.0 20.0 Favours treatment Favours control

Analysis 5.14. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 14 Amniotic leakage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 14 Amniotic leakage after test

Study or subgroup	Early amniocentesis n/N	CVS n/N	M-H,	Risk Ratio Random,95% Cl	Weight	Risk Ratio M-H,Random,95% Cl
Copenhagen 1997	24/559	0/562			27.3 %	49.26 [3.00, 808.08]
Leiden 1998	0/55	1/60		•	24.1 %	0.36 [0.02, 8.73]
NICHD EATA 2004	195/1820	90/1878			48.6 %	2.24 [1.76, 2.85]
Total (95% CI)	2434	2500		-	100.0 %	3.35 [0.37, 30.09]
Total events: 219 (Early am	nniocentesis), 91 (CVS)					
Heterogeneity: Tau ² = 2.57	7; Chi ² = 6.43, df = 2 (P = 0.0	14); l ² =69%				
Test for overall effect: Z =	1.08 (P = 0.28)					
			0.0010 0.	I I.O IO.O IOOO.C)	
			Favours treatme	ent Favours control		

Analysis 5.15. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 15 Vaginal bleeding after 20 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 15 Vaginal bleeding after 20 weeks

Study or subgroup	EAC n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
NICHD EATA 2004	13/1820	19/1878		100.0 %	0.71 [0.35, 1.43]
Total (95% CI)	1820	1878	-	100.0 %	0.71 [0.35, 1.43]
Total events: 13 (EAC), 19 (C	CVS)				
Heterogeneity: not applicable	2				
Test for overall effect: $Z = 0.9$	97 (P = 0.33)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		

Favours EAC Favours CVS

Analysis 5.16. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 16 Prelabour ruptured membranes less than 28 weeks.

Review: Amniocentesis and	d chorionic villus san	npling for prenatal d	iagnosis		
Comparison: 5 Early amnic	ocentesis versus tran	sabdominal CVS			
Outcome: 16 Prelabour ru	ptured membranes	less than 28 weeks			
Study or subgroup	EAC n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
NICHD EATA 2004	15/1820	31/1878		100.0 %	0.50 [0.27, 0.92]
Total (95% CI) Total events: 15 (EAC), 31 (C Heterogeneity: not applicable Test for overall effect: Z = 2.2	2	1878		100.0 %	0.50 [0.27, 0.92]
			0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours EAC Favours CVS		

Analysis 5.18. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 18 Delivery before 37 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 18 Delivery before 37 weeks

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	27/559	24/562		57.5 %	1.13 [0.66, 1.94]
King's 1996	19/257	15/262		35.7 %	1.29 [0.67, 2.49]
Leiden 1998	2/55	3/60		6.9 %	0.73 [0.13, 4.19]
Total (95% CI)	871	884	*	100.0 %	1.16 [0.78, 1.74]
Total events: 48 (Early amn	iocentesis), 42 (CVS)				
Heterogeneity: Chi ² = 0.38	8, df = 2 (P = 0.83); $I^2 = 0.0\%$				
Test for overall effect: $Z = 0$	0.72 (P = 0.47)				

^{0.1 0.2 0.5 1.0 2.0 5.0 10.0} Favours treatment Favours control

Analysis 5.19. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 19 Delivery before 33 weeks.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 19 Delivery before 33 weeks

-

Study or subgroup	Early amniocentesis n/N	CVS n/N		Risk Ratio xed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	2/559	4/562			100.0 %	0.50 [0.09, 2.73]
Total (95% CI)	559	562			100.0 %	0.50 [0.09, 2.73]
Total events: 2 (Early amni	ocentesis), 4 (CVS)					
Heterogeneity: not applica	ble					
Test for overall effect: $Z =$	0.80 (P = 0.43)					
			0.05 0.2 1.0	5.0 20.0		
			Favours treatment	Favours control		

Analysis 5.20. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 20 All known pregnancy loss (including termination of pregnancy).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	30/559	27/562		32.4 %	1.12 [0.67, 1.85]
King's 1996	22/278	15/277		18.1 %	1.46 [0.77, 2.76]
Leiden 1998	4/56	3/61		3.5 %	1.45 [0.34, 6.21]
NICHD EATA 2004	39/1820	39/1878		46.1 %	1.03 [0.67, 1.60]
Total (95% CI) Total events: 95 (Early amnic Heterogeneity: Chi ² = 0.89, Test for overall effect: Z = 0	df = 3 (P = 0.83); $I^2 = 0.0\%$	2778	•	100.0 %	1.15 [0.86, 1.54]

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 5.21. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 21 Termination of pregnancy (all).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 21 Termination of pregnancy (all)

-

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	9/559	13/562		38.3 %	0.70 [0.30, 1.62]
King's 1996	6/278	10/277		29.6 %	0.60 [0.22, 1.62]
Leiden 1998	0/55	0/60		0.0 %	0.0 [0.0, 0.0]
NICHD EATA 2004	10/1820	/ 878	_	32.0 %	0.94 [0.40, 2.20]
Total (95% CI)	2712	2777	-	100.0 %	0.74 [0.45, 1.24]
Total events: 25 (Early amn	iocentesis), 34 (CVS)				
Heterogeneity: Chi ² = 0.49	, df = 2 (P = 0.78); $I^2 = 0.0\%$				
Test for overall effect: $Z =$	1.13 (P = 0.26)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			Favours treatment Favours control		

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 5.24. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 24 Spontaneous miscarriage.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 24 Spontaneous miscarriage

Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
20/559	13/562		36.4 %	1.55 [0.78, 3.08]
16/278	5/277		14.1 %	3.19 [1.18, 8.58]
4/56	3/61		8.1 %	1.45 [0.34, 6.21]
22/1820	15/1878		41.5 %	1.51 [0.79, 2.91]
2713	2778	•	100.0 %	1.76 [1.17, 2.64]
ocentesis), 36 (CVS)				
df = 3 (P = 0.62); I ² =0.0%				
72 (P = 0.0066)				
	n/N 20/559 16/278 4/56 22/1820	n/N n/N 20/559 13/562 16/278 5/277 4/56 3/61 22/1820 15/1878 2713 2778 ocentesis), 36 (CVS) df = 3 (P = 0.62); I ² =0.0%	n/N n/N M-H,Fixed,95% CI 20/559 13/562 16/278 5/277 4/56 3/61 22/1820 15/1878 2713 2778 wcentesis), 36 (CVS) df = 3 (P = 0.62); I ² =0.0%	n/N n/N M-H,Fixed,95% Cl 20/559 13/562 16/278 5/277 4/56 3/61 22/1820 15/1878 41.5 % 2713 2778 100.0 % ocentesis), 36 (CVS) df = 3 (P = 0.62); l ² =0.0%

0.1 0.2 0.5 1.0 2.0 5.0 10.0

Favours treatment Favours control

Analysis 5.25. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 25 Spontaneous miscarriage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 25 Spontaneous miscarriage after test

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	17/559	12/562		35.6 %	1.42 [0.69, 2.95]
King's 1996	16/278	5/277		14.9 %	3.19 [1.18, 8.58]
Leiden 1998	3/55	2/60		5.7 %	1.64 [0.28, 9.43]
NICHD EATA 2004	22/1820	15/1878		43.9 %	1.51 [0.79, 2.91]
Total (95% CI) Total events: 58 (Early amnic Heterogeneity: $Chi^2 = 1.91$, Test for overall effect: Z = 2.	df = 3 (P = 0.59); $l^2 = 0.0\%$	2777	•	100.0 %	1.74 [1.14, 2.64]

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 5.26. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 26 Perinatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 26 Perinatal deaths

Study or subgroup	Early amniocentesis	CVS		Ratio Weight	Risk Ratio
	n/N	n/N	M-H,Fixed	,95% Cl	M-H,Fixed,95% Cl
Copenhagen 1997	1/527	1/531		7.2 %	1.01 [0.06, 16.07]
King's 1996	0/278	0/277	•	0.0 %	0.0 [0.0, 0.0]
Leiden 1998	0/56	0/61	4	0.0 %	0.0 [0.0, 0.0]
NICHD EATA 2004	4/ 820	3/ 878		92.8 %	. [0.52, 2.36]
Total (95% CI)	2681	2747	+	100.0 %	1.10 [0.53, 2.28]
Total events: 15 (Early amr	niocentesis), 14 (CVS)				
Heterogeneity: $Chi^2 = 0.0$	0, df = 1 (P = 0.95); l ² =0.0%				
Test for overall effect: Z =	0.27 (P = 0.79)				
			0.02 0.1 1.0	10.0 50.0	
			Favours treatment	Favours control	

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 5.27. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 27 Stillbirths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 27 Stillbirths

Study or subgroup	Early amniocentesis	CVS		Risk Ratio	Weight	Risk Ratio
	n/N	n/N		M-H,Fixed,95% Cl		M-H,Fixed,95% Cl
Copenhagen 1997	0/527	0/531	•		0.0 %	0.0 [0.0, 0.0]
King's 1996	0/278	0/277			0.0 %	0.0 [0.0, 0.0]
Leiden 1998	0/56	0/61			0.0 %	0.0 [0.0, 0.0]
NICHD EATA 2004	14/1820	3/ 878			100.0 %	. [0.52, 2.36]
Total (95% CI)	2681	2747			100.0 %	1.11 [0.52, 2.36]
Total events: 14 (Early am	niocentesis), 13 (CVS)					
Heterogeneity: $Chi^2 = 0.0$), df = 0 (P = 1.00); $I^2 = 0.0\%$					
Test for overall effect: Z =	0.27 (P = 0.78)					

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 5.28. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 28 Neonatal deaths.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 28 Neonatal deaths

-

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% CI
Copenhagen 1997	1/559	1/562		22.4 %	1.01 [0.06, 16.03]
King's 1996	0/257	0/262	•	0.0 %	0.0 [0.0, 0.0]
Leiden 1998	0/56	0/61		0.0 %	0.0 [0.0, 0.0]
NICHD EATA 2004	0/1820	3/1878		77.6 %	0.15 [0.01, 2.85]
Total (95% CI)	2692	2763	-	100.0 %	0.34 [0.05, 2.17]
Total events: I (Early amnic	ocentesis), 4 (CVS)				
Heterogeneity: Chi ² = 0.89	, df = 1 (P = 0.34); $I^2 = 0.0\%$				
Test for overall effect: $Z =$	I.I4 (P = 0.25)				

0.0050 0.1 1.0 10.0 200.0

Favours treatment Favours control

Analysis 5.29. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 29 All recorded deaths after viability.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 29 All recorded deaths after viability

Study or subgroup	Early amniocentesis	CVS	Risk R	atio Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95	5% CI	M-H,Fixed,95% Cl
Copenhagen 1997	1/559	1/562		14.4 %	1.01 [0.06, 16.03]
King's 1996	0/257	0/262	•	0.0 %	0.0 [0.0, 0.0]
Leiden 1998	0/55	0/60	•	0.0 %	0.0 [0.0, 0.0]
NICHD EATA 2004	7/1820	6/1878		85.6 %	1.20 [0.41, 3.58]
Total (95% CI)	2691	2762	+	100.0 %	1.18 [0.43, 3.23]
Total events: 8 (Early amn	iocentesis), 7 (CVS)				
Heterogeneity: $Chi^2 = 0.0$), df = $ (P = 0.91); ^2 = 0.0\%$				
Test for overall effect: Z =	: 0.31 (P = 0.75)				
			0.02 0.1 1.0	10.0 50.0	
			Favours treatment Fav	vours control	

Amniocentesis and chorionic villus sampling for prenatal diagnosis (Review)

Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Analysis 5.30. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 30 Anomalies (all recorded).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 30 Anomalies (all recorded)

21/527	8/531			
			24.3 %	2.64 [1.18, 5.92]
11/257	8/262		22.6 %	1.40 [0.57, 3.43]
5/52	16/58	_ _	21.9 %	0.35 [0.14, 0.89]
41/1776	36/1842		31.3 %	1.18 [0.76, 1.84]
2612	2693	-	100.0 %	1.14 [0.57, 2.30]
8 (CVS)				
68, df = 3 (P = 0.	01); I ² =72%			
I)				
	2612 3 (CVS) 8, df = 3 (P = 0.	2612 2693 B (CVS) 8, df = 3 (P = 0.01); l ² =72%	2612 2693 B (CVS) 8, df = 3 (P = 0.01); I ² =72%	2612 2693 100.0 % B (CVS) B, df = 3 (P = 0.01); I ² =72%

0.1 0.2 0.5 1.0 2.0 5.0 10.0

Favours treatment Favours control

Analysis 5.32. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 32 Talipes equinovarus.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 32 Talipes equinovarus

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	9/527	0/531		9.3 %	19.14 [1.12, 328.08]
King's 1996	5/257	1/262		18.4 %	5.10 [0.60, 43.33]
Leiden 1998	1/52	1/58	_	17.6 %	1.12 [0.07, 17.39]
NICHD EATA 2004	9/1776	3/1842	-	54.8 %	3. [0.84, .47]
Total (95% CI)	2612	2693	•	100.0 %	4.61 [1.82, 11.66]
Total events: 24 (Early amni	iocentesis), 5 (CVS)				
Heterogeneity: Chi ² = 2.35	, df = 3 (P = 0.50); $I^2 = 0.0\%$				
Test for overall effect: $Z = 3$	3.23 (P = 0.0012)				

0.0010 0.1 1.0 10.0 1000.0

Favours treatment Favours control

Analysis 5.33. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 33 Haemangioma.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 33 Haemangioma

Study or subgroup	Early amniocentesis n/N	CVS n/N	M-H,F	Risk Ratio ïxed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	3/527	1/531	_		0.7 %	3.02 [0.32, 28.97]
King's 1996	0/257	1/262	•	+	1.1 %	0.34 [0.01, 8.30]
Leiden 1998	0/52	7/58		+	5.1 %	0.07 [0.00, 1.27]
NICHD EATA 2004	115/1776	32/ 842			93.1 %	0.90 [0.71, 1.15]
Total (95% CI)	2612	2693		•	100.0 %	0.87 [0.69, 1.10]
Total events: 118 (Early am	niocentesis), 141 (CVS) 3, df = 3 (P = 0.21); $I^2 = 33\%$					
Test for overall effect: $Z =$						
	, , ,				1	
			0.0020 0.1	1.0 10.0 5	00.0	
			Favours treatment	Favours con	trol	

Analysis 5.35. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 35 Neonatal respiratory distress syndrome.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 35 Neonatal respiratory distress syndrome

Study or subgroup	Early amniocentesis n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Copenhagen 1997	5/527	4/531	-	33.3 %	1.26 [0.34, 4.66]
King's 1996	0/74	6/86		50.3 %	0.09 [0.01, 1.56]
Leiden 1998	0/52	0/58	•	0.0 %	0.0 [0.0, 0.0]
NICHD EATA 2004	4/1667	2/1730		16.4 %	2.08 [0.38, .32]
Total (95% CI) Total events: 9 (Early amnioc Heterogeneity: Chi ² = 3.92, 4 Test for overall effect: Z = 0.	df = 2 (P = 0.14); $I^2 = 49\%$	2405	•	1 00.0 %	0.80 [0.34, 1.89]

0.0010 0.1 1.0 10.0 1000.0 Favours treatment Favours control

Analysis 5.36. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 36 Birthweight below 10th centile.

Review: Amniocentesis and	d chorionic villus sam	pling for prenatal dia	gnosis		
Comparison: 5 Early amnic	ocentesis versus trans	abdominal CVS			
Outcome: 36 Birthweight b	below 10th centile				
Study or subgroup	EAC n/N	CVS n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
NICHD EATA 2004	118/1776	46/ 842	-	100.0 %	0.84 [0.66, 1.06]
Total (95% CI)	1776	1842	•	100.0 %	0.84 [0.66, 1.06]
Total events: 118 (EAC), 146 Heterogeneity: not applicable Test for overall effect: $Z = 1.4$					
			0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours EAC Favours CVS		

Analysis 5.37. Comparison 5 Early amniocentesis versus transabdominal CVS, Outcome 37 Birthweight below 5th centile.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 5 Early amniocentesis versus transabdominal CVS

Outcome: 37 Birthweight below 5th centile

Study or subgroup	Early amniocentesis	CVS	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fixed,95% Cl
King's 1996	9/257	5/262		53.8 %	1.84 [0.62, 5.40]
Leiden 1998	0/52	4/58		46.2 %	0.12 [0.01, 2.24]
Total (95% CI)	309	320	+	100.0 %	1.04 [0.43, 2.56]
Total events: 9 (Early amr	niocentesis), 9 (CVS)				
Heterogeneity: $Chi^2 = 3$.	13, df = 1 (P = 0.08); $I^2 = 68\%$				
Test for overall effect: Z =	= 0.09 (P = 0.93)				

0.0010 0.1 1.0 10.0 1000.0

Favours treatment Favours control

Analysis 6.2. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 2 Sampling failure.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis Comparison: 6 Ultrasound versus no ultrasound before second trimester amniocentesis Outcome: 2 Sampling failure Ultrasound No ultrasound Risk Ratio Weight Risk Ratio Study or subgroup M-H,Fixed,95% CI M-H,Fixed,95% Cl n/N n/N 5/112 10.90 [0.61, 194.85] Nolan 1981 0/111 100.0 % Total (95% CI) 112 111 100.0 % 10.90 [0.61, 194.85] Total events: 5 (Ultrasound), 0 (No ultrasound) Heterogeneity: not applicable Test for overall effect: Z = 1.62 (P = 0.10) 0.0010 0.1 1.0 10.0 1000.0 Favours treatment Favours control

Analysis 6.3. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 3 Multiple insertions.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 6 Ultrasound versus no ultrasound before second trimester amniocentesis

Outcome: 3 Multiple insertions

Study or subgroup	Ultrasound n/N	No ultrasound n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Nolan 1981	21/112	31/111		100.0 %	0.67 [0.41, 1.09]
Total (95% CI)	112	111	-	100.0 %	0.67 [0.41, 1.09]
Total events: 21 (Ultrasou	und), 31 (No ultrasoun	d)			
Heterogeneity: not applic	able				
Test for overall effect: Z =	= 1.60 (P = 0.11)				
			01 02 05 10 20 50 100		

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

Analysis 6.20. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 20 All known pregnancy loss (including termination of pregnancy).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 6 Ultrasound versus no ultrasound before second trimester amniocentesis

Outcome: 20 All known pregnancy loss (including termination of pregnancy)

Study or subgroup	Ultrasound n/N	No ultrasound n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Nolan 1981	0/112	1/111		100.0 %	0.33 [0.01, 8.02]
Total (95% CI) Total events: 0 (Ultrasour Heterogeneity: not applic Test for overall effect: Z =	able	111		100.0 %	0.33 [0.01, 8.02]
			0.0050 0.1 1.0 10.0 200.0 Favours treatment Favours control		

Analysis 6.24. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 24 Spontaneous miscarriage.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 6 Ultrasound versus no ultrasound before second trimester amniocentesis

Outcome: 24 Spontaneous miscarriage

Study or subgroup	Ultrasound n/N	No ultrasound n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Nolan 1981	0/112	1/111		100.0 %	0.33 [0.01, 8.02]
Total (95% CI)	112	111		100.0 %	0.33 [0.01, 8.02]
Total events: 0 (Ultrasoun	id), I (No ultrasound)				
Heterogeneity: not application	able				
Test for overall effect: Z =	= 0.68 (P = 0.50)				
			0.0050 0.1 1.0 10.0 200.0		

Favours treatment Favours control

Analysis 6.25. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 25 Spontaneous miscarriage after test.

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 6 Ultrasound versus no ultrasound before second trimester amniocentesis

Outcome: 25 Spontaneous miscarriage after test

Study or subgroup	Ultrasound n/N	No ultrasound n/N	Risk Ratio M-H,Fixed,95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
Nolan 1981	0/112	1/111	— — —	100.0 %	0.33 [0.01, 8.02]
Total (95% CI)	112	111		100.0 %	0.33 [0.01, 8.02]
Total events: 0 (Ultrasoun	id), I (No ultrasound)				
Heterogeneity: not applica	able				
Test for overall effect: Z =	= 0.68 (P = 0.50)				
			0.0020 0.1 1.0 10.0 500.0		

Favours treatment Favours control

Analysis 6.38. Comparison 6 Ultrasound versus no ultrasound before second trimester amniocentesis, Outcome 38 Bloody tap (not prespecified).

Review: Amniocentesis and chorionic villus sampling for prenatal diagnosis

Comparison: 6 Ultrasound versus no ultrasound before second trimester amniocentesis

Outcome: 38 Bloody tap (not prespecified)

Study or subgroup	Ultrasound n/N	No ultrasound n/N	Odds Ratio M-H,Fixed,95% Cl	Weight	Odds Ratio M-H,Fixed,95% Cl
				100.0.0/	
Nolan 1981	17/112	9/111		100.0 %	2.03 [0.86, 4.77]
Total (95% CI)	112	111		100.0 %	2.03 [0.86, 4.77]
Total events: 17 (Ultrasound), 9 (No ultrasound)					
Heterogeneity: not applicable					
Test for overall effect: Z =	= 1.62 (P = 0.11)				

0.1 0.2 0.5 1.0 2.0 5.0 10.0 Favours treatment Favours control

WHAT'S NEW

Last assessed as up-to-date: 28 June 2008.

29 June 2009	New search has been performed	New included study added (NICHD EATA 2004). Other minor amend- ments made including updating the reference list. There are no significant changes to the conclusions.
29 December 2007	Amended	Converted to new review format.

HISTORY

Protocol first published: Issue 3, 2001

Review first published: Issue 3, 2003

CONTRIBUTIONS OF AUTHORS

Z Alfirevic developed the protocol, interpreted the data and wrote the review. K Sundberg and F Mujezinovic extracted the data and co-wrote the review.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

• The University of Liverpool, UK.

External sources

• No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)

Amniocentesis [*adverse effects; standards]; Chorionic Villi Sampling [*adverse effects; standards]; Congenital Abnormalities [diagnosis]; Pregnancy Trimester, First; Pregnancy Trimester, Second; Randomized Controlled Trials as Topic

MeSH check words

Female; Humans; Pregnancy